Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
46.2 /100
Rank 16 out of 27 Sectors -
Advance/Decline
468/209
-
No. of Companies677
-
Avg. Market Cap6,605
-
Price to Earning Ratio5.44
-
Price to Earning Growth Ratio0.71
-
Price to Book Ratio23.55
-
Return on Equity45.68
-
Return on Capital Employed-
-
Return on Assets10.51
-
Dividend yield 1 year %0.87 %
-
Net Profit Growth Annual YoY %-14.06 %
-
Net Profit Growth Qtr YoY %38.33 %
-
Net Profit Growth Qtr QoQ %665.71 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie |
|
389,031.5
|
220.2
|
L
 4.1%
H
216.8
221.8
|
L
 4.0%
H
207.6
221.8
|
L
 11.2%
H
196.9
221.8
|
L
 16.2%
H
181.7
221.8
|
L
 10.5%
H
163.8
221.8
|
L
 55.7%
H
131.0
221.8
|
L
 145.6%
H
79.1
221.8
|
L
 269.6%
H
45.5
221.8
|
Adc Therapeutics SA |
|
374.6
|
3.3
|
L
 3.1%
H
3.2
3.4
|
L
 1.2%
H
3.2
3.6
|
L
 24.3%
H
2.6
3.6
|
L
 -9.3%
H
2.6
4.0
|
L
 13.7%
H
1.1
4.0
|
L
 -46.0%
H
0.4
6.2
|
L
 -91.3%
H
0.4
46.2
|
L
H
0.4
56.6
|
Amneal Pharmaceuticals Inc |
|
3,169.1
|
10.1
|
L
 2.8%
H
9.9
10.3
|
L
 5.8%
H
9.3
10.3
|
L
 18.2%
H
8.5
10.3
|
L
 29.2%
H
7.7
10.3
|
L
 20.4%
H
6.7
10.3
|
L
 336.8%
H
1.2
10.3
|
L
 169.8%
H
1.2
10.3
|
L
 -76.9%
H
1.2
45
|
Annovis Bio Inc |
|
46.6
|
2.4
|
L
 3.5%
H
2.3
2.4
|
L
 4.8%
H
2.2
2.4
|
L
 -6.3%
H
2.2
3.0
|
L
 -17.0%
H
2.1
3.2
|
L
 -70.7%
H
1.1
10.5
|
L
 -84.4%
H
1.1
23.9
|
L
 -51.7%
H
1.1
132
|
L
H
1.1
132
|
Bausch Health Companies Inc |
|
2,681.0
|
7.3
|
L
 1.4%
H
7.2
7.3
|
L
 -1.4%
H
7.1
7.4
|
L
 26.1%
H
5.8
8.7
|
L
 42.2%
H
5.0
8.7
|
L
 16%
H
4.3
9.9
|
L
 -2.0%
H
4.0
11.5
|
L
 -53.7%
H
4.0
34.8
|
L
 -96.8%
H
4.0
245.8
|
Bristol-Myers Squibb |
|
96,764.6
|
47.5
|
L
 0.8%
H
47.2
48.2
|
L
 0.1%
H
45.9
48.2
|
L
 3.5%
H
45.7
49.6
|
L
 -4.9%
H
43.0
50.8
|
L
 -3.5%
H
43.0
63.3
|
L
 -32.2%
H
39.4
81.4
|
L
 -18.4%
H
39.4
81.4
|
L
 -19.1%
H
39.4
81.4
|
Emergent Biosolutions Inc |
|
439.1
|
8.2
|
L
 3.3%
H
8.0
8.4
|
L
 5.1%
H
7.5
8.5
|
L
 -4.0%
H
7.5
9.7
|
L
 21.9%
H
5.6
9.7
|
L
 9.2%
H
4.0
12.7
|
L
 -67.2%
H
1.4
25.5
|
L
 -91.7%
H
1.4
127.2
|
L
 -72.9%
H
1.4
137.6
|
Elanco Animal Health Inc |
|
9,330.2
|
18.8
|
L
 2.5%
H
18.4
18.9
|
L
 8.2%
H
17.1
19.1
|
L
 12.7%
H
16.9
19.1
|
L
 31.3%
H
13.2
19.1
|
L
 29.3%
H
8.0
19.1
|
L
 25.2%
H
7.9
19.1
|
L
 -31.0%
H
7.9
37.5
|
L
H
7.9
37.6
|
GSK Plc ADR |
|
83,508.5
|
41.5
|
L
 2.4%
H
40.8
41.5
|
L
 5.4%
H
39.2
41.5
|
L
 9.7%
H
37.7
41.5
|
L
 0.4%
H
35.5
42.6
|
L
 -5.9%
H
31.7
44.0
|
L
 30.1%
H
28.5
45.9
|
L
 5.1%
H
28.5
47.8
|
L
 1.3%
H
28.5
49.1
|
Johnson & Johnson |
|
429,888.5
|
178.5
|
L
 1.5%
H
175.6
178.8
|
L
 0.3%
H
174.3
179.5
|
L
 3.0%
H
171.8
181.2
|
L
 14.1%
H
149.0
181.2
|
L
 6.6%
H
140.7
181.2
|
L
 7.7%
H
140.7
181.2
|
L
 21.5%
H
133.7
186.7
|
L
 92.5%
H
89.9
186.7
|
Eli Lilly |
|
677,972.3
|
756.3
|
L
 0.2%
H
750.4
761.1
|
L
 2.5%
H
719.2
761.1
|
L
 20.9%
H
625.9
761.1
|
L
 -6.3%
H
623.8
825
|
L
 -16.1%
H
623.8
942.4
|
L
 138.0%
H
296.3
972.5
|
L
 417.2%
H
129.2
972.5
|
L
 835.5%
H
64.2
972.5
|
Merck & Company |
|
212,686.2
|
85.2
|
L
 1.3%
H
84
85.6
|
L
 1.2%
H
82.8
85.6
|
L
 5.5%
H
79.6
87.8
|
L
 4.7%
H
76.7
87.8
|
L
 -26.2%
H
73.3
119.4
|
L
 -2.5%
H
73.3
134.6
|
L
 6.8%
H
68.4
134.6
|
L
 69.3%
H
45.8
134.6
|
Nuvation Bio Inc Ordinary |
|
1,146.6
|
3.4
|
L
 0.9%
H
3.2
3.4
|
L
 6.4%
H
3.2
4.1
|
L
 45.7%
H
2.2
4.1
|
L
 32.4%
H
1.6
4.1
|
L
 14.0%
H
1.5
4.1
|
L
 18.0%
H
1.0
4.2
|
L
 -70.8%
H
1.0
15.2
|
L
H
1.0
15.2
|
Novo Nordisk ADR |
|
241,278.3
|
54.3
|
L
 -0.1%
H
53.6
54.6
|
L
 -4.3%
H
52.7
56.5
|
L
 6.3%
H
49.4
58.3
|
L
 -31.6%
H
45.1
81.4
|
L
 -58.2%
H
45.1
138.2
|
L
 0.1%
H
45.1
148.2
|
L
 65.0%
H
31.6
148.2
|
L
 91.9%
H
15.5
148.2
|
Novartis AG ADR |
|
247,208.5
|
127.7
|
L
 0.9%
H
127.3
128.1
|
L
 -0.4%
H
126.1
130.5
|
L
 9.3%
H
117.5
130.5
|
L
 7.7%
H
112.3
130.5
|
L
 9.2%
H
96.1
130.5
|
L
 54.6%
H
74.1
130.5
|
L
 44.3%
H
74.1
130.5
|
L
 50.0%
H
59.2
130.5
|
Organon Co |
|
2,771.2
|
10.7
|
L
 3.9%
H
10.3
10.7
|
L
 8.4%
H
9.6
10.7
|
L
 15.6%
H
8.9
10.7
|
L
 6.2%
H
8.3
10.7
|
L
 -46.9%
H
8.0
21.1
|
L
 -64.3%
H
8.0
32.4
|
L
H
8.0
39.5
|
L
H
8.0
39.5
|
Prestige Consumer Healthcare |
|
3,199.9
|
65.0
|
L
 0.0%
H
64.8
65.6
|
L
 -2.8%
H
63.8
67.2
|
L
 -0.9%
H
63.0
68.6
|
L
 -25.0%
H
63.0
87.1
|
L
 -9.8%
H
63.0
90.0
|
L
 24.8%
H
48.5
90.0
|
L
 78.2%
H
32.2
90.0
|
L
 40.8%
H
26.3
90.0
|
Pfizer |
|
141,342.8
|
24.9
|
L
 1.2%
H
24.5
24.9
|
L
 0.3%
H
24.3
25.0
|
L
 1.1%
H
24.3
26.1
|
L
 2.3%
H
23.1
26.1
|
L
 -16.4%
H
20.9
30.4
|
L
 -48.0%
H
20.9
54.9
|
L
 -26.4%
H
20.9
61.7
|
L
 -19.5%
H
20.9
61.7
|
Perrigo Company plc |
|
3,102.5
|
22.6
|
L
 1.9%
H
22.2
22.6
|
L
 -3.3%
H
22
23.7
|
L
H
21.8
24.6
|
L
 -18.3%
H
21.0
28.4
|
L
 -16.9%
H
21.0
30.9
|
L
 -42.4%
H
21.0
41.4
|
L
 -53.3%
H
21.0
51.1
|
L
 -87.3%
H
21.0
184.8
|
Arcus Biosciences Inc |
|
1,224.0
|
11.5
|
L
 -1.9%
H
11.4
12.1
|
L
 -1.2%
H
11.0
12.2
|
L
 26.9%
H
8.9
12.2
|
L
 14.8%
H
7.9
12.2
|
L
 -31.1%
H
6.5
19.0
|
L
 -54.8%
H
6.5
36.1
|
L
 -49.7%
H
6.5
49.1
|
L
H
6.3
49.1
|
Dr Reddys Laboratories ADR |
|
12,261.2
|
14.7
|
L
 1.0%
H
14.5
14.7
|
L
 3.8%
H
14.1
14.7
|
L
 6.7%
H
13.8
14.7
|
L
 -7.3%
H
13.3
16.2
|
L
 -6.7%
H
12.3
74.9
|
L
 37.8%
H
10.0
74.9
|
L
 23.2%
H
9.6
74.9
|
L
 20.9%
H
5.6
74.9
|
Takeda Pharmaceutical Co ADR |
|
48,447.1
|
15.3
|
L
 0.3%
H
15.2
15.4
|
L
 1.3%
H
14.9
15.7
|
L
 6.2%
H
14.4
15.7
|
L
 0.7%
H
13.5
15.7
|
L
 3.0%
H
12.8
15.7
|
L
 11.8%
H
12.3
17.2
|
L
 -14.7%
H
12.3
20.0
|
L
 -35.8%
H
12.3
30.6
|
Teva Pharmaceutical Industries |
|
22,816.8
|
19.9
|
L
 1.6%
H
19.5
19.9
|
L
 6.0%
H
18.5
20.0
|
L
 21.5%
H
16.3
20.0
|
L
 13.1%
H
15.0
20.0
|
L
 13.5%
H
12.5
22.8
|
L
 116.9%
H
7.1
22.8
|
L
 127.1%
H
6.8
22.8
|
L
 -67.9%
H
6.1
66.6
|
Usana Health Sciences Inc |
|
563.9
|
30.9
|
L
 2.4%
H
30.0
30.9
|
L
 -2.6%
H
29.7
32.3
|
L
 7.0%
H
29.0
32.3
|
L
H
28.5
38.3
|
L
 -17.4%
H
23.1
41.8
|
L
 -50.7%
H
23.1
69.6
|
L
 -60.3%
H
23.1
107.9
|
L
 -55.6%
H
23.1
138.0
|
Zoetis |
|
66,747.9
|
150.6
|
L
 0.8%
H
149.4
152
|
L
 -1.2%
H
146.5
155.2
|
L
 2.2%
H
146.5
160.5
|
L
 -9.9%
H
144.3
168.8
|
L
 -21.3%
H
139.7
200.2
|
L
 -8.3%
H
124.2
201.9
|
L
 -4.7%
H
124.2
249.3
|
L
 239.7%
H
38.3
249.3
|
Biohaven |
|
1,488.5
|
14.1
|
L
 0.4%
H
13.8
14.2
|
L
 -13.2%
H
13.6
17.1
|
L
 -4.6%
H
12.8
17.3
|
L
 -16.2%
H
12.8
17.3
|
L
 -60.9%
H
12.8
55.6
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
Whitehawk Therapeutics Inc |
|
94.7
|
2.0
|
L
 12.3%
H
1.8
2.0
|
L
 11.1%
H
1.8
2.0
|
L
 14.9%
H
1.6
2.0
|
L
 1.0%
H
1.6
2.2
|
L
 12.9%
H
1.4
3.8
|
L
 -84.0%
H
1.2
14.8
|
L
 -89.1%
H
1.2
49.8
|
L
H
1.2
101.3
|
AbCellera Biologics Inc |
|
1,377.6
|
4.6
|
L
 7.7%
H
4.3
4.7
|
L
 15.5%
H
3.8
4.7
|
L
 8.5%
H
3.8
4.8
|
L
 52.7%
H
3.0
5.8
|
L
 78.7%
H
1.9
5.8
|
L
 -58.8%
H
1.9
15.0
|
L
H
1.9
71.9
|
L
H
1.9
71.9
|
Abeona Therapeutics Inc |
|
346.1
|
6.8
|
L
 3.4%
H
6.6
6.8
|
L
 -2.9%
H
6.5
7
|
L
 7.8%
H
6.2
7.5
|
L
 4.5%
H
5.5
7.5
|
L
 21.4%
H
3.9
7.5
|
L
 72.2%
H
2.2
9.0
|
L
 -86.8%
H
2.2
94.8
|
L
 -94.9%
H
2.2
568.8
|
Oruka Therapeutics Inc |
|
604.8
|
16.2
|
L
 2.4%
H
15.5
16.2
|
L
 4.6%
H
14.7
16.9
|
L
 23.4%
H
12.8
16.9
|
L
 22.4%
H
10.8
16.9
|
L
 -42.5%
H
5.5
31.1
|
L
 -42.0%
H
2.2
53.9
|
L
 -70.5%
H
2.2
66
|
L
 -98.8%
H
2.2
1505.5
|
Acumen Pharmaceuticals Inc |
|
84.2
|
1.4
|
L
 3.0%
H
1.3
1.4
|
L
H
1.3
1.5
|
L
 2.2%
H
1.2
1.6
|
L
 17.8%
H
1.1
1.8
|
L
 -44.6%
H
0.9
3.4
|
L
 -79.4%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
Arbutus Biopharma Corp |
|
939.3
|
4.9
|
L
 6.1%
H
4.6
5.1
|
L
 24.7%
H
3.9
5.1
|
L
 44.1%
H
3.3
5.1
|
L
 38.0%
H
3.0
5.1
|
L
 7.5%
H
2.7
5.1
|
L
 118.8%
H
1.7
5.1
|
L
 103.3%
H
1.7
6.5
|
L
 -29.7%
H
0.8
12.6
|
ABVC BioPharma Inc |
|
65.2
|
2.8
|
L
 3.4%
H
2.7
2.8
|
L
 2.2%
H
2.5
2.8
|
L
 2.6%
H
2.5
3.4
|
L
 66.9%
H
1.6
5.5
|
L
 313.4%
H
0.4
5.5
|
L
 -74.8%
H
0.4
18.7
|
L
 -93.0%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
Acadia Pharmaceuticals Inc |
|
4,082.8
|
24.2
|
L
 1.7%
H
24.0
24.5
|
L
 -5.9%
H
23.7
25.9
|
L
 -1.6%
H
23.7
26.7
|
L
 9.0%
H
20.7
26.7
|
L
 54.5%
H
13.4
26.7
|
L
 39.2%
H
13.4
33.9
|
L
 -33.6%
H
12.2
57.5
|
L
 -41.2%
H
12.2
58.7
|
Adicet Bio Inc |
|
73.3
|
0.9
|
L
 10%
H
0.8
0.9
|
L
 20.6%
H
0.7
0.9
|
L
 41.9%
H
0.6
0.9
|
L
 7.3%
H
0.6
0.9
|
L
 -38.5%
H
0.5
1.6
|
L
 -94.6%
H
0.5
21.9
|
L
 -94.0%
H
0.5
21.9
|
L
H
0.5
147.7
|
Achieve Life Sciences Inc |
|
161.5
|
3.2
|
L
 -3.7%
H
3.1
3.3
|
L
 10.5%
H
2.7
3.3
|
L
 26.4%
H
2.4
3.5
|
L
 -14.4%
H
2
3.9
|
L
 -26.5%
H
1.8
5.3
|
L
 -31.3%
H
1.8
10.3
|
L
 -60.7%
H
1.8
16.1
|
L
 -99.9%
H
1.8
6886
|
AC Immune SA |
|
239.4
|
2.4
|
L
 -0.8%
H
2.3
2.4
|
L
 5.3%
H
2.1
2.4
|
L
 11.2%
H
2.0
2.4
|
L
 8.2%
H
1.7
2.5
|
L
 -22.7%
H
1.4
4.0
|
L
 -14.7%
H
1.4
5.1
|
L
 -69.3%
H
1.4
12.6
|
L
H
1.4
20.0
|
Arcellx Inc |
|
4,308.0
|
77.7
|
L
 6.8%
H
72.1
77.7
|
L
 9.1%
H
70.0
77.7
|
L
 10.2%
H
66.5
77.7
|
L
 16.6%
H
60.9
77.7
|
L
 4.7%
H
47.9
107.4
|
L
 301.2%
H
16.7
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
Aclaris Therapeutics Inc |
|
213.4
|
2.0
|
L
 -3.4%
H
2.0
2.1
|
L
 -4.4%
H
2.0
2.2
|
L
 20.9%
H
1.6
2.2
|
L
 30.5%
H
1.3
2.2
|
L
 68.4%
H
1.1
5.2
|
L
 -87.9%
H
0.6
19.0
|
L
 -10.0%
H
0.6
30.4
|
L
H
0.6
33.9
|
Acrivon Therapeutics Inc |
|
48.8
|
1.6
|
L
 -4.9%
H
1.5
1.7
|
L
 15.7%
H
1.3
2.7
|
L
 25%
H
1.2
2.7
|
L
 21.1%
H
1.2
2.7
|
L
 -81.9%
H
1.1
10
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
Acelrx Pharmaceuticals Inc |
|
17.0
|
1
|
L
 17.7%
H
0.8
1.0
|
L
 85.2%
H
0.5
1.1
|
L
 143.9%
H
0.4
1.1
|
L
 96.1%
H
0.4
1.1
|
L
 100%
H
0.4
1.1
|
L
 -82.1%
H
0.4
5.6
|
L
 -95.4%
H
0.4
58.8
|
L
 -98.7%
H
0.4
117.6
|
Grace Therapeutics Inc |
|
44.5
|
3.2
|
L
 -1.2%
H
3.2
3.3
|
L
 8.4%
H
3.0
3.3
|
L
H
2.9
3.4
|
L
 8.1%
H
2.8
3.7
|
L
 35.3%
H
1.8
5.0
|
L
 -32.9%
H
1.7
5.1
|
L
 -66.5%
H
1.7
58.6
|
L
 -97.9%
H
1.7
175.7
|
Acurx Pharmaceuticals Inc |
|
6.8
|
4.3
|
L
 4.9%
H
4.0
4.3
|
L
 3.1%
H
3.8
4.3
|
L
 -4.5%
H
3.8
7.2
|
L
 -39.7%
H
3.8
21
|
L
 -89.3%
H
3.8
44
|
L
 -95.1%
H
3.8
176.4
|
L
H
3.8
176.4
|
L
H
3.8
176.4
|
Adial Pharmaceuticals Inc |
|
7.6
|
0.4
|
L
H
0.4
0.4
|
L
 -5.4%
H
0.3
0.4
|
L
 -7.9%
H
0.3
0.4
|
L
 -40.7%
H
0.2
0.8
|
L
 -65.4%
H
0.2
1.3
|
L
 -97.3%
H
0.2
15
|
L
 -98.9%
H
0.2
127
|
L
H
0.2
236
|
Adma Biologics Inc |
|
3,844.3
|
16.1
|
L
 2.2%
H
15.9
16.5
|
L
 -4.7%
H
15.7
17.2
|
L
 -2.5%
H
15.7
17.9
|
L
 -22.8%
H
14.6
22.4
|
L
 -6.8%
H
13.5
25.7
|
L
 465.3%
H
2.2
25.7
|
L
 606.6%
H
1.0
25.7
|
L
 79.2%
H
1.0
25.7
|
Adaptive Biotechnologies Corp |
|
2,054.2
|
13.5
|
L
 8.6%
H
12.5
13.7
|
L
 5.0%
H
12.3
13.7
|
L
 10.6%
H
11.9
13.7
|
L
 29.0%
H
9.9
13.7
|
L
 216.7%
H
4.0
13.7
|
L
 51.4%
H
2.3
13.7
|
L
 -65.6%
H
2.3
71.3
|
L
H
2.3
71.3
|
Aditxt Inc |
|
5.3
|
1.1
|
L
 9.2%
H
1
1.1
|
L
 7%
H
0.9
1.1
|
L
 -10.1%
H
0.9
1.2
|
L
 -28.2%
H
0.8
2.2
|
L
 -94.6%
H
0.0
20.6
|
L
 -100.0%
H
0.0
45584
|
L
 -100.0%
H
0.0
538400
|
L
H
0.0
766400
|
Adverum Biotechnologies Inc |
|
65.9
|
3.1
|
L
 -5.1%
H
3.1
3.4
|
L
 -3.4%
H
3.1
3.6
|
L
 37.1%
H
2.2
3.6
|
L
 12.5%
H
2.1
3.6
|
L
 -56.3%
H
1.8
8.6
|
L
 -97.2%
H
1.8
297
|
L
 -99.7%
H
1.8
1479
|
L
 -99.7%
H
1.8
2698
|
Agenus Inc |
|
151.0
|
4.7
|
L
 -1.9%
H
4.6
5.1
|
L
 11.3%
H
4.1
5.2
|
L
 -1.3%
H
4.1
5.2
|
L
 -11.7%
H
4.1
7.3
|
L
 -7.1%
H
1.4
7.3
|
L
 -91.0%
H
1.4
196
|
L
 -95.3%
H
1.4
196
|
L
 -96.4%
H
1.4
196
|
Agios Pharmaceuticals Inc |
|
2,120.7
|
36.5
|
L
 2.3%
H
35.9
36.8
|
L
 -10.1%
H
32.7
37.9
|
L
 2.1%
H
32.7
41.1
|
L
 5.8%
H
26.8
41.7
|
L
 -18.0%
H
23.4
62.6
|
L
 6.9%
H
19.8
62.6
|
L
 -4.7%
H
16.8
62.6
|
L
 -59.4%
H
16.8
99.8
|
Aeglea BioTherapeutics Inc |
|
65.6
|
16.2
|
L
 0.1%
H
16.1
16.6
|
L
 -3.6%
H
15.8
17.6
|
L
 6.9%
H
14.7
17.8
|
L
 -12.7%
H
13.9
19.2
|
L
 6.7%
H
13.9
19.2
|
L
 32.1%
H
2.7
39
|
L
 -90.6%
H
2.7
247.5
|
L
H
2.7
318.8
|
Akebia Therapeutics Inc |
|
792.8
|
3.0
|
L
 2.1%
H
2.9
3.0
|
L
 -4.2%
H
2.9
3.2
|
L
 -12.6%
H
2.9
3.4
|
L
 -23.7%
H
2.9
4.1
|
L
 102.0%
H
1.3
4.1
|
L
 579.5%
H
0.2
4.1
|
L
 15%
H
0.2
5.1
|
L
 -69.1%
H
0.2
20.3
|
Akero Therapeutics Inc |
|
3,593.9
|
44.9
|
L
 3.9%
H
43.0
45.1
|
L
 -1.5%
H
42.6
46.2
|
L
 -11.0%
H
42.6
50.2
|
L
 -17.6%
H
42.6
57.4
|
L
 74.6%
H
21.3
58.4
|
L
 283.7%
H
11.3
58.4
|
L
 32.0%
H
7.5
58.4
|
L
H
7.5
58.4
|
Avalon GloboCare Corp |
|
10.4
|
2.7
|
L
 8.8%
H
2.5
2.8
|
L
 31.4%
H
2.1
2.8
|
L
 22.5%
H
1.9
2.8
|
L
 -13.4%
H
1.9
4.7
|
L
 677.1%
H
0.2
11.7
|
L
 -50.4%
H
0.2
11.7
|
L
 -78.4%
H
0.2
16.5
|
L
H
0.2
135
|
Aldeyra Therapeutics Inc |
|
333.9
|
5.6
|
L
 0.4%
H
5.5
5.8
|
L
 -4.6%
H
5.4
5.9
|
L
 5.7%
H
5.0
6.2
|
L
 107.5%
H
2.6
6.2
|
L
 -6.2%
H
1.1
7.2
|
L
 -15.4%
H
1.1
12.0
|
L
 -18.0%
H
1.1
16.0
|
L
 -18.5%
H
1.1
16.7
|
Alector Inc |
|
290.5
|
2.9
|
L
 1.1%
H
2.8
3
|
L
 2.9%
H
2.7
3.1
|
L
 33.5%
H
2.0
3.1
|
L
 80.5%
H
1.3
3.1
|
L
 -50.3%
H
0.9
6.4
|
L
 -70.2%
H
0.9
10.2
|
L
 -77.2%
H
0.9
43.3
|
L
H
0.9
43.3
|
Aligos Therapeutics Inc |
|
75.6
|
10.9
|
L
 1.6%
H
10.4
11
|
L
 0.7%
H
10.0
11.7
|
L
 41.5%
H
7.3
11.7
|
L
 49.0%
H
6.8
11.7
|
L
 -21.1%
H
3.8
46.3
|
L
 -67.0%
H
3.8
60.3
|
L
H
3.8
937.8
|
L
H
3.8
937.8
|
Alkermes plc |
|
4,574.3
|
27.7
|
L
 2.9%
H
27.0
27.7
|
L
 -7.6%
H
25.2
30.2
|
L
 3.7%
H
25.2
31.7
|
L
 -10.8%
H
25.2
31.7
|
L
 2.7%
H
25.2
36.5
|
L
 15.4%
H
21.8
36.5
|
L
 61.4%
H
15.4
36.5
|
L
 -60.2%
H
12.0
80.7
|
Allogene Therapeutics Inc |
|
259.6
|
1.2
|
L
 5.4%
H
1.1
1.2
|
L
 4.5%
H
1.1
1.2
|
L
 12.5%
H
1.0
1.3
|
L
 -19.9%
H
1.0
1.7
|
L
 -58.7%
H
0.9
3.8
|
L
 -92.2%
H
0.9
15.3
|
L
 -96.4%
H
0.9
44.9
|
L
H
0.9
55
|
Allarity Therapeutics Inc |
|
27.2
|
1.9
|
L
 2.8%
H
1.8
1.9
|
L
 2.2%
H
1.7
2.1
|
L
 91.8%
H
0.8
2.1
|
L
 104.4%
H
0.8
2.1
|
L
 1590.9%
H
0.6
4.0
|
L
 -100.0%
H
0.1
42000
|
L
H
0.1
509600
|
L
H
0.1
509600
|
Alnylam Pharmaceuticals Inc |
|
61,421.0
|
468.6
|
L
 -0.2%
H
465.2
474.3
|
L
 4.7%
H
444.7
484.2
|
L
 6.8%
H
421.8
484.2
|
L
 54.9%
H
295.8
484.2
|
L
 82.9%
H
205.9
484.2
|
L
 109.9%
H
142.0
484.2
|
L
 286.6%
H
117.6
484.2
|
L
 343.1%
H
31.4
484.2
|
Rein Therapeutics Inc |
|
24.9
|
1.1
|
L
 -9.2%
H
1.1
1.2
|
L
 -14.3%
H
1.1
1.5
|
L
 -2.7%
H
1.1
1.5
|
L
 -44.3%
H
1.0
2.0
|
L
 -60.6%
H
1.0
4.4
|
L
 -71.6%
H
1.0
7.4
|
L
 -95.5%
H
1.0
49.4
|
L
H
1.0
309.6
|
Altimmune Inc |
|
325.7
|
3.7
|
L
 0.5%
H
3.7
3.7
|
L
 0.3%
H
3.5
3.8
|
L
 7.0%
H
3.3
3.9
|
L
 -45.3%
H
2.9
7.7
|
L
 -47.0%
H
2.9
11.2
|
L
 -81.5%
H
2.1
21.6
|
L
 -69.1%
H
2.1
24.6
|
L
 -99.2%
H
1.5
1050
|
Alvotech |
|
2,508.4
|
8.1
|
L
 0.3%
H
8.0
8.2
|
L
 1.3%
H
8.0
8.4
|
L
 -4.9%
H
7.8
9.1
|
L
 -22.4%
H
7.8
10.3
|
L
 -26.3%
H
7.4
13.7
|
L
 0.6%
H
5.5
18
|
L
H
5.2
18
|
L
H
5.2
18
|
Kalaris Therapeutics Inc |
|
80.0
|
4.3
|
L
 -5.9%
H
4
4.7
|
L
 -6.4%
H
4
5
|
L
 60.3%
H
2.1
7.3
|
L
 39.0%
H
2.1
7.3
|
L
 463.2%
H
0.4
12.9
|
L
 -51.1%
H
0.4
12.9
|
L
 -80.7%
H
0.4
49.0
|
L
H
0.4
49.0
|
Alzamend Neuro Inc |
|
7.5
|
2.4
|
L
 2.1%
H
2.3
2.4
|
L
 1.7%
H
2.2
2.5
|
L
 2.1%
H
2.2
2.5
|
L
 -27.7%
H
2.1
3.6
|
L
 -87.4%
H
2.1
19.1
|
L
 -99.8%
H
2.1
2025
|
L
H
2.1
45292.5
|
L
H
2.1
45292.5
|
Amgen |
|
152,211.0
|
282.7
|
L
 1.5%
H
278
282.9
|
L
 -0.4%
H
275.2
285.3
|
L
 -1.9%
H
275.2
301.5
|
L
 -3.7%
H
267.8
311.3
|
L
 -14.1%
H
253.3
339.2
|
L
 14.1%
H
211.7
346.9
|
L
 17.5%
H
198.6
346.9
|
L
 84.6%
H
130.1
346.9
|
Amylyx Pharmaceuticals Inc |
|
1,055.7
|
11.8
|
L
 0.1%
H
11.4
12.1
|
L
 20.3%
H
9.7
12.3
|
L
 55.0%
H
7.6
12.3
|
L
 105.6%
H
4.8
12.3
|
L
 345.1%
H
2.4
12.3
|
L
 -60.4%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
Amphastar Pharmaceuticals Inc |
|
1,333.5
|
28.7
|
L
 1.0%
H
28.4
28.9
|
L
 -2.4%
H
28.3
29.8
|
L
 20.5%
H
24.7
31.3
|
L
 6.5%
H
20.4
31.3
|
L
 -35.4%
H
20.4
54.0
|
L
 1.8%
H
20.4
67.7
|
L
 47.3%
H
16.9
67.7
|
L
 108.3%
H
10.5
67.7
|
AnaptysBio Inc |
|
649.0
|
23.2
|
L
 1.8%
H
22.8
23.6
|
L
 3.0%
H
20.6
23.6
|
L
 10.3%
H
19.5
23.6
|
L
 -3.2%
H
19.2
28.5
|
L
 -34.0%
H
12.2
40.7
|
L
 -9.7%
H
12.2
41.3
|
L
 56.8%
H
12.2
41.3
|
L
H
10
134
|
Anebulo Pharmaceuticals Inc |
|
82.6
|
2.0
|
L
 -2.4%
H
1.8
2.1
|
L
 -18.3%
H
1.8
2.4
|
L
 -16.6%
H
1.8
2.8
|
L
 84.4%
H
1.1
3.4
|
L
 4.2%
H
0.8
3.4
|
L
 -47.8%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
ANI Pharmaceuticals Inc |
|
2,141.3
|
98.7
|
L
 1.3%
H
96.5
98.8
|
L
 4.0%
H
93.9
99.5
|
L
 21.2%
H
81.4
99.5
|
L
 57.0%
H
61.2
99.5
|
L
 78.0%
H
52.5
99.5
|
L
 166.2%
H
30.5
99.5
|
L
 256.7%
H
22.3
99.5
|
L
 90.0%
H
22.3
99.5
|
Anixa Biosciences Inc |
|
95.0
|
3.0
|
L
 -2.3%
H
2.9
3.0
|
L
 -1.3%
H
2.9
3.1
|
L
 -1.0%
H
2.9
3.2
|
L
 -15.5%
H
2.9
3.8
|
L
 -5.1%
H
2.1
4.2
|
L
 -28.7%
H
2.1
6.5
|
L
 48.2%
H
1.9
8.1
|
L
 -32.2%
H
0.6
8.1
|
Annexon Inc |
|
280.2
|
2.6
|
L
 11.4%
H
2.3
2.7
|
L
 24.4%
H
2.0
2.7
|
L
 8.1%
H
2.0
2.7
|
L
 -3.4%
H
1.9
3.1
|
L
 -59.2%
H
1.3
7.9
|
L
 -60.5%
H
1.3
8.4
|
L
 -90.0%
H
1.3
38.0
|
L
H
1.3
38.0
|
AN2 Therapeutics Inc |
|
34.7
|
1.3
|
L
 3.3%
H
1.2
1.3
|
L
 -1.6%
H
1.1
1.3
|
L
 17.6%
H
1.1
1.3
|
L
 14.4%
H
1.0
1.3
|
L
 23.3%
H
1.0
1.7
|
L
 -86.6%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
Applied Dna Sciences Inc |
|
3.3
|
2.5
|
L
 -2.7%
H
2.4
2.6
|
L
 -13.7%
H
2.1
3.8
|
L
 -40.8%
H
2.1
4.3
|
L
 -45.8%
H
2.1
6.0
|
L
 -99.7%
H
0.7
1410
|
L
 -100.0%
H
0.7
48000
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
5820000
|
Apollomics Inc Ordinary |
|
13.4
|
6.3
|
L
 1.3%
H
6.0
6.4
|
L
 49.6%
H
4.2
6.4
|
L
 10.4%
H
3.7
6.4
|
L
 -7.0%
H
3.7
8.2
|
L
 -53.0%
H
0.1
36.0
|
L
 -99.4%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
Apellis Pharmaceuticals Inc |
|
3,207.8
|
25.4
|
L
 -2.5%
H
24.8
26.3
|
L
 -8.6%
H
24.8
29.0
|
L
 4.2%
H
23.8
29.0
|
L
 29.7%
H
17.2
29.0
|
L
 -35.2%
H
16.1
39.5
|
L
 -62.4%
H
16.1
94.8
|
L
 -13.7%
H
16.1
94.8
|
L
H
11.5
94.8
|
Applied Therapeutics Inc |
|
63.4
|
0.4
|
L
H
0.4
0.5
|
L
 -13.7%
H
0.4
0.5
|
L
 2.3%
H
0.4
0.5
|
L
 12.8%
H
0.3
0.5
|
L
 -91.5%
H
0.3
10.6
|
L
 -69.9%
H
0.3
10.6
|
L
 -98.2%
H
0.3
29.8
|
L
H
0.3
57.4
|
Aptorum Group Ordinary |
|
13.2
|
1.9
|
L
 7.6%
H
1.7
2.0
|
L
 8.2%
H
1.6
2.0
|
L
 46.8%
H
1.3
4.5
|
L
 72.9%
H
0.9
4.5
|
L
 -36.2%
H
0.5
7.5
|
L
 -87.2%
H
0.5
17.5
|
L
 -89.5%
H
0.5
142.3
|
L
H
0.5
332.8
|
Aprea Therapeutics Inc |
|
9.1
|
1.6
|
L
 2.0%
H
1.6
1.7
|
L
 2.6%
H
1.5
1.7
|
L
 -7.7%
H
1.5
1.8
|
L
 -15.6%
H
1.5
2.2
|
L
 -52.1%
H
1.4
5.0
|
L
 -89.2%
H
1.4
20.8
|
L
 -99.7%
H
1.4
629
|
L
H
1.4
1062.2
|
Aptevo Therapeutics Inc |
|
4.9
|
1.5
|
L
H
1.5
1.5
|
L
 -11.2%
H
1.5
1.7
|
L
 -33.6%
H
1.5
2.2
|
L
 -67.9%
H
1.5
13.1
|
L
 -99.4%
H
1.5
381.5
|
L
 -100.0%
H
1.5
234432
|
L
 -100.0%
H
1.5
1953600
|
L
H
1.5
3778913.6
|
AquaBounty Technologies Inc |
|
4.5
|
1.2
|
L
H
1.2
1.2
|
L
 -1.7%
H
1.1
1.5
|
L
 53.3%
H
0.7
1.6
|
L
 30.7%
H
0.7
1.6
|
L
 22.3%
H
0.5
1.6
|
L
 -94.9%
H
0.5
23.6
|
L
 -98.4%
H
0.5
266.4
|
L
H
0.5
610
|
Aquestive Therapeutics Inc |
|
598.8
|
5.0
|
L
 1.4%
H
4.9
5.0
|
L
 25.3%
H
4.2
5.6
|
L
 26.9%
H
3.7
5.6
|
L
 38.3%
H
3.1
5.6
|
L
 7.4%
H
2.1
5.8
|
L
 239.0%
H
0.7
6.2
|
L
 -42.8%
H
0.6
9.5
|
L
H
0.6
20.7
|
Arcturus Therapeutics Holdings |
|
489.9
|
18.0
|
L
 0.3%
H
17.7
18.7
|
L
 4.9%
H
16.2
18.7
|
L
 51.5%
H
11.3
20.0
|
L
 39.8%
H
11.3
20.0
|
L
 -8.7%
H
8.0
25.9
|
L
 16.9%
H
8.0
45
|
L
 -55.4%
H
8.0
129.7
|
L
 -67.4%
H
4.1
129.7
|
Ardelyx Inc |
|
1,609.8
|
6.7
|
L
 0.6%
H
6.6
6.8
|
L
 2.6%
H
6.4
6.8
|
L
 28.2%
H
5.2
6.8
|
L
 78.6%
H
3.5
6.8
|
L
 17.4%
H
3.2
7.2
|
L
 421.9%
H
1.1
10.1
|
L
 13.8%
H
0.5
10.1
|
L
 -67.7%
H
0.5
22.5
|
Arcutis Biotherapeutics Inc |
|
2,121.1
|
17.7
|
L
 0.7%
H
17.5
17.9
|
L
 11.0%
H
15.9
18.2
|
L
 19.8%
H
14.0
18.2
|
L
 27.4%
H
12.7
18.2
|
L
 62.7%
H
8.0
18.2
|
L
 -13.4%
H
1.8
21.9
|
L
 -26.4%
H
1.8
38.5
|
L
H
1.8
40.9
|
Artelo Biosciences Inc |
|
6.5
|
4.9
|
L
 1.9%
H
4.6
5.1
|
L
 -43.8%
H
4.2
5.1
|
L
 -41.1%
H
4.2
10.6
|
L
 -27.4%
H
4.2
28.6
|
L
 -27.7%
H
4.2
28.6
|
L
 -79.0%
H
4.2
28.6
|
L
 -94.2%
H
4.2
330.3
|
L
H
4.2
15552
|
Arvinas Inc |
|
573.4
|
7.8
|
L
 -0.3%
H
7.7
8.1
|
L
 -1.1%
H
7.5
8.2
|
L
 24.2%
H
6.3
8.2
|
L
 -0.1%
H
6.1
8.3
|
L
 -69.4%
H
5.9
29.6
|
L
 -84.1%
H
5.9
58.0
|
L
 -67.9%
H
5.9
108.5
|
L
H
5.9
108.5
|
Arrowhead Pharmaceuticals Inc |
|
4,109.0
|
29.7
|
L
 2.9%
H
27.9
29.8
|
L
 6.9%
H
27.1
29.8
|
L
 81%
H
15.8
29.8
|
L
 75.1%
H
14.3
29.8
|
L
 38.4%
H
9.6
29.8
|
L
 -22.9%
H
9.6
42.5
|
L
 -15.6%
H
9.6
93.7
|
L
 419.6%
H
1.2
93.7
|
Assembly Biosciences Inc |
|
173.3
|
22.6
|
L
 1.5%
H
22.0
22.9
|
L
 -5.5%
H
22.0
25.3
|
L
 -5.8%
H
22.0
27.2
|
L
 31.0%
H
15.8
27.2
|
L
 34.9%
H
7.8
27.2
|
L
 -6.8%
H
7.7
27.2
|
L
 -89.3%
H
7.7
223.2
|
L
 -86.5%
H
7.7
808.3
|
ASP Isotopes Inc |
|
795.0
|
8.7
|
L
 3.4%
H
8.4
9.1
|
L
 7.5%
H
7.7
9.1
|
L
 -7.2%
H
7.7
11.7
|
L
 -0.7%
H
6.6
11.7
|
L
 272.8%
H
2.3
11.7
|
L
H
0.3
11.7
|
L
H
0.3
11.7
|
L
H
0.3
11.7
|
Assertio Holdings Inc |
|
77.0
|
0.8
|
L
H
0.8
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
 9.6%
H
0.7
0.9
|
L
 21.2%
H
0.6
0.9
|
L
 -35.5%
H
0.5
1.4
|
L
 -70.8%
H
0.5
8.0
|
L
 -72.4%
H
0.5
8.0
|
L
 -99.3%
H
0.5
117.8
|
ATAI Life Sciences NV |
|
986.0
|
4.6
|
L
 -2.5%
H
4.5
4.7
|
L
 1.8%
H
4.2
5.0
|
L
 11.4%
H
3.6
5.3
|
L
 104.4%
H
2
5.3
|
L
 268%
H
1.0
5.3
|
L
 5.7%
H
1.0
5.3
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
Athira Pharma Inc |
|
15.0
|
0.4
|
L
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 11.8%
H
0.3
0.5
|
L
 -22.5%
H
0.2
0.8
|
L
 -89.1%
H
0.2
4.4
|
L
H
0.2
34.8
|
L
H
0.2
34.8
|
ETHZilla Corp |
|
399.2
|
2.4
|
L
 -2.4%
H
2.3
2.6
|
L
 -4.4%
H
2.1
2.7
|
L
 -19.7%
H
2.1
17.5
|
L
 131.7%
H
0.7
17.5
|
L
 32.4%
H
0.7
17.8
|
L
 -99.2%
H
0.7
354.5
|
L
 -99.9%
H
0.7
4957.1
|
L
H
0.7
4957.1
|
Atossa Therapeutics Inc |
|
105.9
|
0.8
|
L
 2.5%
H
0.8
0.8
|
L
 6.5%
H
0.8
0.8
|
L
 3.8%
H
0.7
0.8
|
L
 -7.9%
H
0.7
1.0
|
L
 -43.8%
H
0.6
1.7
|
L
 -13.7%
H
0.5
2.3
|
L
 -60%
H
0.5
9.8
|
L
 -99.5%
H
0.5
221.4
|
Atara Biotherapeutics Inc |
|
85.4
|
12.2
|
L
 3.2%
H
11.8
12.2
|
L
 -3.7%
H
11.7
13.2
|
L
 11.0%
H
10.3
13.2
|
L
 33.3%
H
7.5
13.5
|
L
 41.6%
H
5
18.7
|
L
 -89.9%
H
0.4
141
|
L
 -96.6%
H
0.4
705
|
L
 -99.0%
H
0.4
1361.3
|
Astria Therapeutics Inc |
|
442.4
|
7.8
|
L
 4.7%
H
7.4
7.9
|
L
 12.2%
H
6.5
7.9
|
L
 24.8%
H
6.1
7.9
|
L
 37.3%
H
5.3
7.9
|
L
 -30.8%
H
3.6
12.9
|
L
 -20.6%
H
3.6
16.9
|
L
 -80.6%
H
2.4
47.8
|
L
 -98.8%
H
2.4
687
|
Aurinia Pharmaceuticals Inc |
|
1,682.2
|
12.8
|
L
 4.6%
H
12.2
12.8
|
L
 6.5%
H
12.0
12.8
|
L
 12.4%
H
11.2
12.8
|
L
 56.8%
H
7.3
12.8
|
L
 94.8%
H
6.4
12.8
|
L
 76.0%
H
4.1
12.8
|
L
 -10.3%
H
4.1
34.0
|
L
 277.0%
H
1.4
34.0
|
Aura Biosciences Inc |
|
412.5
|
6.6
|
L
 3.1%
H
6.4
6.7
|
L
 4.7%
H
6.2
6.7
|
L
 -2.4%
H
6.1
7.4
|
L
 -4.7%
H
5.9
7.5
|
L
 -26.4%
H
4.3
12.4
|
L
 -57.1%
H
4.3
19.2
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
Atea Pharmaceuticals Inc |
|
261.9
|
3.3
|
L
 4.8%
H
3.1
3.3
|
L
 -4.6%
H
3.1
3.5
|
L
 -2.4%
H
3.1
3.9
|
L
 2.5%
H
3.1
4.0
|
L
 -11.1%
H
2.5
4.0
|
L
 -58.1%
H
2.5
8.3
|
L
H
2.5
94.2
|
L
H
2.5
94.2
|
Tectonic Therapeutic Inc |
|
337.4
|
18.0
|
L
 4.2%
H
17.2
18.1
|
L
 10.5%
H
15.3
18.6
|
L
 -19.2%
H
15.3
27.3
|
L
 -28.3%
H
15.3
27.3
|
L
 3.0%
H
13.7
61.1
|
L
 69.5%
H
1.4
61.1
|
L
 -90.7%
H
1.4
240.8
|
L
H
1.4
644.4
|
Jade Biosciences Inc |
|
253.2
|
7.8
|
L
 2.4%
H
7.7
7.9
|
L
 3.5%
H
7.2
8.1
|
L
 3.6%
H
6.7
8.4
|
L
 9.9%
H
6.6
11.3
|
L
 -88.3%
H
6.6
105
|
L
 -98.7%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
Avalo Therapeutics Inc |
|
143.1
|
10.9
|
L
 -1.3%
H
10.7
11.6
|
L
 3.0%
H
10.1
12.4
|
L
 21.8%
H
8.3
12.4
|
L
 125.7%
H
4.5
12.4
|
L
 34.3%
H
3.4
16
|
L
 123.0%
H
0.0
34.5
|
L
 -64.7%
H
0.0
54
|
L
H
0.0
91.8
|
Anavex Life Sciences |
|
822.9
|
9.6
|
L
 7.9%
H
9
9.7
|
L
 0.7%
H
8.8
10.4
|
L
 -13.5%
H
8.8
11.7
|
L
 18.0%
H
8.0
14.0
|
L
 91.6%
H
4.9
14.4
|
L
 -7.0%
H
3.3
15.2
|
L
 146.9%
H
3.3
31.5
|
L
 74.8%
H
1.3
31.5
|
Axsome Therapeutics Inc |
|
6,135.9
|
123.0
|
L
 -0.9%
H
122.0
124.5
|
L
 0.8%
H
121.8
130
|
L
 17.3%
H
102.7
130
|
L
 11.9%
H
96.1
130
|
L
 32.7%
H
75.6
139.1
|
L
 98.1%
H
38.9
139.1
|
L
 68.4%
H
19.4
139.1
|
L
H
1.9
139.1
|
Aytu BioPharma Inc |
|
20.6
|
2.3
|
L
 0.9%
H
2.2
2.3
|
L
 -1.7%
H
2.2
2.4
|
L
 -3.0%
H
2.1
2.4
|
L
 13.9%
H
1.9
2.8
|
L
 -7.3%
H
1.0
2.8
|
L
 -49.2%
H
1.0
4.9
|
L
 -98.9%
H
1.0
280
|
L
 -100.0%
H
1.0
4320000
|
Aziyo Biologics Inc Ordinary |
|
-
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 -34.2%
H
1.3
2.1
|
L
 -34.8%
H
1.3
2.4
|
L
 -34.2%
H
1.3
2.6
|
L
 -23.8%
H
1.3
2.6
|
L
 -82.1%
H
1.1
9.0
|
L
H
1.1
18.2
|
L
H
1.1
18.2
|
Adagene Inc ADR |
|
110.3
|
2.3
|
L
 -2.1%
H
2.3
2.5
|
L
 7.3%
H
2.1
3.2
|
L
 7.8%
H
1.7
3.2
|
L
 19.4%
H
1.6
3.2
|
L
 -24.5%
H
1.3
3.6
|
L
 48.1%
H
0.9
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
Adaptimmune Therapeutics Plc |
|
13.3
|
0.1
|
L
H
0.1
0.1
|
L
H
0.0
0.1
|
L
 -37.5%
H
0.0
0.1
|
L
 -82.1%
H
0.0
0.4
|
L
 -95.4%
H
0.0
1.2
|
L
 -97.4%
H
0.0
2.7
|
L
 -99.4%
H
0.0
10.9
|
L
 -99.6%
H
0.0
14.8
|
Addex Therapeutics ADR |
|
9.4
|
8.8
|
L
 13.3%
H
7.7
8.8
|
L
 8.5%
H
7.7
8.8
|
L
 7.7%
H
7.5
8.8
|
L
 2.5%
H
7.5
9.9
|
L
 -16.7%
H
6.5
11.8
|
L
 -57.8%
H
5
45.6
|
L
 -96.7%
H
5
700
|
L
H
5
750.4
|
Akari Therapeutics Plc ADR |
|
25.1
|
0.8
|
L
 -2.5%
H
0.8
0.8
|
L
 16.7%
H
0.7
0.9
|
L
 -22.2%
H
0.6
1.1
|
L
 -39.8%
H
0.6
1.3
|
L
 -77.5%
H
0.6
3.9
|
L
 -96.3%
H
0.6
16.6
|
L
 -97.7%
H
0.6
84.2
|
L
 -99.8%
H
0.6
738.8
|
Amarin Corp ADR |
|
309.6
|
15.0
|
L
 -0.2%
H
14.8
15.2
|
L
 -0.5%
H
14.6
15.5
|
L
 -0.1%
H
14.6
16.5
|
L
 16.8%
H
12.3
17.5
|
L
 2395%
H
0.4
17.5
|
L
 992.7%
H
0.4
17.5
|
L
 258.1%
H
0.4
17.5
|
L
 526.4%
H
0.4
26.1
|
Argen X SE ADR |
|
46,727.3
|
763.5
|
L
 0.1%
H
745.8
773.3
|
L
 5.8%
H
729.7
779.0
|
L
 15.4%
H
631.5
779.0
|
L
 32.7%
H
510.1
779.0
|
L
 42.7%
H
510.1
779.0
|
L
 95.1%
H
327.7
779.0
|
L
 254.3%
H
217.9
779.0
|
L
H
17.3
779.0
|
Ascendis Pharma AS ADR |
|
11,969.8
|
197.7
|
L
 -0.4%
H
196.5
202.6
|
L
 -1.2%
H
195
208.2
|
L
 3.2%
H
187.2
208.2
|
L
 14.7%
H
160.9
208.2
|
L
 72.3%
H
111.1
208.2
|
L
 95.0%
H
64.3
208.2
|
L
 38.5%
H
61.6
208.2
|
L
 861.9%
H
11.9
208.2
|
Alterity Therapeutics ADR |
|
75.8
|
4.9
|
L
 -2.6%
H
4.9
5.1
|
L
 -2.6%
H
4.9
5.3
|
L
 -8.5%
H
4.9
5.6
|
L
 6.7%
H
3.8
7
|
L
 292.1%
H
1
7
|
L
 -13.3%
H
1
7
|
L
 -76.3%
H
1
35.8
|
L
 -90.4%
H
1
66.9
|
Autolus Therapeutics plc ADR |
|
380.6
|
1.4
|
L
 3.6%
H
1.4
1.5
|
L
 -0.7%
H
1.3
1.5
|
L
 -38.6%
H
1.3
2.5
|
L
 -38.6%
H
1.3
2.7
|
L
 -65.3%
H
1.1
5
|
L
 -52.3%
H
1.1
7.5
|
L
 -88.8%
H
1.1
14.4
|
L
H
1.1
53.2
|
Avadel Pharmaceuticals plc |
|
1,540.0
|
15.9
|
L
 0.3%
H
15.3
16
|
L
 8.2%
H
14.5
16.0
|
L
 24.4%
H
12.5
16.0
|
L
 55.0%
H
8.5
16.0
|
L
 10.2%
H
6.4
16.7
|
L
 156.2%
H
4.6
19.1
|
L
 186.3%
H
1.1
19.1
|
L
 -31.9%
H
1.0
25.0
|
Astrazeneca plc ADR |
|
251,450.7
|
81.1
|
L
 0.4%
H
80.7
81.3
|
L
 -1.2%
H
80.2
82.4
|
L
 10.3%
H
73.7
82.4
|
L
 9.9%
H
68.6
82.4
|
L
 -0.1%
H
61.2
82.4
|
L
 33.3%
H
52.7
87.7
|
L
 52.8%
H
46.5
87.7
|
L
 143.7%
H
25.6
87.7
|
BridgeBio Pharma Inc |
|
10,055.5
|
52.6
|
L
 -0.7%
H
52.4
53.6
|
L
 1.5%
H
50.5
54.6
|
L
 12.9%
H
46.3
54.6
|
L
 31.2%
H
38.6
54.6
|
L
 75.4%
H
21.7
54.6
|
L
 345.4%
H
6.6
54.6
|
L
 59.0%
H
5.0
73.5
|
L
H
5.0
73.5
|
BioAtla Inc |
|
45.2
|
0.8
|
L
 14.9%
H
0.7
0.8
|
L
 57.1%
H
0.5
0.8
|
L
 120%
H
0.3
0.8
|
L
 60.4%
H
0.3
0.8
|
L
 -57.5%
H
0.2
2.5
|
L
 -91.3%
H
0.2
11.7
|
L
H
0.2
76.6
|
L
H
0.2
76.6
|
BioCardia Inc |
|
13.2
|
2.3
|
L
 7.1%
H
2.1
2.3
|
L
 11.3%
H
2.0
2.3
|
L
 26.8%
H
1.7
2.3
|
L
 -0.9%
H
1.7
2.5
|
L
 -11.7%
H
1.6
3.3
|
L
 -92.1%
H
1.6
43.8
|
L
 -93.1%
H
1.6
129
|
L
 -98.2%
H
1.6
2073.6
|
Biocryst Pharmaceuticals Inc |
|
1,694.1
|
8.1
|
L
 0.8%
H
8.0
8.1
|
L
 -2.7%
H
7.9
8.4
|
L
 -2.8%
H
7.9
8.7
|
L
 -26.7%
H
7.9
11.1
|
L
 4.5%
H
6.0
11.3
|
L
 -40%
H
4.0
14.5
|
L
 115.8%
H
3.3
20.0
|
L
 -35.3%
H
1.4
20.0
|
BriaCell Therapeutics Corp |
|
14.3
|
8.1
|
L
 4.9%
H
7.8
8.2
|
L
 -1.5%
H
7.6
8.3
|
L
 -88.6%
H
7.3
79
|
L
 -97.7%
H
7.3
360
|
L
 -99.1%
H
7.3
2940
|
L
 -99.9%
H
7.3
12316.5
|
L
 -99.9%
H
7.3
18526.5
|
L
 -100.0%
H
7.3
138373.2
|
Black Diamond Therapeutics Inc |
|
191.9
|
3.4
|
L
 5.0%
H
3.2
3.4
|
L
 17.0%
H
2.8
3.4
|
L
 40.4%
H
2.3
3.4
|
L
 37.0%
H
2.2
3.4
|
L
 -44.4%
H
1.2
6.3
|
L
 14.6%
H
1.2
7.7
|
L
 -88.4%
H
1.2
37.8
|
L
H
1.2
46.3
|
Beam Therapeutics Inc |
|
2,180.0
|
21.6
|
L
 8.4%
H
19.6
21.6
|
L
 14.9%
H
17.7
21.6
|
L
 22.3%
H
15.6
21.6
|
L
 19.2%
H
15.6
22.8
|
L
 -8.9%
H
13.5
35.3
|
L
 -62.5%
H
13.5
61.4
|
L
 -16.2%
H
13.5
138.5
|
L
H
13
138.5
|
Biofrontera Inc |
|
8.9
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -4.6%
H
0.8
0.9
|
L
 -12.6%
H
0.8
1.1
|
L
 36.1%
H
0.6
1.2
|
L
 -27.2%
H
0.5
2.2
|
L
 -96.7%
H
0.5
25.8
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
Biogen |
|
21,822.1
|
148.8
|
L
 4.4%
H
142.9
149.1
|
L
 5.1%
H
137.1
149.1
|
L
 13.9%
H
127.7
149.1
|
L
 9.9%
H
121.1
149.1
|
L
 -25.8%
H
110.0
204.2
|
L
 -29.7%
H
110.0
319.8
|
L
 -44.2%
H
110.0
468.6
|
L
 -48.3%
H
110.0
468.6
|
BioVie Inc |
|
14.2
|
1.9
|
L
 -1.6%
H
1.9
2
|
L
 12.6%
H
1.5
2
|
L
 12.6%
H
1.4
2
|
L
 -82.9%
H
1.4
12.1
|
L
 -93.1%
H
1.4
75
|
L
 -99.3%
H
1.4
1438
|
L
 -99.9%
H
1.4
4609.8
|
L
 -99.9%
H
1.4
5625
|
Biomea Fusion Inc |
|
117.8
|
2.0
|
L
 7.6%
H
1.9
2.0
|
L
 3.1%
H
1.8
2.0
|
L
 28.6%
H
1.5
2.1
|
L
 -21.7%
H
1.5
3.1
|
L
 -73.9%
H
1.3
13.1
|
L
 -85.1%
H
1.3
43.7
|
L
H
1.3
43.7
|
L
H
1.3
43.7
|
Biomarin Pharmaceutical Inc |
|
10,735.5
|
55.9
|
L
 2.6%
H
54.2
55.9
|
L
 -5.2%
H
54.2
58.9
|
L
 -2.5%
H
54.2
59.8
|
L
 -2.7%
H
53.7
64.0
|
L
 -34.1%
H
52.9
85
|
L
 -39.8%
H
52.9
117.8
|
L
 -22.2%
H
52.9
117.8
|
L
 -58.0%
H
52.9
133.9
|
Bionano Genomics Inc |
|
19.0
|
4.1
|
L
 -17.5%
H
3.9
5.5
|
L
 4.6%
H
3.6
5.5
|
L
 39.5%
H
2.9
5.5
|
L
 10.6%
H
2.9
5.5
|
L
 822.7%
H
0.1
11.6
|
L
 -83.8%
H
0.1
30.1
|
L
 -24.4%
H
0.1
156.9
|
L
H
0.1
156.9
|
Benitec Biopharma Inc |
|
367.0
|
14.0
|
L
 4.8%
H
13.3
14.0
|
L
 0.5%
H
13.3
14.3
|
L
 18.5%
H
11.1
14.3
|
L
 -13.6%
H
10.5
17.1
|
L
 59.8%
H
8.1
17.2
|
L
 20.9%
H
1.9
17.2
|
L
 -85.7%
H
1.9
178.3
|
L
 -99.2%
H
1.9
1876.8
|
Bolt Biotherapeutics Inc |
|
10.1
|
5.3
|
L
 0.2%
H
5.3
5.4
|
L
 8.9%
H
4.8
5.5
|
L
 -5.4%
H
4.6
6.0
|
L
 -20.6%
H
4.6
6.9
|
L
 -58.3%
H
4.6
14.4
|
L
 -85.1%
H
4.6
40.6
|
L
H
4.6
861.4
|
L
H
4.6
861.4
|
Bon Natural Life |
|
6.8
|
1.8
|
L
 -5.7%
H
1.8
2.0
|
L
 23.0%
H
1.5
3.4
|
L
 38.9%
H
1.3
3.4
|
L
 10.3%
H
1.2
3.4
|
L
 -95.2%
H
1.1
73.8
|
L
 -99.6%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
23052.5
|
BioXcel Therapeutics Inc |
|
54.3
|
3.4
|
L
 -3.7%
H
3.4
3.8
|
L
 -6.4%
H
3.4
4.3
|
L
 -16.1%
H
3.4
8.1
|
L
 70.4%
H
1.3
8.1
|
L
 527.8%
H
0.2
8.1
|
L
 -76.8%
H
0.2
34.1
|
L
 -92.3%
H
0.2
67.7
|
L
H
0.2
71.5
|
Blue Water Biotech Inc |
|
55.8
|
3.1
|
L
 13.8%
H
2.8
3.2
|
L
 6.5%
H
2.6
3.2
|
L
 10.2%
H
2.6
3.2
|
L
 3812.5%
H
0.1
5.9
|
L
 3812.5%
H
0.1
5.9
|
L
 7.9%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
BeyondSpring Inc |
|
75.4
|
1.9
|
L
 -2.1%
H
1.9
1.9
|
L
 2.8%
H
1.8
2
|
L
 -6.5%
H
1.7
2.1
|
L
 -25.5%
H
1.7
3.4
|
L
 -10.5%
H
1.0
3.4
|
L
 20.6%
H
0.5
4
|
L
 -86.5%
H
0.5
33
|
L
H
0.5
48.5
|
Bicycle Therapeutics Plc ADR |
|
486.5
|
7.0
|
L
 0.3%
H
6.8
7.3
|
L
 -1.1%
H
6.8
7.3
|
L
 -8.2%
H
6.8
8.1
|
L
 -18.8%
H
6.8
9.4
|
L
 -74.0%
H
6.1
28.7
|
L
 -72.0%
H
6.1
33.5
|
L
 -57.5%
H
6.1
62.1
|
L
H
6.1
62.1
|
Biodexa Pharmaceuticals Plc |
|
3.7
|
5.9
|
L
 3.3%
H
5.6
6.3
|
L
 4.2%
H
5
6.3
|
L
 -16.8%
H
5
7.2
|
L
 -48.0%
H
5
13.3
|
L
 -99.8%
H
5
2701.3
|
L
 -100.0%
H
5
10400000
|
L
 -100.0%
H
5
38295000
|
L
H
5
4045000000
|
BeiGene ADR |
|
35,757.7
|
335.7
|
L
 6.9%
H
324.5
336.8
|
L
 -0.2%
H
312.3
351.3
|
L
 16.5%
H
283.1
351.3
|
L
 27.4%
H
239.3
351.3
|
L
 69.8%
H
171.0
351.3
|
L
 96.6%
H
124.5
351.3
|
L
 40.9%
H
118.2
426.6
|
L
H
22.5
426.6
|
Bioline Rx ADR |
|
17.1
|
4.0
|
L
 -5.4%
H
3.8
4.1
|
L
 10.5%
H
3.4
4.4
|
L
 12.6%
H
3.4
4.4
|
L
 -31.1%
H
3.4
5.9
|
L
 -84.1%
H
0.1
26.8
|
L
 -94.5%
H
0.1
101.2
|
L
 -93.9%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1128
|
Belite Bio Inc ADR |
|
2,250.7
|
68.6
|
L
 3.4%
H
66
69.3
|
L
 7.9%
H
64
69.7
|
L
 -1.9%
H
60
74.5
|
L
 12.0%
H
56.1
74.5
|
L
 40.2%
H
43.7
86.5
|
L
 77.5%
H
11
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
Neuphoria Therapeutics Inc |
|
26.3
|
14.0
|
L
 0.5%
H
14.0
14.3
|
L
 7.6%
H
11.4
15.1
|
L
 88.3%
H
6.8
15.1
|
L
 94.9%
H
6.0
15.1
|
L
 2271.2%
H
0.2
15.1
|
L
 70.6%
H
0.2
15.1
|
L
H
0.2
22
|
L
H
0.2
22
|
BioNTech SE ADR |
|
25,076.0
|
104.3
|
L
 3.3%
H
100.7
104.5
|
L
 3.9%
H
99.8
114.9
|
L
 -6.6%
H
99.0
114.9
|
L
 -2.4%
H
99.0
115.5
|
L
 3.7%
H
81.2
131.5
|
L
 -30.9%
H
76.5
189.0
|
L
 70.4%
H
58.8
464
|
L
H
12.5
464
|
Biondvax Pharmaceuticals ADR |
|
-
|
1.6
|
L
 2.6%
H
1.5
1.6
|
L
 -1.9%
H
1.5
1.6
|
L
 4.0%
H
1.4
2.0
|
L
 -38.3%
H
1.4
3.5
|
L
 -45.7%
H
1.4
6.2
|
L
 -84.9%
H
0.6
99
|
L
 -99.6%
H
0.6
435.7
|
L
 -95.9%
H
0.6
620
|
Cabaletta Bio Inc |
|
165.6
|
1.8
|
L
 4.0%
H
1.7
1.8
|
L
 15.3%
H
1.4
1.8
|
L
 33.1%
H
1.3
1.8
|
L
 -23.0%
H
1.3
2.1
|
L
 -59.2%
H
1.0
5.5
|
L
 92.6%
H
0.6
26.4
|
L
 -82.5%
H
0.6
26.4
|
L
H
0.6
26.4
|
CalciMedica Inc |
|
47.9
|
3.4
|
L
 -1.7%
H
3.2
3.6
|
L
 6.5%
H
3
3.7
|
L
 25.2%
H
2.3
3.7
|
L
 85.4%
H
1.4
4.3
|
L
 -29.6%
H
1.4
5.5
|
L
 -77.1%
H
1
16.4
|
L
H
1
530.3
|
L
H
1
530.3
|
Capricor Therapeutics Inc |
|
294.4
|
6.4
|
L
 1.7%
H
6.0
6.5
|
L
 2.6%
H
5.7
6.8
|
L
 -29%
H
5.7
8.6
|
L
 -53.6%
H
5.7
14.3
|
L
 50.5%
H
4.1
23.4
|
L
 9.2%
H
2.7
23.4
|
L
 37.6%
H
2.6
23.4
|
L
 -83.9%
H
0.9
54
|
Tvardi Therapeutics Inc |
|
332.0
|
35.4
|
L
 7.8%
H
32.3
35.8
|
L
 23.1%
H
28.7
35.8
|
L
 48.0%
H
22.7
35.8
|
L
 35.9%
H
21.1
35.8
|
L
 249.8%
H
8.1
35.8
|
L
 -91.0%
H
8.1
461.2
|
L
 -93.5%
H
8.1
1067.3
|
L
 -95.2%
H
8.1
1067.3
|
Carisma Therapeutics Inc |
|
15.9
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 2.7%
H
0.3
0.4
|
L
 40.7%
H
0.2
0.6
|
L
 -65.8%
H
0.2
0.8
|
L
 -61.6%
H
0.1
1.3
|
L
 -97.1%
H
0.1
13.7
|
L
 -98.1%
H
0.1
120.8
|
L
 -99.4%
H
0.1
120.8
|
CASI Pharmaceuticals Inc |
|
36.1
|
2.3
|
L
 -1.3%
H
2.3
2.5
|
L
H
2.2
2.5
|
L
 42.9%
H
1.6
3.1
|
L
 24.6%
H
1.1
3.1
|
L
 -68.3%
H
1.1
7.7
|
L
 -45.7%
H
1.1
8.5
|
L
 -85.5%
H
1.1
39
|
L
 -80.9%
H
1.1
88.9
|
Crescent Biopharma Inc |
|
-
|
12.6
|
L
 2.6%
H
12.3
13
|
L
 -5.1%
H
12.1
14.5
|
L
 -2.3%
H
12.1
15.8
|
L
 39.4%
H
7.9
21.4
|
L
 10.6%
H
7.6
21.4
|
L
 163.7%
H
2.8
21.4
|
L
 10.8%
H
0.9
21.4
|
L
 -96.5%
H
0.9
368.7
|
C4 Therapeutics Inc |
|
194.3
|
2.7
|
L
 3.4%
H
2.6
2.8
|
L
 6.6%
H
2.6
2.9
|
L
 9.2%
H
2.2
3.1
|
L
 73.9%
H
1.4
3.1
|
L
 -58.1%
H
1.1
7.2
|
L
 -75.7%
H
1.1
12.6
|
L
H
1.1
51.2
|
L
H
1.1
51.2
|
Cidara Therapeutics Inc |
|
1,645.0
|
64.9
|
L
 2.3%
H
62.9
65.4
|
L
 2.3%
H
61.0
66.5
|
L
 4.6%
H
59.8
69.4
|
L
 147.9%
H
20.2
69.4
|
L
 442.9%
H
10.1
69.4
|
L
 -76.7%
H
10
840
|
L
 -94.4%
H
10
1358.6
|
L
 -98.9%
H
10
7228
|
Niagen Bioscience Inc |
|
767.2
|
9.6
|
L
 0.2%
H
9.5
9.8
|
L
 -0.5%
H
9.1
9.8
|
L
 -1.1%
H
9.1
10.5
|
L
 -28.9%
H
8.8
14.7
|
L
 190.6%
H
3.2
14.7
|
L
 572.7%
H
1.2
14.7
|
L
 116.2%
H
1.2
23.7
|
L
 124.8%
H
1.2
23.7
|
Cullinan Oncology Inc |
|
391.1
|
6.6
|
L
 2.3%
H
6.5
6.6
|
L
 -14.3%
H
6.4
7.7
|
L
 -9.3%
H
6.4
8.3
|
L
 -26.7%
H
6.4
9.3
|
L
 -62.9%
H
6.4
18.6
|
L
 -51.2%
H
6.4
30.2
|
L
H
6.4
59.9
|
L
H
6.4
59.9
|
Compugen |
|
130.9
|
1.4
|
L
H
1.4
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -6.7%
H
1.4
1.6
|
L
 -21.8%
H
1.4
1.8
|
L
 -27.8%
H
1.1
2.7
|
L
 34.6%
H
0.5
3.0
|
L
 -90.6%
H
0.5
18.9
|
L
 -73.7%
H
0.5
19.9
|
Cognition Therapeutics Inc |
|
208.2
|
2.4
|
L
 -6.0%
H
2.3
2.6
|
L
 -0.4%
H
2.3
2.7
|
L
 210.5%
H
0.8
3.8
|
L
 661.3%
H
0.3
3.8
|
L
 286.9%
H
0.2
3.8
|
L
 27.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
Coherus Biosciences Inc |
|
154.6
|
1.3
|
L
 1.5%
H
1.3
1.3
|
L
 5.6%
H
1.3
1.4
|
L
 62.2%
H
0.8
1.4
|
L
 66.3%
H
0.7
1.4
|
L
 -2.2%
H
0.7
2.4
|
L
 -87.4%
H
0.7
11.0
|
L
 -92.7%
H
0.7
22.2
|
L
 -94.8%
H
0.7
32.0
|
Cingulate Inc |
|
21.3
|
3.9
|
L
 2.3%
H
3.8
4.1
|
L
 6.2%
H
3.6
4.1
|
L
 -5.8%
H
3.5
4.4
|
L
 -20.6%
H
3.5
6.0
|
L
 -27.9%
H
3.0
7
|
L
 153.5%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
Clene Inc |
|
61.7
|
6.2
|
L
 -4.5%
H
6.1
6.7
|
L
 10.6%
H
5.7
7.1
|
L
 67.9%
H
3.5
7.1
|
L
 45.1%
H
3.3
7.1
|
L
 6.2%
H
2.3
7.1
|
L
 -89.1%
H
2.3
64.6
|
L
 1023.6%
H
0.5
356.4
|
L
H
0.5
356.4
|
Cellectar Biosciences Inc |
|
16.9
|
5.3
|
L
 5.6%
H
4.8
5.3
|
L
 10.5%
H
4.6
5.3
|
L
 11.6%
H
4.1
5.3
|
L
 -51.9%
H
4.1
14.0
|
L
 -91.7%
H
4.1
67.5
|
L
 -96.4%
H
4.1
148.5
|
L
 -98.4%
H
4.1
894
|
L
 -100.0%
H
4.1
93720
|
Clearside Biomedical Inc |
|
27.5
|
0.4
|
L
 6.1%
H
0.3
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -14.6%
H
0.3
0.5
|
L
 -56.8%
H
0.3
0.9
|
L
 -69.0%
H
0.3
1.7
|
L
 -73.9%
H
0.3
2.1
|
L
 -78.9%
H
0.3
7.7
|
L
H
0.3
25.1
|
Clearmind Medicine Inc |
|
5.6
|
1.1
|
L
 2.9%
H
1.0
1.1
|
L
 4.0%
H
1.0
1.1
|
L
 6.1%
H
1.0
1.1
|
L
 16.7%
H
0.8
1.3
|
L
 -21.1%
H
0.8
2.2
|
L
 -85.4%
H
0.1
9
|
L
 -11.8%
H
0.1
21.9
|
L
H
0.1
21.9
|
Compass Therapeutics Inc |
|
605.7
|
3.5
|
L
 0.3%
H
3.4
3.7
|
L
 4.8%
H
3.3
3.7
|
L
 30.7%
H
2.7
3.7
|
L
 40.6%
H
2.2
3.7
|
L
 123.4%
H
1.3
4.1
|
L
 18.1%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
Cns Pharmaceuticals Inc |
|
4.3
|
7.5
|
L
 7.4%
H
6.8
7.7
|
L
 22.9%
H
5.9
7.7
|
L
 12.2%
H
4.9
7.7
|
L
 -36.1%
H
4.9
12.4
|
L
 -99.8%
H
4.9
11100
|
L
 -100.0%
H
4.9
12960000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
Context Therapeutics Inc |
|
75.4
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
H
0.8
0.9
|
L
 16.7%
H
0.7
0.9
|
L
 25.4%
H
0.6
1
|
L
 -60.6%
H
0.5
2.6
|
L
 -53.8%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
Cocrystal Pharma Inc |
|
14.8
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -1.4%
H
1.4
1.6
|
L
 -11.1%
H
1.4
1.7
|
L
 -10.6%
H
1.4
2.2
|
L
 -15.8%
H
1.1
3.3
|
L
 -66.7%
H
1.1
4.6
|
L
 -86.9%
H
1.1
41.5
|
L
 -99.5%
H
1.1
331.2
|
CoDiagnostics Inc |
|
13.1
|
0.3
|
L
 9.7%
H
0.3
0.4
|
L
 3.0%
H
0.3
0.4
|
L
 36%
H
0.3
0.4
|
L
 17.2%
H
0.2
0.4
|
L
 -73.2%
H
0.2
1.4
|
L
 -89.6%
H
0.2
3.8
|
L
 -97.1%
H
0.2
20.7
|
L
H
0.2
31.0
|
Coeptis Therapeutics Holdings |
|
59.9
|
12.4
|
L
 -0.6%
H
12.1
12.5
|
L
 -3.1%
H
11.8
13.5
|
L
 11.4%
H
10.8
14.7
|
L
 36%
H
6.8
14.7
|
L
 249.2%
H
2.3
14.7
|
L
 21.9%
H
2.3
242.6
|
L
H
2.3
242.6
|
L
H
2.3
242.6
|
Cogent Biosciences Inc |
|
1,789.6
|
12.8
|
L
 0.5%
H
12.6
12.9
|
L
 -2.1%
H
12.5
13.2
|
L
 16.9%
H
10.7
13.5
|
L
 72.6%
H
6.9
13.5
|
L
 19.9%
H
3.7
13.5
|
L
 -21.8%
H
3.7
17.5
|
L
 32.3%
H
3.7
18.1
|
L
H
1.2
70.6
|
Collegium Pharmaceutical Inc |
|
1,230.5
|
39.1
|
L
 3.6%
H
37.5
39.1
|
L
 -1.3%
H
37.1
39.6
|
L
 11.8%
H
34.9
40.0
|
L
 28.6%
H
29.1
40.0
|
L
 8.3%
H
23.2
42.3
|
L
 125.3%
H
15.4
42.3
|
L
 115.1%
H
14.0
42.3
|
L
 190.4%
H
7.4
42.3
|
Corcept Therapeutics Inc |
|
7,832.3
|
74.3
|
L
 3.8%
H
71.4
74.5
|
L
 4.2%
H
67.3
74.5
|
L
 2.8%
H
67.3
75.2
|
L
 2.9%
H
62.4
77.4
|
L
 112.2%
H
34.9
117.3
|
L
 186.0%
H
17.9
117.3
|
L
 307.5%
H
15.8
117.3
|
L
 1371.9%
H
3.2
117.3
|
Cosmos Health Inc |
|
25.4
|
0.8
|
L
 10.5%
H
0.7
0.9
|
L
 7.7%
H
0.6
0.9
|
L
 5%
H
0.6
1
|
L
 71.4%
H
0.4
1.3
|
L
 -23.6%
H
0.3
1.3
|
L
 -90.3%
H
0.3
23.8
|
L
 -99.0%
H
0.3
225
|
L
 -99.4%
H
0.3
312.5
|
Cumberland Pharmaceuticals Inc |
|
51.3
|
3.4
|
L
 0.9%
H
3.4
3.5
|
L
 -5.0%
H
3.3
3.7
|
L
 6.2%
H
2.6
3.7
|
L
 -37.8%
H
2.5
5.9
|
L
 165.9%
H
1.0
7.3
|
L
 52.4%
H
1.0
7.3
|
L
 4.9%
H
1.0
7.5
|
L
 -42.8%
H
1.0
8.0
|
Catalyst Pharmaceuticals Inc |
|
2,478.4
|
20.3
|
L
 2.6%
H
19.7
20.3
|
L
 2.3%
H
19.2
20.8
|
L
 2.0%
H
19.2
21.8
|
L
 -23.0%
H
19.2
26.5
|
L
 4.6%
H
19
26.6
|
L
 37.1%
H
11.1
26.6
|
L
 536.8%
H
2.9
26.6
|
L
 389.1%
H
0.5
26.6
|
Corbus Pharmaceuticals |
|
116.4
|
9.5
|
L
 -1.7%
H
9.3
9.7
|
L
 -3.6%
H
9.3
10.2
|
L
 12.7%
H
8.6
10.7
|
L
 2.8%
H
6.7
10.7
|
L
 -83.1%
H
4.6
56.9
|
L
 54.0%
H
2.1
61.9
|
L
 -86.0%
H
2.1
120
|
L
 -82.9%
H
2.1
323.4
|
Caribou Biosciences Inc |
|
177.9
|
1.9
|
L
 7.3%
H
1.8
1.9
|
L
 1.1%
H
1.8
1.9
|
L
 10.4%
H
1.6
2.2
|
L
 56.6%
H
1.0
2.7
|
L
 -2.6%
H
0.7
3
|
L
 -83.3%
H
0.7
13.2
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
Cardiol Therapeutics Inc |
|
89.6
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -1.8%
H
1.0
1.1
|
L
 8.1%
H
1.0
1.4
|
L
 -26.2%
H
0.9
1.6
|
L
 -48.8%
H
0.8
2.6
|
L
 -7.0%
H
0.5
3.1
|
L
 -66.5%
H
0.5
5.3
|
L
H
0.5
8.5
|
Curis Inc |
|
22.7
|
1.8
|
L
 1.7%
H
1.8
2.0
|
L
 5.8%
H
1.6
2.0
|
L
 6.4%
H
1.5
2.0
|
L
 -27.5%
H
1.5
3.1
|
L
 -63.1%
H
1.0
6.4
|
L
 -90.5%
H
1.0
20
|
L
 -91.3%
H
1.0
348
|
L
 -99.3%
H
1.0
372
|
CorMedix Inc |
|
977.2
|
13.1
|
L
 2.4%
H
12.8
13.3
|
L
 -4.5%
H
11.6
13.9
|
L
 26.7%
H
9.9
15.0
|
L
 -12.1%
H
9.6
17.4
|
L
 110.1%
H
5.6
17.4
|
L
 251.9%
H
2.6
17.4
|
L
 190.9%
H
2.6
18.8
|
L
 1.1%
H
0.9
22.7
|
Crinetics Pharmaceuticals Inc |
|
3,176.6
|
33.7
|
L
 -3.6%
H
33.2
34.5
|
L
 -2.7%
H
33.2
37.2
|
L
 25.6%
H
26.5
37.2
|
L
 2.0%
H
25.8
37.2
|
L
 -33.1%
H
24.1
62.5
|
L
 60.4%
H
15.2
62.5
|
L
 120.0%
H
11.6
62.5
|
L
H
10.6
62.5
|
Cronos Group Inc |
|
988.0
|
2.6
|
L
 2.0%
H
2.5
2.6
|
L
 2.0%
H
2.5
2.6
|
L
 12.2%
H
2.4
2.8
|
L
 32.3%
H
1.8
2.8
|
L
 17.3%
H
1.6
2.8
|
L
 -18.9%
H
1.6
3.6
|
L
 -51.2%
H
1.6
15.8
|
L
H
0.2
25.1
|
CRISPR Therapeutics AG |
|
5,083.2
|
55.9
|
L
 7.9%
H
51.9
56
|
L
 5.5%
H
51.6
56
|
L
 1.6%
H
50.8
61.4
|
L
 30.2%
H
39.8
71.1
|
L
 22.6%
H
30.0
71.1
|
L
 -16.5%
H
30.0
91.1
|
L
 -31.7%
H
30.0
220.2
|
L
H
11.6
220.2
|
Corvus Pharmaceuticals Inc |
|
451.6
|
6.1
|
L
 2.2%
H
5.9
6.1
|
L
 7.8%
H
5.6
6.3
|
L
 40.6%
H
4.3
6.3
|
L
 42.6%
H
3.6
6.3
|
L
 30.6%
H
2.5
10
|
L
 506%
H
0.6
10
|
L
 53.4%
H
0.6
10
|
L
H
0.6
22.1
|
Champions Oncology Inc |
|
89.1
|
6.5
|
L
 0.3%
H
6.3
6.6
|
L
 -7.1%
H
6.3
7.0
|
L
 0.8%
H
6.1
8.2
|
L
H
5.9
9.6
|
L
 63.5%
H
3.8
12.0
|
L
 -12.8%
H
3.6
12.0
|
L
 -8.4%
H
3.6
14.7
|
L
 -5%
H
1.1
17.9
|
CytomX Therapeutics Inc |
|
344.7
|
2.1
|
L
 1.0%
H
2.0
2.2
|
L
 -1.4%
H
2.0
2.3
|
L
 -11.1%
H
1.7
2.4
|
L
 -22.6%
H
1.7
3.1
|
L
 59.5%
H
0.4
3.1
|
L
 30.6%
H
0.4
5.9
|
L
 -69.5%
H
0.4
10.1
|
L
H
0.4
35
|
Cue Biopharma Inc |
|
59.2
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -2.5%
H
0.8
0.8
|
L
 -7.2%
H
0.8
0.9
|
L
 22.2%
H
0.5
1.0
|
L
 35.1%
H
0.5
2.0
|
L
 -76.5%
H
0.5
5.1
|
L
 -95.3%
H
0.5
18.4
|
L
H
0.5
31.7
|
CureVac NV |
|
1,213.7
|
5.4
|
L
 0.2%
H
5.4
5.4
|
L
 0.6%
H
5.3
5.4
|
L
 -0.9%
H
5.3
5.5
|
L
 26.2%
H
4.1
5.7
|
L
 76.7%
H
2.4
5.7
|
L
 -44.3%
H
2.2
12.8
|
L
 -90.2%
H
2.2
151.8
|
L
H
2.2
151.8
|
Cadrenal Therapeutics Inc |
|
27.6
|
13.5
|
L
 1.9%
H
13.3
13.7
|
L
 4.9%
H
12.4
13.7
|
L
 21.1%
H
10.3
14.1
|
L
 -10%
H
8.7
16.0
|
L
 91.2%
H
7.1
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
Cyclacel Pharmaceuticals Inc |
|
14.2
|
6.4
|
L
 -6.1%
H
6.1
7.0
|
L
 -17.2%
H
5.9
7.6
|
L
 -27.6%
H
5.9
9.5
|
L
 52.2%
H
3.1
19.9
|
L
 -97.5%
H
3.1
597.6
|
L
 -99.9%
H
3.1
6300
|
L
 -99.9%
H
3.1
41112
|
L
 -100.0%
H
3.1
907200
|
Cyclerion Therapeutics Inc |
|
8.2
|
2.6
|
L
 8.1%
H
2.4
2.6
|
L
 5.4%
H
2.1
2.6
|
L
 11.4%
H
2.1
2.9
|
L
 -18.8%
H
2.1
3.7
|
L
 -7.3%
H
1.3
8.4
|
L
 -86.6%
H
1.3
21.8
|
L
 -98.1%
H
1.3
179.2
|
L
H
1.3
457
|
Cytokinetics Inc |
|
6,380.1
|
53.3
|
L
 2.5%
H
51.5
53.6
|
L
 6.7%
H
48.9
54.2
|
L
 56.3%
H
32.9
54.2
|
L
 54.4%
H
32.0
54.2
|
L
 -1.5%
H
29.3
59.4
|
L
 -2.2%
H
26.0
110
|
L
 134.0%
H
14.7
110
|
L
 621.5%
H
5.8
110
|
Cellectis ADR |
|
299.0
|
3.0
|
L
 -2.3%
H
2.9
3.4
|
L
 15.1%
H
2.5
3.4
|
L
 14.6%
H
2.5
3.4
|
L
 111.4%
H
1.3
3.4
|
L
 34.2%
H
1.1
3.4
|
L
 -11.3%
H
1.0
4.0
|
L
 -82.6%
H
1.0
34.7
|
L
 -90.9%
H
1.0
45.3
|
Chemomab Therapeutics ADR |
|
15.8
|
3.1
|
L
 2.0%
H
3.0
3.1
|
L
 1.0%
H
3.0
3.1
|
L
 -21.4%
H
3.0
4.1
|
L
 -41.4%
H
3.0
5.2
|
L
 -64.2%
H
3.0
9.8
|
L
 -78.0%
H
1.7
21.4
|
L
 -95.1%
H
1.7
675.2
|
L
H
1.7
736
|
Compass Pathways Plc ADR |
|
502.7
|
5.2
|
L
 3.8%
H
5
5.3
|
L
 11.3%
H
4.7
5.4
|
L
 19.4%
H
4.0
5.4
|
L
 10.1%
H
2.3
5.4
|
L
 -23.1%
H
2.3
7.5
|
L
 -66.7%
H
2.3
16
|
L
H
2.3
61.7
|
L
H
2.3
61.7
|
Centessa Pharmaceuticals plc |
|
3,039.4
|
22.7
|
L
 -0.2%
H
22.5
23.2
|
L
 42.5%
H
15.6
23.2
|
L
 33.2%
H
15.0
23.2
|
L
 87.1%
H
11.8
23.2
|
L
 55.5%
H
9.6
23.2
|
L
 461.1%
H
3
23.2
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
Connect Biopharma Holdings |
|
90.8
|
1.6
|
L
 -7.4%
H
1.6
1.8
|
L
 -18.1%
H
1.6
2.0
|
L
 -21.3%
H
1.6
2.5
|
L
 103.8%
H
0.8
2.9
|
L
 28.4%
H
0.5
2.9
|
L
 16.4%
H
0.5
2.9
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
Dare Bioscience Inc |
|
28.4
|
2.1
|
L
 -0.9%
H
2.1
2.1
|
L
 2.4%
H
2.1
2.2
|
L
 9.9%
H
1.9
2.4
|
L
 -33.9%
H
1.8
9.2
|
L
 -34.5%
H
1.8
9.2
|
L
 -84.3%
H
0.3
16.8
|
L
 -83.3%
H
0.3
46.2
|
L
 -99.6%
H
0.3
624
|
Day One Biopharmaceuticals Inc |
|
754.9
|
7.4
|
L
 1.5%
H
7.2
7.4
|
L
 -1.5%
H
7.2
7.6
|
L
 20.8%
H
5.9
7.7
|
L
 5.6%
H
5.6
7.7
|
L
 -48.6%
H
5.6
16.8
|
L
 -71.1%
H
5.6
26.7
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
Journey Medical Corp |
|
193.4
|
7.4
|
L
 1.7%
H
7.2
7.5
|
L
 5.8%
H
6.9
7.5
|
L
 -2.9%
H
6.7
8.9
|
L
 0.7%
H
6.2
8.9
|
L
 54.4%
H
3.5
8.9
|
L
 130.4%
H
1.0
8.9
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
Diffusion Pharmaceuticals Inc |
|
-
|
9.2
|
L
 -3.4%
H
9.2
9.7
|
L
 -13.9%
H
9.2
10.8
|
L
 -6.6%
H
8.8
11.3
|
L
 19.2%
H
5.5
13.1
|
L
 4.8%
H
5.5
13.1
|
L
 -5.6%
H
4.1
14.4
|
L
 -85.3%
H
4.1
138.8
|
L
 -99.9%
H
4.1
29250
|
DiaMedica Therapeutics Inc |
|
376.3
|
7.3
|
L
 2.1%
H
6.8
7.4
|
L
 37.4%
H
5.2
7.5
|
L
 55.9%
H
4.4
7.5
|
L
 76.7%
H
3.5
7.5
|
L
 73.8%
H
3.2
7.5
|
L
 378.9%
H
1.1
7.5
|
L
 78.9%
H
1.1
10.9
|
L
 306.7%
H
1.1
13.8
|
Denali Therapeutics Inc |
|
2,166.9
|
14.8
|
L
 1.2%
H
14.7
15.1
|
L
 -3.2%
H
14.5
15.7
|
L
 6.2%
H
12.9
16.2
|
L
 -2.9%
H
12.9
16.2
|
L
 -43.7%
H
10.6
33.3
|
L
 -52.7%
H
10.6
34.8
|
L
 -53.8%
H
10.6
93.9
|
L
H
10.6
93.9
|
Dominari Holdings Inc |
|
108.2
|
7.0
|
L
 4.7%
H
6.6
7
|
L
 17.6%
H
5.6
7.2
|
L
 21.5%
H
5.2
7.6
|
L
 27.5%
H
4.3
7.6
|
L
 255.1%
H
0.8
13.6
|
L
 18.4%
H
0.8
13.6
|
L
 -36.8%
H
0.8
43.4
|
L
 -99.0%
H
0.8
850.9
|
DarioHealth Corp |
|
17.0
|
7.1
|
L
 -7.2%
H
7.1
7.9
|
L
 -24.7%
H
7.1
10.6
|
L
 -34.4%
H
7.1
11.8
|
L
 -50.4%
H
7.1
14.8
|
L
 -55.0%
H
7.1
31
|
L
 -91.8%
H
7.1
135.6
|
L
 -97.7%
H
7.1
637
|
L
 -99.7%
H
7.1
4669.9
|
Dermata Therapeutics Inc |
|
3.7
|
5.4
|
L
 -1.8%
H
5.4
5.7
|
L
 -8.5%
H
5.0
5.9
|
L
 -16.4%
H
5.0
6.6
|
L
 620%
H
0.6
7.1
|
L
 235.4%
H
0.6
7.1
|
L
 -53.1%
H
0.2
13.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
Durect Corp |
|
59.3
|
1.9
|
L
 -1.0%
H
1.9
2.0
|
L
 -1.6%
H
1.9
2.0
|
L
 2.1%
H
1.9
2.0
|
L
 229.3%
H
0.5
2.6
|
L
 27.3%
H
0.5
2.6
|
L
 -70.5%
H
0.5
9.5
|
L
 -88.1%
H
0.5
29.5
|
L
 -91.5%
H
0.5
39.5
|
Bright Minds Biosciences Inc |
|
350.0
|
49.4
|
L
 17.1%
H
42.5
49.4
|
L
 14.1%
H
39.7
49.4
|
L
 27.2%
H
37.5
49.4
|
L
 74.7%
H
23.2
49.4
|
L
 3882.3%
H
0.9
79.0
|
L
 529.0%
H
0.9
79.0
|
L
H
0.9
79.0
|
L
H
0.9
79.0
|
Design Therapeutics Inc |
|
339.4
|
6.0
|
L
 -2.8%
H
5.9
6.4
|
L
H
5.6
6.7
|
L
 39.3%
H
4.2
6.7
|
L
 48.6%
H
3.3
6.7
|
L
 5.7%
H
2.6
7.8
|
L
 -75.8%
H
1.9
25.0
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
Precision Biosciences Inc |
|
58.9
|
5
|
L
 -0.2%
H
4.9
5.1
|
L
 -1.0%
H
4.9
5.2
|
L
 14.2%
H
4.2
5.2
|
L
 -3.9%
H
4.0
5.3
|
L
 -51.2%
H
3.6
10.7
|
L
 203.0%
H
0.3
19.4
|
L
 -7.1%
H
0.3
19.4
|
L
H
0.3
23.7
|
Dynavax Technologies Corp |
|
1,142.2
|
9.7
|
L
 0.2%
H
9.6
9.8
|
L
 -3.9%
H
9.5
10.3
|
L
 -5.7%
H
9.5
11.5
|
L
 -6.6%
H
9.5
12.1
|
L
 -13.0%
H
9.2
14.6
|
L
 -16.4%
H
9.2
15.2
|
L
 94.8%
H
3.6
21.4
|
L
 -68.1%
H
1.8
32.5
|
Dyne Therapeutics Inc |
|
1,875.0
|
13.2
|
L
 -0.8%
H
12.6
13.3
|
L
 -2.2%
H
12.6
14.3
|
L
 18.1%
H
10.8
14.3
|
L
 -10.8%
H
8.1
15.2
|
L
 -59.4%
H
6.4
37.1
|
L
 -11.6%
H
6.4
47.5
|
L
H
4.3
47.5
|
L
H
4.3
47.5
|
DBV Technologies ADR |
|
272.3
|
10.0
|
L
 4.5%
H
9.6
10.2
|
L
 9.2%
H
8.7
10.2
|
L
 1.3%
H
8.7
10.3
|
L
 10.6%
H
8.5
12.0
|
L
 161.8%
H
0.5
12.8
|
L
 -56.0%
H
0.5
24.3
|
L
 -47.9%
H
0.5
73.8
|
L
 -97.3%
H
0.5
505.7
|
Editas Medicine Inc |
|
243.7
|
2.7
|
L
 5.9%
H
2.6
2.8
|
L
 8.4%
H
2.4
2.8
|
L
 22.6%
H
2.1
3.2
|
L
 29.1%
H
1.9
3.6
|
L
 -28.1%
H
0.9
4.1
|
L
 -82.9%
H
0.9
16.2
|
L
 -91.1%
H
0.9
100.0
|
L
H
0.9
100.0
|
Edesa Biotech Inc |
|
17.0
|
2.4
|
L
 -1.2%
H
2.4
2.5
|
L
 -1.6%
H
2.4
2.5
|
L
 13.7%
H
2.1
2.6
|
L
 26.8%
H
1.9
2.6
|
L
 -46.2%
H
1.6
5
|
L
 -80.9%
H
1.6
19.7
|
L
 -95.7%
H
1.6
84
|
L
 -99.9%
H
1.6
2646
|
Eledon Pharmaceuticals Inc |
|
152.1
|
2.5
|
L
 -1.9%
H
2.5
2.6
|
L
 -1.9%
H
2.5
2.8
|
L
 -6.6%
H
2.5
2.8
|
L
 -15.1%
H
2.4
4.1
|
L
 -4.2%
H
2.4
5.4
|
L
 -28.0%
H
1.1
5.4
|
L
 -63.0%
H
1.1
27.3
|
L
 -99.9%
H
1.1
2303.6
|
Elicio Therapeutics Inc |
|
189.2
|
11.6
|
L
 -1.7%
H
11.3
11.9
|
L
 11.8%
H
10.0
11.9
|
L
 25.9%
H
8.5
12.4
|
L
 44.4%
H
7.6
12.4
|
L
 165.6%
H
3.9
12.4
|
L
 2.9%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
Enliven Therapeutics Inc |
|
1,180.0
|
19.9
|
L
 3.6%
H
18.8
20.0
|
L
 -4.9%
H
18.8
21.0
|
L
 12.6%
H
17.8
21.4
|
L
 -8.2%
H
17.4
24.4
|
L
 -14.4%
H
13.3
30.0
|
L
 138.3%
H
8.1
30.0
|
L
 -78.3%
H
3.9
119.7
|
L
H
3.9
250.8
|
Climb Bio Inc |
|
162.6
|
2.4
|
L
 0.8%
H
2.4
2.4
|
L
 -1.6%
H
2.3
2.6
|
L
 41.2%
H
1.6
2.6
|
L
 75.2%
H
1.2
2.6
|
L
 -69.3%
H
1.1
8.8
|
L
 -22.6%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
Enlivex Therapeutics |
|
25.5
|
1.1
|
L
 4.9%
H
1.0
1.1
|
L
 0.9%
H
1
1.1
|
L
 -25.2%
H
1.0
2.1
|
L
 11.5%
H
0.9
2.1
|
L
 -15.8%
H
0.8
2.1
|
L
 -78.2%
H
0.8
5.4
|
L
 -76.9%
H
0.8
29.4
|
L
 -99.5%
H
0.8
318
|
Enochian Biosciences Inc |
|
-
|
0.2
|
L
 -4.8%
H
0.2
0.2
|
L
 -9.1%
H
0.2
0.2
|
L
 -20%
H
0.2
0.3
|
L
 -47.4%
H
0.2
0.4
|
L
 -37.5%
H
0.2
0.5
|
L
 -90.3%
H
0.2
2.5
|
L
 -95%
H
0.2
13.8
|
L
 -95.1%
H
0.2
13.8
|
Ensysce Biosciences Inc |
|
6.3
|
2.1
|
L
 -0.5%
H
2.1
2.2
|
L
 -1.8%
H
2.0
2.2
|
L
 -2.3%
H
2.0
2.2
|
L
 4.4%
H
2.0
2.4
|
L
 526.5%
H
0.1
9.9
|
L
 -97.4%
H
0.1
109.9
|
L
 -99.9%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
Enanta Pharmaceuticals Inc |
|
185.1
|
8.7
|
L
 4.0%
H
8.2
8.8
|
L
 -1.8%
H
8.2
9.1
|
L
 25.5%
H
6.5
9.2
|
L
 14.3%
H
6.4
9.2
|
L
 -27.3%
H
4.1
13.4
|
L
 -86.5%
H
4.1
64.3
|
L
 -81.3%
H
4.1
102
|
L
 -78.4%
H
4.1
127.8
|
Entera Bio |
|
84.5
|
1.9
|
L
 -0.5%
H
1.8
1.9
|
L
 -8.9%
H
1.8
2.2
|
L
 1.7%
H
1.8
2.2
|
L
 -12.7%
H
1.7
2.4
|
L
 -0.5%
H
1.5
2.8
|
L
 33.1%
H
0.5
3.4
|
L
 63.7%
H
0.5
10.2
|
L
H
0.5
10.2
|
Enveric Biosciences Inc |
|
3.2
|
1
|
L
 8.7%
H
0.9
1
|
L
 -4.8%
H
0.9
1.1
|
L
 -9.9%
H
0.9
1.5
|
L
 -21.9%
H
0.9
1.5
|
L
 92.3%
H
0.3
4.8
|
L
 -81.5%
H
0.3
7.0
|
L
 -99.6%
H
0.3
752
|
L
 -100.0%
H
0.3
67500
|
Evolus Inc |
|
485.8
|
7.5
|
L
 2.2%
H
7.2
7.5
|
L
 1.8%
H
7.2
7.7
|
L
 27.3%
H
5.7
8.0
|
L
 -23.9%
H
5.7
10.6
|
L
 -50.5%
H
5.7
17.8
|
L
 -27.5%
H
5.7
17.8
|
L
 109.2%
H
2.9
17.8
|
L
H
2.9
39.5
|
Essa Pharma Inc |
|
9.9
|
0.2
|
L
 5%
H
0.2
0.2
|
L
 -12.5%
H
0.2
0.2
|
L
 -89.0%
H
0.2
1.9
|
L
 -87.7%
H
0.2
1.9
|
L
 -96.8%
H
0.2
7.9
|
L
 -91.1%
H
0.2
11.7
|
L
 -97.2%
H
0.2
36
|
L
 -99.8%
H
0.2
140
|
Equillium Inc |
|
71.1
|
2.0
|
L
 8.2%
H
1.8
2
|
L
 6.4%
H
1.7
2.4
|
L
 298%
H
0.8
2.4
|
L
 468.6%
H
0.3
2.4
|
L
 126.1%
H
0.3
2.4
|
L
 -12.7%
H
0.3
3.3
|
L
 -61.1%
H
0.3
11.3
|
L
H
0.3
27.1
|
Erasca Inc |
|
456.7
|
1.6
|
L
 3.9%
H
1.5
1.7
|
L
 12.6%
H
1.4
1.7
|
L
 15%
H
1.3
1.7
|
L
H
1.2
1.8
|
L
 -48.1%
H
1.0
3.3
|
L
 -81.1%
H
1.0
9.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
Esperion Therapeutics Inc |
|
562.5
|
2.8
|
L
 7.3%
H
2.6
2.8
|
L
 14.8%
H
2.4
2.8
|
L
 49.2%
H
1.7
2.8
|
L
 128.7%
H
1.0
2.8
|
L
 61.3%
H
0.7
3.9
|
L
 -62.1%
H
0.7
8.9
|
L
 -92.8%
H
0.7
40.2
|
L
 -94.0%
H
0.7
82.7
|
89bio Inc |
|
1,282.9
|
8.7
|
L
 1.5%
H
8.5
8.7
|
L
 -6.4%
H
8.3
9.5
|
L
 -5.6%
H
8.3
9.7
|
L
 -15.9%
H
8.3
11.4
|
L
 3.8%
H
4.2
11.8
|
L
 81.0%
H
4.2
22.9
|
L
 -75.7%
H
2
40.9
|
L
H
2
47.3
|
Eton Pharmaceuticals Inc |
|
471.2
|
17.6
|
L
 0.9%
H
17.2
18.0
|
L
 0.7%
H
17.2
18.3
|
L
 2.5%
H
15.6
18.3
|
L
 11.8%
H
13.1
18.3
|
L
 267.6%
H
4.7
21.5
|
L
 674.0%
H
2.0
21.5
|
L
 130.6%
H
2.0
21.5
|
L
H
2.0
21.5
|
Evoke Pharma Inc |
|
8.1
|
5.2
|
L
 2.4%
H
5.1
5.2
|
L
 -2.3%
H
4.9
5.3
|
L
 -4.8%
H
4.6
7.0
|
L
 81.8%
H
2.5
9.9
|
L
 26.3%
H
1.9
12.3
|
L
 -81.8%
H
0.4
71.5
|
L
 -99.3%
H
0.4
776.2
|
L
 -98.9%
H
0.4
1599.8
|
Edgewise Therapeutics Inc |
|
1,545.4
|
14.7
|
L
H
14.4
14.9
|
L
 0.2%
H
14.1
15.8
|
L
 15.7%
H
12.3
15.8
|
L
 -5.1%
H
12.2
16.3
|
L
 -15.1%
H
10.6
38.1
|
L
 18.1%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
Exelixis Inc |
|
10,517.7
|
39.1
|
L
 3.6%
H
37.6
39.1
|
L
 5.7%
H
36.8
39.1
|
L
 3.6%
H
36.2
39.1
|
L
 -8.1%
H
35.9
49.6
|
L
 48.5%
H
25.2
49.6
|
L
 118.3%
H
14.9
49.6
|
L
 87.0%
H
14.9
49.6
|
L
 565.6%
H
3.6
49.6
|
Hyperion DeFi Inc |
|
68.3
|
12.0
|
L
 13.1%
H
10.0
12.3
|
L
 103.9%
H
5.5
12.3
|
L
 60.7%
H
5.5
12.3
|
L
 193.9%
H
2.1
17.2
|
L
 -74.4%
H
0.0
47.3
|
L
 -93.8%
H
0.0
468
|
L
 -95.7%
H
0.0
617.6
|
L
H
0.0
859.2
|
EyePoint Pharmaceuticals Inc |
|
918.8
|
13.3
|
L
 -1.6%
H
13.2
13.8
|
L
 11.1%
H
11.4
14.4
|
L
 30.3%
H
9.8
14.4
|
L
 44.7%
H
7.9
14.4
|
L
 66%
H
3.9
14.4
|
L
 48.8%
H
2.2
31.0
|
L
 162.4%
H
2.2
31.0
|
L
 -64.5%
H
2.2
58.1
|
Evaxion Biotech AS ADR |
|
18.2
|
2.9
|
L
 2.1%
H
2.7
2.9
|
L
 11.2%
H
2.5
3.0
|
L
 1.8%
H
2.5
3.4
|
L
 -4.6%
H
2.1
3.4
|
L
 -10%
H
0.8
9.8
|
L
 -85.9%
H
0.8
35.2
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
Evotec SE ADR |
|
1,236.1
|
3.5
|
L
 2.1%
H
3.5
3.6
|
L
 1.2%
H
3.4
3.6
|
L
 -11.5%
H
3.4
3.9
|
L
 -15.7%
H
3.4
4.4
|
L
 3.6%
H
2.8
5.6
|
L
 -69.7%
H
2.8
13.5
|
L
 -73.3%
H
2.8
26.6
|
L
 61.1%
H
1.6
26.6
|
Fate Therapeutics Inc |
|
117.6
|
1.0
|
L
 2%
H
1
1.1
|
L
 2%
H
0.9
1.1
|
L
 10.9%
H
0.9
1.2
|
L
 -38.9%
H
0.9
1.7
|
L
 -73.3%
H
0.7
4.2
|
L
 -96.4%
H
0.7
29.4
|
L
 -96.8%
H
0.7
121.2
|
L
 -83%
H
0.7
121.2
|
Fortress Biotech Inc |
|
114.0
|
3.8
|
L
 -0.8%
H
3.7
3.9
|
L
 29.8%
H
2.8
3.9
|
L
 110.4%
H
1.8
3.9
|
L
 84.1%
H
1.7
3.9
|
L
 116.4%
H
1.3
3.9
|
L
 -77.6%
H
1.2
17.4
|
L
 -93.8%
H
1.2
91.5
|
L
 -90.0%
H
1.2
91.5
|
Forte Biosciences Inc |
|
130.0
|
10.5
|
L
 -4.0%
H
10.3
11
|
L
 -5.5%
H
10.3
11.6
|
L
 2.8%
H
9.9
13.6
|
L
 -14.6%
H
9.1
19.6
|
L
 47.3%
H
4.1
28
|
L
 -67.4%
H
4.1
34
|
L
 -98.8%
H
4.1
1349.8
|
L
H
0.0
1349.8
|
4D Molecular Therapeutics Inc |
|
330.2
|
7.1
|
L
 1.9%
H
6.8
7.2
|
L
 9.3%
H
6.1
7.4
|
L
 25.6%
H
5.3
7.6
|
L
 58.2%
H
3.7
7.6
|
L
 -54.4%
H
2.2
17.4
|
L
 -22.0%
H
2.2
36.3
|
L
H
2.2
55.1
|
L
H
2.2
55.1
|
Fennec Pharmaceuticals Inc |
|
251.3
|
9.0
|
L
 0.2%
H
9.0
9.1
|
L
 1.9%
H
8.8
9.3
|
L
 8.4%
H
7.2
9.4
|
L
 8.7%
H
7.2
9.4
|
L
 72.3%
H
4.0
9.4
|
L
 42.4%
H
4.0
11.9
|
L
 58.1%
H
3.8
11.9
|
L
 349.3%
H
0.3
15.0
|
FibroGen Inc |
|
50.3
|
12.4
|
L
 8.0%
H
11.3
12.5
|
L
 3.9%
H
10.7
12.5
|
L
 42.7%
H
8.3
12.6
|
L
 61.0%
H
4.9
12.6
|
L
 24.3%
H
4.5
22.0
|
L
 -96.1%
H
4.5
642.3
|
L
 -98.8%
H
4.5
1430.2
|
L
 -98.2%
H
4.5
1713.8
|
Foghorn Therapeutics Inc |
|
298.5
|
5.3
|
L
 2.5%
H
5.1
5.4
|
L
 0.2%
H
5.1
5.9
|
L
 15.3%
H
4.6
5.9
|
L
 14.0%
H
4.3
6.8
|
L
 -45.3%
H
2.9
10.2
|
L
 -48.5%
H
2.7
10.7
|
L
H
2.7
28.3
|
L
H
2.7
28.3
|
Q32 Bio Inc |
|
22.9
|
1.9
|
L
 5.6%
H
1.7
2.0
|
L
 9.9%
H
1.6
2.0
|
L
 15.3%
H
1.6
2.1
|
L
 11.9%
H
1.3
3.8
|
L
 -96.1%
H
1.3
53.8
|
L
 -95.1%
H
1.3
53.8
|
L
 -99.0%
H
1.3
274.3
|
L
H
1.3
572.4
|
Flora Growth Corp |
|
13.8
|
23.8
|
L
 8.2%
H
22.5
23.8
|
L
 5.5%
H
21.5
23.8
|
L
 26.9%
H
17.6
24.9
|
L
 -11.7%
H
15.2
30.8
|
L
 -36.4%
H
15.2
82.3
|
L
 -97.2%
H
15.2
990.6
|
L
H
15.2
16731
|
L
H
15.2
16731
|
Amicus Therapeutics Inc |
|
2,472.1
|
8.0
|
L
 1.0%
H
7.9
8.1
|
L
 2.2%
H
7.8
8.2
|
L
 18.6%
H
6.6
8.2
|
L
 31.3%
H
5.5
8.2
|
L
 -28.7%
H
5.5
12.7
|
L
 -29.8%
H
5.5
14.6
|
L
 -39.7%
H
5.5
25.4
|
L
 -55.3%
H
4.4
25.4
|
Frequency Therapeutics Inc |
|
-
|
34.4
|
L
 -3.2%
H
33.0
37.0
|
L
 32.1%
H
24.1
37.0
|
L
 114.9%
H
14.2
37.0
|
L
 117.0%
H
11.5
37.0
|
L
 127.6%
H
10.3
37.0
|
L
 -67.9%
H
9.2
279.5
|
L
 -96.3%
H
9.2
2918.5
|
L
H
9.2
2918.5
|
Fulcrum Therapeutics Inc |
|
378.1
|
7.0
|
L
H
6.9
7.2
|
L
 7.2%
H
6.4
7.9
|
L
 7.7%
H
6.3
7.9
|
L
 1.3%
H
6.2
8.5
|
L
 -17.1%
H
2.3
8.9
|
L
 -15.9%
H
2.3
15
|
L
 -9.8%
H
2.3
33.1
|
L
H
2.3
33.1
|
First Wave BioPharma Inc |
|
3.6
|
2.3
|
L
 -7.3%
H
2.3
2.6
|
L
 -17.0%
H
2.2
2.7
|
L
 538.9%
H
0.5
3.0
|
L
 289.8%
H
0.4
3.0
|
L
 447.6%
H
0.4
3.0
|
L
 -99.5%
H
0.4
509.6
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
Galectin Therapeutics Inc |
|
380.5
|
5.9
|
L
 18.8%
H
5.0
6.0
|
L
 32.3%
H
4.4
6.0
|
L
 43.1%
H
3.5
6.0
|
L
 343.3%
H
1.3
6.0
|
L
 134.8%
H
0.7
6.0
|
L
 228.2%
H
0.7
6.0
|
L
 103.4%
H
0.7
6.0
|
L
 172.5%
H
0.5
9.5
|
Gain Therapeutics Inc |
|
61.8
|
1.7
|
L
 -0.6%
H
1.7
1.8
|
L
 -10.4%
H
1.6
2.0
|
L
 16.2%
H
1.5
2.1
|
L
 -9.0%
H
1.4
2.1
|
L
 35.4%
H
1.3
3.2
|
L
 -55.7%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
Generation Bio Co |
|
40.5
|
6.0
|
L
 0.5%
H
5.9
6.1
|
L
 0.5%
H
5.6
6.3
|
L
 46.6%
H
4.0
7.0
|
L
 41.4%
H
3
7.0
|
L
 -75.9%
H
3
29.1
|
L
 -89.0%
H
3
73.5
|
L
 -98.0%
H
3
557.2
|
L
H
3
557.2
|
CytoMed Therapeutics |
|
23.6
|
2.0
|
L
 1.5%
H
2.0
2.1
|
L
 3.1%
H
1.8
2.1
|
L
 7.5%
H
1.7
2.1
|
L
 -2.0%
H
1.7
2.4
|
L
 24.1%
H
1.2
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
Geron Corp |
|
842.2
|
1.3
|
L
 2.3%
H
1.3
1.3
|
L
 -5.7%
H
1.3
1.4
|
L
 3.1%
H
1.3
1.6
|
L
 -17.5%
H
1.1
1.6
|
L
 -69.6%
H
1.1
4.8
|
L
 -50.2%
H
1.1
5.3
|
L
 -28.6%
H
1.0
5.3
|
L
 -60.9%
H
0.8
7.0
|
GH Research PLC |
|
774.1
|
12.5
|
L
 -3.2%
H
12.4
13.2
|
L
 -11.0%
H
12.4
14.6
|
L
 0.6%
H
11.3
14.6
|
L
 -2.8%
H
11.3
19.5
|
L
 55.8%
H
6
20.5
|
L
 -10.3%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
Gilead Sciences |
|
146,241.5
|
117.9
|
L
 2.3%
H
115.2
118.1
|
L
 4.3%
H
112.3
118.1
|
L
 -1.3%
H
111.3
121.8
|
L
 7.1%
H
104.5
121.8
|
L
 44.7%
H
79.6
121.8
|
L
 80.5%
H
61.4
121.8
|
L
 84.8%
H
56.6
121.8
|
L
 9.9%
H
56.6
121.8
|
Galmed Pharmaceuticals |
|
8.5
|
1.6
|
L
 9.9%
H
1.4
1.6
|
L
 20.2%
H
1.3
1.6
|
L
 6.9%
H
1.2
1.6
|
L
 -3.1%
H
1.2
2.3
|
L
 -56.5%
H
1.2
13.6
|
L
 -98.0%
H
0.2
170.1
|
L
 -99.8%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
Greenwich LifeSciences Inc |
|
155.7
|
11.4
|
L
 0.3%
H
11.1
12.1
|
L
 -1.0%
H
10.6
13
|
L
 -6.2%
H
10.6
13
|
L
 18.5%
H
8.6
13
|
L
 -22.2%
H
8.1
15.5
|
L
 18.6%
H
7.6
21.5
|
L
H
3.3
158.1
|
L
H
3.3
158.1
|
Galecto Inc |
|
3.7
|
2.8
|
L
 -6.0%
H
2.7
3.4
|
L
 -5.7%
H
2.5
4.0
|
L
 -17.2%
H
2.5
4.0
|
L
 -16.7%
H
2.5
4.1
|
L
 -76.2%
H
2.0
14.8
|
L
 7.7%
H
0.5
14.8
|
L
H
0.5
18.0
|
L
H
0.5
18.0
|
Monte Rosa Therapeutics Inc |
|
302.0
|
4.9
|
L
 1.9%
H
4.8
5.0
|
L
 -2.2%
H
4.8
5.2
|
L
 11.6%
H
4.2
5.2
|
L
 -3.7%
H
4.1
6.3
|
L
 -23.1%
H
3.5
12.4
|
L
 -46.0%
H
2.4
12.4
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
GlycoMimetics Inc |
|
809.9
|
12.6
|
L
 2.6%
H
12.3
13
|
L
 -5.1%
H
12.1
14.5
|
L
 -2.3%
H
12.1
15.8
|
L
 -26.2%
H
10.8
21.4
|
L
 -21.1%
H
10.8
63
|
L
 -82.8%
H
10.8
416
|
L
 -96.3%
H
10.8
440
|
L
 -98.2%
H
10.8
2605
|
Genelux Corp |
|
137.9
|
3.7
|
L
H
3.6
3.8
|
L
 10.3%
H
3.3
3.8
|
L
 15.9%
H
3.0
4.1
|
L
 36.7%
H
2.5
4.1
|
L
 45.4%
H
2.0
5.9
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
Genprex Inc |
|
8.7
|
0.3
|
L
 4%
H
0.2
0.3
|
L
 62.5%
H
0.2
0.4
|
L
 23.8%
H
0.1
0.4
|
L
 -18.8%
H
0.1
0.4
|
L
 -43.5%
H
0.1
4.0
|
L
 -85.2%
H
0.1
8.0
|
L
 -92.9%
H
0.1
8.0
|
L
H
0.1
19.5
|
Gossamer Bio Inc |
|
786.7
|
3.5
|
L
 11.3%
H
3.1
3.5
|
L
 34.1%
H
2.4
3.5
|
L
 96.6%
H
1.7
3.5
|
L
 176.8%
H
1.2
3.5
|
L
 276.1%
H
0.7
3.5
|
L
 -75.4%
H
0.5
14.6
|
L
 -74.3%
H
0.5
15.2
|
L
H
0.5
27.2
|
Geovax Labs Inc |
|
18.3
|
0.7
|
L
 4.4%
H
0.7
0.7
|
L
 -4%
H
0.7
0.8
|
L
 5.9%
H
0.7
0.8
|
L
 -41.0%
H
0.4
1.4
|
L
 -78.1%
H
0.4
3.7
|
L
 -56.1%
H
0.3
11.1
|
L
 -89.3%
H
0.3
11.1
|
L
 -100.0%
H
0.3
1000000
|
Graphite Bio Inc |
|
2,376.6
|
40.8
|
L
 -2.2%
H
40.1
42.0
|
L
 3.9%
H
38.9
42.8
|
L
 17.7%
H
34.9
42.8
|
L
 45.3%
H
27.8
42.8
|
L
 52.2%
H
25.9
42.8
|
L
 -75.8%
H
25.9
413
|
L
H
25.9
1666
|
L
H
25.9
1666
|
GT Biopharma Inc |
|
2.6
|
0.7
|
L
 -7.5%
H
0.6
0.8
|
L
 -21.3%
H
0.6
1.0
|
L
 -58.7%
H
0.6
1.8
|
L
 -75.7%
H
0.6
3.9
|
L
 -64.3%
H
0.6
4.1
|
L
 -70.6%
H
0.2
10.7
|
L
 -73.6%
H
0.2
19.7
|
L
 -100.0%
H
0.2
31492.5
|
Galapagos NV ADR |
|
2,144.9
|
32.6
|
L
 0.7%
H
32.2
32.7
|
L
 4.1%
H
30.9
33.6
|
L
 0.0%
H
30.9
33.6
|
L
 15.0%
H
26.6
33.9
|
L
 12.3%
H
22.4
33.9
|
L
 -32.4%
H
22.4
52.6
|
L
 -74.1%
H
22.4
148.7
|
L
 -44.9%
H
22.4
274.0
|
Genmab ADR |
|
17,610.8
|
28.6
|
L
 3.2%
H
28.3
28.7
|
L
 5.7%
H
26.9
28.7
|
L
 33.5%
H
21
28.7
|
L
 25.3%
H
20.2
28.7
|
L
 4.0%
H
17.2
28.7
|
L
 -23.6%
H
17.2
47.5
|
L
 -18.8%
H
17.2
49.1
|
L
 192.5%
H
9.0
49.1
|
Genfit ADR |
|
209.5
|
4.2
|
L
 1.2%
H
4.2
4.2
|
L
 6.1%
H
3.9
4.3
|
L
 10.3%
H
3.7
4.6
|
L
 -1.2%
H
3.4
4.6
|
L
 -1.0%
H
2.6
6.4
|
L
 -6.3%
H
2.6
6.4
|
L
 -9.7%
H
2.6
7.2
|
L
H
2.6
26.3
|
Genenta Science SpA ADR |
|
50.3
|
2.8
|
L
 -19.8%
H
2.6
3.5
|
L
 -23.0%
H
2.6
3.7
|
L
 -25.9%
H
2.6
4.5
|
L
 -31.3%
H
2.6
4.5
|
L
 -34.8%
H
2.6
7.3
|
L
 -42.1%
H
2.2
7.3
|
L
H
2.2
13.1
|
L
H
2.2
13.1
|
Grifols SA ADR Level III |
|
6,832.3
|
10.0
|
L
 1.9%
H
9.9
10.1
|
L
 4.7%
H
9.8
10.2
|
L
 -5.8%
H
9.6
10.8
|
L
 11.3%
H
8.2
11.1
|
L
 19.4%
H
6.2
11.1
|
L
 17.7%
H
5.3
12.2
|
L
 -35.6%
H
5.3
20.5
|
L
 -36.7%
H
5.3
25.7
|
Halozyme Therapeutics Inc |
|
9,068.4
|
77.5
|
L
 2.3%
H
75.7
77.6
|
L
 3.6%
H
72.4
77.6
|
L
 23.3%
H
62.5
77.6
|
L
 44.2%
H
51.1
77.6
|
L
 30.8%
H
42.7
77.6
|
L
 87.3%
H
29.9
77.6
|
L
 187.7%
H
25.2
77.6
|
L
 337.3%
H
7.0
77.6
|
HCW Biologics Inc |
|
7.1
|
3.3
|
L
 -0.9%
H
3.3
3.4
|
L
 -30.8%
H
3.3
4.8
|
L
 -28.1%
H
2.8
7.4
|
L
 -39.5%
H
2.8
7.4
|
L
 -85.2%
H
0.2
100.8
|
L
 -97.0%
H
0.2
111.6
|
L
H
0.2
311
|
L
H
0.2
311
|
Hillstream BioPharma Inc |
|
36.7
|
3.1
|
L
 2.6%
H
2.9
3.2
|
L
 -34.4%
H
2.8
4.8
|
L
 154.5%
H
1.1
9.1
|
L
 96.9%
H
1.1
9.1
|
L
 135.3%
H
1.1
9.1
|
L
 -87.2%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
HilleVax Inc |
|
104.8
|
2.1
|
L
 -1.0%
H
2.1
2.1
|
L
 -0.5%
H
2.1
2.1
|
L
 1.5%
H
2.1
2.1
|
L
 7.2%
H
1.8
2.2
|
L
 20.1%
H
1.3
2.2
|
L
 -89.0%
H
1.3
24.4
|
L
H
1.3
24.4
|
L
H
1.3
24.4
|
Hoth Therapeutics Inc |
|
21.2
|
1.6
|
L
 -0.6%
H
1.6
1.8
|
L
 20.3%
H
1.3
1.8
|
L
 34.5%
H
1.1
1.8
|
L
 28%
H
1.1
1.8
|
L
 42.9%
H
0.7
3.8
|
L
 -84.1%
H
0.6
12.5
|
L
 -97.1%
H
0.6
87.5
|
L
H
0.6
347
|
Werewolf Therapeutics Inc |
|
65.4
|
1.4
|
L
 1.4%
H
1.4
1.5
|
L
 4.4%
H
1.3
1.5
|
L
 22.2%
H
1.2
1.5
|
L
 7.5%
H
1.0
1.5
|
L
 -35.9%
H
0.6
4.2
|
L
 -80.7%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
Harmony Biosciences Holdings |
|
1,922.7
|
33.4
|
L
 0.6%
H
33.2
33.8
|
L
 -11.0%
H
32.9
37.5
|
L
 -2.3%
H
32.9
38.3
|
L
 -6.8%
H
31.3
38.3
|
L
 -11%
H
26.5
41.6
|
L
 -28.9%
H
18.6
62.1
|
L
 -24.7%
H
18.6
62.1
|
L
H
18.6
62.1
|
Harrow Health Inc |
|
1,459.7
|
39.5
|
L
 1.5%
H
38.9
40.3
|
L
 5.7%
H
35.6
41.3
|
L
 14.6%
H
29.8
41.3
|
L
 26.6%
H
29.7
41.3
|
L
 -3.9%
H
20.9
59.2
|
L
 334.5%
H
7.5
59.2
|
L
 520.3%
H
4.7
59.2
|
L
 425.3%
H
1.4
59.2
|
Heron Therapeutics Inc |
|
196.2
|
1.3
|
L
 0.8%
H
1.3
1.3
|
L
 -3.8%
H
1.3
1.4
|
L
 -3.0%
H
1.2
1.5
|
L
 -39.6%
H
1.2
2.3
|
L
 -29.7%
H
1.0
2.7
|
L
 -74.7%
H
0.5
5.1
|
L
 -91.2%
H
0.5
22.4
|
L
 -96.7%
H
0.5
42.9
|
Quantum BioPharma Ordinary |
|
61.1
|
16.0
|
L
 -0.9%
H
15
16.4
|
L
 2.0%
H
12.1
17.8
|
L
 -45.2%
H
12.1
31.9
|
L
 10.1%
H
12.1
38.3
|
L
 319.4%
H
2.7
38.3
|
L
 -73.1%
H
2.7
136.5
|
L
 -90.7%
H
2.7
288.6
|
L
H
2.7
11431.9
|
Humacyte Inc |
|
237.6
|
1.5
|
L
 1.4%
H
1.5
1.5
|
L
 2.7%
H
1.4
1.5
|
L
 -39.5%
H
1.4
2.1
|
L
 -43.8%
H
1.4
2.8
|
L
 -71.4%
H
1.2
6.8
|
L
 -66.7%
H
1.2
10.0
|
L
H
1.2
17.5
|
L
H
1.2
17.5
|
HUTCHMED China ADR |
|
2,813.4
|
16.4
|
L
 4.2%
H
16
16.5
|
L
 7.2%
H
14.7
16.5
|
L
 9.1%
H
14.7
16.6
|
L
 -2.8%
H
14.6
19.5
|
L
 2.1%
H
11.5
21.5
|
L
 17.2%
H
7.4
21.9
|
L
 -51.3%
H
7.4
43.9
|
L
H
7.4
43.9
|
ImmunityBio Inc |
|
2,448.2
|
2.6
|
L
 0.8%
H
2.5
2.7
|
L
 9.3%
H
2.3
2.7
|
L
 6.2%
H
2.2
2.9
|
L
 -22.5%
H
2.2
3.4
|
L
 -28.5%
H
1.8
7.5
|
L
 -44.2%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
Immucell Corp |
|
55.5
|
6.1
|
L
 -0.5%
H
6.1
6.4
|
L
 -6.1%
H
6.1
6.8
|
L
 -8.0%
H
5.9
7.0
|
L
 -2.1%
H
5.5
7.6
|
L
 61.3%
H
3.3
7.6
|
L
 -21.0%
H
3.3
8.6
|
L
 18.8%
H
3.3
13.2
|
L
 -13.2%
H
3.3
13.2
|
Ideaya Biosciences Inc |
|
2,185.0
|
24.9
|
L
 0.9%
H
24.5
25.4
|
L
 -3.2%
H
23.2
27.7
|
L
 7.9%
H
22.4
27.7
|
L
 10.2%
H
20.5
27.7
|
L
 -32.0%
H
13.5
37.8
|
L
 169.5%
H
9.8
47.7
|
L
 100.9%
H
8.1
47.7
|
L
H
3.0
47.7
|
InflaRx NV |
|
99.6
|
1.5
|
L
 -7.0%
H
1.5
1.6
|
L
 -15.0%
H
1.5
1.8
|
L
 83.8%
H
0.8
1.8
|
L
 75%
H
0.7
1.8
|
L
H
0.7
2.8
|
L
 -48.2%
H
0.7
7.3
|
L
 -60.4%
H
0.7
7.3
|
L
H
0.7
53.1
|
ImageneBio Inc |
|
102.9
|
9.2
|
L
 3.3%
H
8.9
9.2
|
L
 -32.9%
H
8.0
13.4
|
L
 -37.3%
H
8.0
15.3
|
L
 -47.1%
H
8.0
18
|
L
 -54.6%
H
8.0
23.3
|
L
 -85.4%
H
8.0
91.7
|
L
H
8.0
451.3
|
L
H
8.0
451.3
|
Inhibikase Therapeutics Inc |
|
125.2
|
1.7
|
L
 9.1%
H
1.5
1.7
|
L
 -2.9%
H
1.5
1.7
|
L
 17.5%
H
1.4
1.9
|
L
 -16%
H
1.4
2.1
|
L
 25.4%
H
1.1
4.2
|
L
 -69.6%
H
0.8
6.9
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
Illumina Inc |
|
15,263.9
|
99.3
|
L
 4%
H
95.6
99.6
|
L
 3.4%
H
93.9
100.8
|
L
 5.0%
H
93.9
103.7
|
L
 12.9%
H
85.8
111
|
L
 -20%
H
68.7
156.7
|
L
 -52.8%
H
68.7
248.9
|
L
 -71.3%
H
68.7
555.8
|
L
 -50.3%
H
68.7
555.8
|
IM Cannabis Corp |
|
10.5
|
2.0
|
L
 2.0%
H
1.9
2.0
|
L
 -1.5%
H
1.5
2.1
|
L
 -26.6%
H
1.5
3.1
|
L
 -23.3%
H
1.5
3.8
|
L
 -9.1%
H
1.3
7.1
|
L
 -92.5%
H
0.4
29.6
|
L
 -99.2%
H
0.4
697.8
|
L
H
0.4
697.8
|
Immix Biopharma Inc |
|
64.0
|
2.2
|
L
 1.4%
H
2.2
2.3
|
L
H
2.1
2.3
|
L
 -7.1%
H
2.0
2.5
|
L
 -7.9%
H
2.0
3.2
|
L
 16.8%
H
1.3
3.2
|
L
 23.3%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
Immunome Inc |
|
842.6
|
9.7
|
L
 7.6%
H
9.0
9.7
|
L
 -5.6%
H
8.7
10.7
|
L
 -0.1%
H
8.7
10.7
|
L
 1.2%
H
8.0
11.7
|
L
 -33.8%
H
5.2
16.7
|
L
 80.9%
H
2.2
31.0
|
L
H
2.1
63.8
|
L
H
2.1
63.8
|
Imunon Inc |
|
14.2
|
5.7
|
L
 0.9%
H
5.5
5.9
|
L
 -1.4%
H
5.5
6.0
|
L
 -21.3%
H
5.5
7.2
|
L
 -76.8%
H
5.5
25.8
|
L
 -65.8%
H
5.5
47.4
|
L
 -82.9%
H
5.5
54.8
|
L
 -96.9%
H
5.5
783
|
L
 -99.9%
H
5.5
7276.5
|
Immuneering Corp Ordinary |
|
350.1
|
8.2
|
L
 0.9%
H
7.7
8.5
|
L
 52.9%
H
5.2
9.4
|
L
 152.6%
H
2.9
9.4
|
L
 278.3%
H
1.7
9.4
|
L
 584.2%
H
1.1
9.4
|
L
 -7.4%
H
1
16.2
|
L
H
1
34.0
|
L
H
1
34.0
|
Immatics NV |
|
719.6
|
5.9
|
L
 1.9%
H
5.8
6
|
L
 8.6%
H
5.3
6.3
|
L
 -4.2%
H
5.1
6.5
|
L
 -0.3%
H
5.1
6.8
|
L
 -50.4%
H
3.3
13.1
|
L
 -53.9%
H
3.3
13.8
|
L
 -35.3%
H
3.3
18.4
|
L
H
3.3
18.4
|
Immunic Inc |
|
83.9
|
0.9
|
L
 -2.3%
H
0.8
0.9
|
L
 6.3%
H
0.7
0.9
|
L
 -2.3%
H
0.7
1
|
L
 -3.4%
H
0.7
1.2
|
L
 -42.6%
H
0.6
2.1
|
L
 -82.0%
H
0.6
11.8
|
L
 -94.9%
H
0.6
28.2
|
L
 -99.3%
H
0.6
472
|
Immunovant Inc |
|
2,928.5
|
16.8
|
L
 3.7%
H
16.1
17.2
|
L
 0.6%
H
16.1
17.4
|
L
 8.7%
H
14.3
17.4
|
L
 0.4%
H
14.3
19.1
|
L
 -43.5%
H
12.7
32.1
|
L
 236%
H
4.3
45.6
|
L
 -54.8%
H
3.1
53.8
|
L
H
3.1
53.8
|
IN8bio Inc |
|
9.5
|
2.1
|
L
 9.4%
H
1.9
2.1
|
L
 -5.9%
H
1.9
2.2
|
L
 -9.5%
H
1.9
2.5
|
L
 -27.4%
H
1.9
2.9
|
L
 596.7%
H
0.1
4.2
|
L
 -15.4%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
Inhibrx Inc |
|
1,347.9
|
28.5
|
L
 2.9%
H
27.6
28.9
|
L
 2.3%
H
27.0
30.2
|
L
 35.1%
H
20.6
30.2
|
L
 85.1%
H
13.9
30.2
|
L
 87.4%
H
10.8
30.2
|
L
 81.0%
H
10.8
39.8
|
L
 67.0%
H
7.7
51.0
|
L
H
7.7
51.0
|
Incyte |
|
16,826.9
|
86.2
|
L
 -0.1%
H
85.9
87.1
|
L
 -0.9%
H
84.5
88.0
|
L
 9.9%
H
78.2
88.0
|
L
 23.0%
H
66.7
88.0
|
L
 36.5%
H
53.6
88.0
|
L
 19.3%
H
50.3
88.0
|
L
 -2.4%
H
50.3
101.5
|
L
 -30.8%
H
50.3
153.2
|
Indaptus Therapeutics Inc |
|
3.1
|
2.8
|
L
 11.0%
H
2.3
2.9
|
L
 -47.6%
H
2.3
5.6
|
L
 -60.5%
H
2.3
8.7
|
L
 757.6%
H
0.3
13.4
|
L
 95.2%
H
0.3
13.4
|
L
 1.1%
H
0.3
13.4
|
L
 -86.3%
H
0.3
36.8
|
L
 -99.4%
H
0.3
8800
|
Indivior Plc |
|
2,979.5
|
23.9
|
L
 -2.1%
H
23.7
24.6
|
L
 -3.2%
H
23.7
25.1
|
L
 8.6%
H
21.8
25.1
|
L
 74.4%
H
13.5
25.1
|
L
 146.7%
H
7.3
25.1
|
L
 646.3%
H
3
26.5
|
L
 1502.7%
H
1.2
26.5
|
L
 602.4%
H
0.4
26.5
|
MiNK Therapeutics Inc |
|
66.3
|
14.7
|
L
 -4.2%
H
14.7
15.6
|
L
 4.1%
H
13.1
16.2
|
L
 21.5%
H
11.7
18.2
|
L
 93.3%
H
6.8
76
|
L
 86.6%
H
0.9
76
|
L
 -47.5%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
InMed Pharmaceuticals Inc |
|
4.3
|
2.2
|
L
 -0.5%
H
2.2
2.2
|
L
 2.4%
H
2.0
2.3
|
L
 -3.6%
H
2.0
2.4
|
L
 -22.0%
H
2.0
5.5
|
L
 -60.2%
H
1.7
8.3
|
L
 -99.0%
H
1.7
390
|
L
 -99.9%
H
1.7
4470
|
L
 -99.9%
H
1.7
32175
|
INmune Bio Inc |
|
52.4
|
2.0
|
L
 11.9%
H
1.8
2.0
|
L
H
1.7
2
|
L
 -23.1%
H
1.7
2.6
|
L
 -75%
H
1.7
11.6
|
L
 -67.2%
H
1.7
11.6
|
L
 -76.2%
H
1.7
14.7
|
L
 -80.0%
H
1.7
30.4
|
L
H
1.7
30.4
|
Inovio Pharmaceuticals Inc |
|
140.8
|
2.7
|
L
 0.4%
H
2.6
2.8
|
L
 -2.2%
H
2.6
3.0
|
L
 87.9%
H
1.4
3.0
|
L
 17.8%
H
1.3
3.0
|
L
 -58.8%
H
1.3
7
|
L
 19.4%
H
0.3
14.8
|
L
 -72.7%
H
0.3
19
|
L
 -62.7%
H
0.3
33.8
|
Insmed Inc |
|
30,814.2
|
145.8
|
L
 -0.1%
H
144.9
147.1
|
L
 1.6%
H
140.3
149.1
|
L
 33.1%
H
109.2
149.1
|
L
 60.3%
H
90.9
149.1
|
L
 103.7%
H
60.4
149.1
|
L
 487.1%
H
16.0
149.1
|
L
 406.9%
H
16.0
149.1
|
L
 485.0%
H
9.0
149.1
|
Innoviva Inc |
|
1,224.5
|
19.4
|
L
 -2.2%
H
19.1
20.0
|
L
 -7.0%
H
19.1
21.1
|
L
 5.9%
H
18.9
21.1
|
L
 -9.8%
H
17.9
22
|
L
 -0.3%
H
16.7
22
|
L
 46.9%
H
10.6
22
|
L
 67.4%
H
9.2
22
|
L
 86.5%
H
6.4
22
|
IO Biotech Inc |
|
125.8
|
1.9
|
L
 7.9%
H
1.8
2.0
|
L
 9.1%
H
1.7
2
|
L
 5.5%
H
1.0
2.8
|
L
 29.1%
H
1.0
2.8
|
L
 114.6%
H
0.7
2.8
|
L
 -36.8%
H
0.7
3.5
|
L
H
0.7
17.9
|
L
H
0.7
17.9
|
Ionis Pharmaceuticals Inc |
|
10,207.4
|
64.0
|
L
 0.1%
H
62.8
64.2
|
L
 5.9%
H
58.8
64.7
|
L
 53.8%
H
40.4
64.7
|
L
 73.8%
H
34.8
64.7
|
L
 51.1%
H
24.0
64.7
|
L
 36.7%
H
24.0
64.7
|
L
 24.3%
H
24.0
64.7
|
L
 20.8%
H
19.6
86.6
|
Iovance Biotherapeutics Inc |
|
875.7
|
2.4
|
L
 1.7%
H
2.4
2.5
|
L
 9.5%
H
2.1
2.5
|
L
 14.7%
H
2.0
2.8
|
L
 1.7%
H
1.7
4.3
|
L
 -73.6%
H
1.6
12.5
|
L
 -78.4%
H
1.6
18.3
|
L
 -92.4%
H
1.6
54.2
|
L
 -66.1%
H
1.6
54.2
|
Century Therapeutics Inc |
|
44.9
|
0.5
|
L
 2.0%
H
0.5
0.5
|
L
 10.6%
H
0.5
0.5
|
L
 2.0%
H
0.5
0.6
|
L
 -18.8%
H
0.5
0.7
|
L
 -66.9%
H
0.3
1.9
|
L
 -95.4%
H
0.3
12.0
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
Disc Medicine Inc |
|
2,096.0
|
60.3
|
L
 0.6%
H
59.9
61.3
|
L
 -2.1%
H
58.6
65.3
|
L
 3.9%
H
57.0
65.3
|
L
 13.6%
H
48.9
65.3
|
L
 21.7%
H
30.8
68.7
|
L
 340.1%
H
11.8
77.6
|
L
 -42.6%
H
11.6
190.9
|
L
H
11.6
190.9
|
Ironwood Pharmaceuticals Inc |
|
201.4
|
1.2
|
L
 7.8%
H
1.2
1.3
|
L
H
1.0
1.3
|
L
 37.8%
H
0.8
1.4
|
L
 55%
H
0.6
1.4
|
L
 -69.6%
H
0.5
5.1
|
L
 -88.7%
H
0.5
15.7
|
L
 -87.1%
H
0.5
15.7
|
L
 -86.7%
H
0.5
17.7
|
Iterum Therapeutics Plc |
|
31.7
|
0.7
|
L
 2.9%
H
0.7
0.8
|
L
 12.7%
H
0.6
0.8
|
L
H
0.6
0.9
|
L
 -31.7%
H
0.6
1.3
|
L
 -25.3%
H
0.6
3.0
|
L
 -69.8%
H
0.6
3.0
|
L
 -92.2%
H
0.6
44.9
|
L
H
0.6
195
|
Invivyd Inc |
|
257.5
|
1.2
|
L
 -4.7%
H
1.2
1.4
|
L
 18.3%
H
1.0
1.5
|
L
 53.8%
H
0.5
1.5
|
L
 35.2%
H
0.5
1.5
|
L
 36.7%
H
0.4
2.7
|
L
 -73.3%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
IMab ADR |
|
318.5
|
3.9
|
L
 -6.7%
H
3.9
4.1
|
L
 -16.1%
H
3.2
4.6
|
L
 14.4%
H
3.2
5.9
|
L
 47.7%
H
1.7
5.9
|
L
 257.8%
H
0.6
5.9
|
L
 -32.4%
H
0.6
7.7
|
L
 -89.7%
H
0.6
85.4
|
L
H
0.6
85.4
|
Immunocore Holdings plc ADR |
|
1,842.7
|
36.6
|
L
 0.5%
H
35.9
36.7
|
L
 3.7%
H
34.6
38.2
|
L
 14.4%
H
31.0
38.2
|
L
 1.8%
H
30.8
38.2
|
L
 6.7%
H
23.2
39.3
|
L
 -18.3%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
Immutep ADR |
|
243.7
|
1.7
|
L
 1.8%
H
1.6
1.7
|
L
 1.8%
H
1.6
1.8
|
L
 -7.3%
H
1.6
1.9
|
L
 -10.8%
H
1.5
1.9
|
L
 -35.7%
H
1.3
2.7
|
L
 -12.2%
H
1.3
3.9
|
L
 3.8%
H
1.3
8.0
|
L
 -62.0%
H
0.5
8.0
|
Immuron ADR |
|
12.8
|
1.9
|
L
 -0.5%
H
1.9
1.9
|
L
 2.7%
H
1.8
1.9
|
L
 11.7%
H
1.6
1.9
|
L
 9.1%
H
1.6
2.0
|
L
 -27.7%
H
1.5
2.8
|
L
 -21.1%
H
1.4
6.0
|
L
 -75.6%
H
1.4
9.5
|
L
H
1.4
29.0
|
Innate Pharma ADR |
|
188.0
|
2.0
|
L
 -1.0%
H
2.0
2.1
|
L
 1.0%
H
1.9
2.2
|
L
 -2.9%
H
1.9
2.4
|
L
 3.0%
H
1.7
2.6
|
L
 -14.3%
H
1.3
3.5
|
L
 -19.4%
H
1.3
4.0
|
L
 -47.6%
H
1.3
12.0
|
L
H
1.3
12.0
|
Inventiva ADR |
|
802.4
|
5.8
|
L
 4.3%
H
5.5
5.8
|
L
H
5.3
5.8
|
L
 61.2%
H
3.4
6.5
|
L
 58.1%
H
2.9
6.5
|
L
 164.7%
H
1.5
6.5
|
L
 43.9%
H
1.5
11.8
|
L
 -49.9%
H
1.5
19.1
|
L
H
1.5
19.1
|
Jaguar Health Inc |
|
4.4
|
2.0
|
L
 -1.9%
H
2.0
2.1
|
L
 20.8%
H
1.6
2.2
|
L
 -5.1%
H
1.6
2.7
|
L
 -47%
H
1.6
3.9
|
L
 81.3%
H
0.4
15.5
|
L
 -99.8%
H
0.4
1156.5
|
L
 -100.0%
H
0.4
60345
|
L
 -100.0%
H
0.4
999999
|
Janux Therapeutics Inc |
|
1,509.6
|
25.1
|
L
 3.3%
H
24.1
25.1
|
L
 9.0%
H
22.8
25.6
|
L
 10.0%
H
22.0
26.1
|
L
 -4.3%
H
22.0
28.4
|
L
 -44.8%
H
22.0
71.7
|
L
 89.9%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
Jazz Pharmaceuticals plc |
|
7,792.2
|
128.5
|
L
 1.2%
H
126.4
129.5
|
L
 -2.5%
H
125.3
133
|
L
 15.4%
H
110.3
133
|
L
 13.7%
H
105
133
|
L
 20.9%
H
95.5
148.1
|
L
 -15.9%
H
95.5
161.0
|
L
 -7.6%
H
95.5
189
|
L
 -20.1%
H
86.9
189
|
Jasper Therapeutics Inc |
|
41.6
|
2.6
|
L
 -0.8%
H
2.5
2.6
|
L
 -5.9%
H
2.5
2.8
|
L
 4.5%
H
2.5
3.1
|
L
 -55.6%
H
2.3
7.2
|
L
 -87.4%
H
2.3
26.1
|
L
 30.6%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
Kala Pharmaceuticals Inc |
|
119.4
|
17
|
L
 11.3%
H
15.6
17.2
|
L
 13.3%
H
13.1
17.2
|
L
 130.4%
H
7.1
17.2
|
L
 258.7%
H
3.8
17.2
|
L
 187.7%
H
2.9
17.2
|
L
 -0.5%
H
2.9
56.7
|
L
 -96.2%
H
2.9
498.5
|
L
H
2.9
1337.5
|
KalVista Pharmaceuticals Inc |
|
745.5
|
14.8
|
L
 -3.8%
H
13.3
17.3
|
L
 4.6%
H
13.3
17.3
|
L
 19.3%
H
12.2
17.3
|
L
 4.2%
H
9.8
17.3
|
L
 32.1%
H
7.3
17.3
|
L
 -6.7%
H
4.1
17.3
|
L
 7.0%
H
4.1
45
|
L
 -79.4%
H
4.1
75.6
|
Kamada |
|
403.7
|
7.0
|
L
 -1.7%
H
7.0
7.3
|
L
 0.7%
H
6.9
7.4
|
L
 -1.4%
H
6.9
7.9
|
L
 0.4%
H
6.8
8.2
|
L
 33.2%
H
5.2
9.2
|
L
 40.4%
H
3.7
9.2
|
L
 -20.3%
H
3.7
9.2
|
L
 102.9%
H
3.2
13.3
|
Kiniksa Pharmaceuticals |
|
2,742.7
|
37.0
|
L
 2.2%
H
36.1
37.1
|
L
 4.3%
H
35.1
37.3
|
L
 15.1%
H
32
37.3
|
L
 24.3%
H
26.3
37.3
|
L
 53.4%
H
17.8
37.3
|
L
 238.9%
H
10.1
37.3
|
L
 138.8%
H
7.4
37.3
|
L
H
5.0
37.3
|
Kodiak Sciences Inc |
|
524.0
|
9.9
|
L
 2.1%
H
9.7
10.2
|
L
 15.8%
H
8.3
10.6
|
L
 25.6%
H
7.8
11.3
|
L
 135.1%
H
3.4
11.3
|
L
 306.6%
H
1.9
11.6
|
L
 -3.1%
H
1.4
11.6
|
L
 -79.9%
H
1.4
171.2
|
L
H
1.4
171.2
|
Kiora Pharmaceuticals Inc |
|
9.3
|
2.7
|
L
 -0.4%
H
2.6
2.8
|
L
 -3.6%
H
2.6
2.8
|
L
 14.4%
H
2.4
3.0
|
L
 -19.2%
H
2.3
3.3
|
L
 -22.9%
H
2.3
4.2
|
L
 -63.7%
H
0.4
11.4
|
L
 -98.2%
H
0.4
327.2
|
L
 -99.9%
H
0.4
3060
|
Karyopharm Therapeutics Inc |
|
57.6
|
6.6
|
L
 6.9%
H
6.2
6.6
|
L
 -6.2%
H
5.7
7.2
|
L
 68.5%
H
3.7
8.2
|
L
 49.9%
H
3.7
8.2
|
L
 -38.9%
H
0.6
17.0
|
L
 -91.7%
H
0.6
90.2
|
L
 -97.0%
H
0.6
270
|
L
 -97.0%
H
0.6
444.2
|
Keros Therapeutics Inc |
|
640.1
|
15.8
|
L
 0.7%
H
15.6
15.9
|
L
H
15.2
16
|
L
 14.8%
H
13.3
16.1
|
L
 14.6%
H
13.1
16.1
|
L
 -71.2%
H
9.1
72.4
|
L
 -59.6%
H
9.1
73
|
L
 -66.6%
H
9.1
88.8
|
L
H
9.1
88.8
|
Krystal Biotech Inc |
|
4,178.2
|
144.4
|
L
 5.0%
H
137.0
144.7
|
L
 -3.9%
H
136.7
153.0
|
L
 4.1%
H
136.7
153.0
|
L
 4.5%
H
128.0
159
|
L
 -22.0%
H
122.8
207.8
|
L
 103.8%
H
61.1
219.3
|
L
 227.1%
H
38.9
219.3
|
L
H
8.0
219.3
|
TuHURA Biosciences Inc |
|
129.6
|
2.6
|
L
 9.3%
H
2.4
2.6
|
L
 -0.4%
H
2.3
2.7
|
L
 12.6%
H
2.3
3.9
|
L
 -4.8%
H
2.1
3.9
|
L
 -57.3%
H
0.2
8.4
|
L
 -99.1%
H
0.2
542.5
|
L
 -99.9%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
Pasithea Therapeutics Corp |
|
5.9
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -7.1%
H
0.7
0.8
|
L
 16.2%
H
0.7
0.9
|
L
 -10.2%
H
0.7
0.9
|
L
 -79.7%
H
0.7
7.5
|
L
 -36.3%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Kura Oncology Inc |
|
765.6
|
8.8
|
L
 8.0%
H
8.1
8.9
|
L
 4.6%
H
7.9
8.9
|
L
 59.2%
H
5.5
8.9
|
L
 29.5%
H
5.5
8.9
|
L
 -55.3%
H
5.4
21.4
|
L
 -39.0%
H
5.4
24.2
|
L
 -67.2%
H
5.4
43
|
L
H
2.5
43
|
Kymera Therapeutics Inc |
|
3,303.2
|
46.2
|
L
 6.3%
H
43.7
46.2
|
L
 6.7%
H
40.7
46.2
|
L
 13.7%
H
36.7
46.2
|
L
 -4.9%
H
36.7
50.3
|
L
 -1.5%
H
19.4
53.3
|
L
 57.4%
H
9.6
53.3
|
L
 58.1%
H
9.6
91.9
|
L
H
9.6
91.9
|
Kezar Life Sciences Inc |
|
29.1
|
4.0
|
L
 -0.5%
H
4.0
4.1
|
L
 2.3%
H
3.8
4.1
|
L
 -0.5%
H
3.8
4.2
|
L
 -15.0%
H
3.8
5
|
L
 -28.9%
H
0.7
9.2
|
L
 -95.9%
H
0.7
105.1
|
L
 -91.5%
H
0.7
185.5
|
L
H
0.7
363.3
|
Kazia Therapeutics ADR |
|
11.1
|
8.2
|
L
 -1.2%
H
7.6
8.9
|
L
 1.5%
H
7.6
8.9
|
L
 0.4%
H
6.2
8.9
|
L
 54.9%
H
5.8
12.9
|
L
 -55.4%
H
2.9
39.1
|
L
 -89.2%
H
2.9
84
|
L
 -97.6%
H
2.9
792.5
|
L
 -98.4%
H
2.9
792.5
|
Lexaria Bioscience Corp |
|
20.9
|
1.1
|
L
 5.9%
H
1.0
1.1
|
L
 20.2%
H
0.9
1.1
|
L
 27.4%
H
0.8
1.1
|
L
 1.9%
H
0.8
1.1
|
L
 -69.9%
H
0.8
3.7
|
L
 -66.2%
H
0.7
6.9
|
L
 -87.1%
H
0.7
12.5
|
L
 -79.3%
H
0.7
76.2
|
Lifecore Biomedical Inc |
|
290.7
|
7.8
|
L
 10.8%
H
7
7.8
|
L
 0.8%
H
7
8.7
|
L
 7.3%
H
7
8.7
|
L
 13.3%
H
6.6
8.9
|
L
 60.5%
H
4.3
8.9
|
L
 -23.4%
H
1.5
11.5
|
L
 -19.8%
H
1.5
12.9
|
L
 -41.0%
H
1.5
15.6
|
Lifevantage Corporation |
|
148.7
|
11.7
|
L
 4.4%
H
11.1
11.8
|
L
 -13.6%
H
10.3
14.3
|
L
 -11.9%
H
10.3
15
|
L
 -6.8%
H
10.3
15
|
L
 22.2%
H
9
27.4
|
L
 197.5%
H
3.0
27.4
|
L
 -16.7%
H
3.0
27.4
|
L
 120.3%
H
2.9
27.4
|
Ligand Pharmaceuticals Inc |
|
3,256.8
|
167.1
|
L
 0.7%
H
165
169
|
L
 0.3%
H
162.7
169.5
|
L
 11.3%
H
137.1
169.5
|
L
 47.3%
H
110
169.5
|
L
 63.4%
H
93.6
169.5
|
L
 169.4%
H
49.3
169.5
|
L
 158.8%
H
46.8
169.5
|
L
 177.3%
H
36.9
179.8
|
Longeveron Inc Ordinary |
|
16.6
|
0.8
|
L
H
0.8
0.8
|
L
 -2.4%
H
0.7
0.9
|
L
 17.7%
H
0.7
0.9
|
L
 -42.0%
H
0.6
1.8
|
L
 -60.8%
H
0.6
2.5
|
L
 -98.4%
H
0.6
52.2
|
L
H
0.6
450
|
L
H
0.6
450
|
Atyr Pharma Inc |
|
515.4
|
5.3
|
L
 0.4%
H
5.2
5.6
|
L
 -7.9%
H
5.1
5.8
|
L
 -0.8%
H
4.6
6.1
|
L
 -4.4%
H
4.5
7.3
|
L
 176.8%
H
1.7
7.3
|
L
 44.5%
H
1.1
7.3
|
L
 34.5%
H
1.1
13.1
|
L
 -98.0%
H
1.1
275.4
|
Lixte Biotechnology Holdings |
|
24.0
|
5.3
|
L
 6.3%
H
4.9
5.7
|
L
 14.1%
H
4.3
5.7
|
L
 9.1%
H
3.1
5.7
|
L
 302.3%
H
0.6
5.7
|
L
 174.5%
H
0.6
5.7
|
L
 -26.8%
H
0.6
27
|
L
 -92.0%
H
0.6
71.9
|
L
 -66.2%
H
0.6
110.4
|
Lipocine Inc |
|
15.9
|
2.9
|
L
 -2%
H
2.9
3.0
|
L
 1.4%
H
2.9
3.0
|
L
 0.3%
H
2.9
3.1
|
L
 -10.9%
H
2.9
3.6
|
L
 -26.1%
H
2.7
6.2
|
L
 -66.4%
H
2.3
11.8
|
L
 -86.3%
H
2.3
41.1
|
L
 -99.0%
H
2.3
308.9
|
Leap Therapeutics Inc |
|
11.6
|
0.3
|
L
H
0.3
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -12.5%
H
0.2
0.4
|
L
 -33.3%
H
0.2
0.5
|
L
 -90.1%
H
0.2
4.8
|
L
 -98.3%
H
0.2
16.1
|
L
 -98.6%
H
0.2
41.7
|
L
H
0.2
102.5
|
Liquidia Corp |
|
2,324.5
|
27
|
L
 -1.1%
H
26.7
27.6
|
L
 -7.6%
H
26.7
29.4
|
L
 32.0%
H
19.9
29.9
|
L
 80.2%
H
11.9
29.9
|
L
 203.4%
H
9.3
29.9
|
L
 343.3%
H
4.4
29.9
|
L
 435.7%
H
2.3
29.9
|
L
H
2.3
38.5
|
Larimar Therapeutics Inc |
|
356.9
|
4.2
|
L
 4.3%
H
3.9
4.3
|
L
 5.8%
H
3.8
4.3
|
L
 16.5%
H
3.5
4.4
|
L
 43.3%
H
2.2
4.4
|
L
 -47.2%
H
1.6
9.5
|
L
 27.1%
H
1.6
13.7
|
L
 -72.3%
H
1.5
25.9
|
L
 -99.1%
H
1.5
575.8
|
Lisata Therapeutics Inc |
|
19.6
|
2.2
|
L
 -2.2%
H
2.2
2.3
|
L
 -2.6%
H
2.1
2.3
|
L
 -13.9%
H
2.1
2.9
|
L
 -13.2%
H
2.1
3.1
|
L
 -28.7%
H
1.9
4.2
|
L
 -70.8%
H
1.9
9.8
|
L
 -91.5%
H
1.9
73.4
|
L
 -99.2%
H
1.9
301.5
|
Lantern Pharma Inc |
|
42.4
|
3.9
|
L
 -0.8%
H
3.9
4.1
|
L
 -8.4%
H
3.7
4.5
|
L
 -21.2%
H
3.7
5.0
|
L
 16.6%
H
3.0
5.7
|
L
 17.3%
H
2.6
6.1
|
L
 -26.3%
H
2.4
12.0
|
L
 -74.4%
H
2.4
24.8
|
L
H
2.4
24.8
|
LAVA Therapeutics NV |
|
40.5
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -1.9%
H
1.5
1.6
|
L
 0.7%
H
1.5
1.6
|
L
 12.4%
H
1.3
1.7
|
L
 -9.4%
H
0.9
2.1
|
L
 -38.4%
H
0.9
7.4
|
L
H
0.9
17.2
|
L
H
0.9
17.2
|
Lexicon Pharmaceuticals Inc |
|
403.4
|
1.1
|
L
 2.8%
H
1.1
1.1
|
L
 2.8%
H
1.0
1.2
|
L
 2.8%
H
1.0
1.2
|
L
 58.6%
H
0.6
1.4
|
L
 -33.5%
H
0.3
2.2
|
L
 -61.7%
H
0.3
3.8
|
L
 -29.7%
H
0.3
9.7
|
L
 -91.2%
H
0.3
19.6
|
Lyell Immunopharma Inc |
|
255.5
|
13.3
|
L
 1.8%
H
12.6
13.5
|
L
 16.4%
H
11.2
13.5
|
L
 21.1%
H
9.3
13.5
|
L
 23.2%
H
8.5
14.2
|
L
 -42.2%
H
7.7
32
|
L
 -91.2%
H
7.7
174.8
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
Lyra Therapeutics Inc |
|
10.4
|
6.3
|
L
 -1.3%
H
6.3
6.5
|
L
 -11.8%
H
6.0
7.2
|
L
 -5.5%
H
6.0
7.6
|
L
 -59.2%
H
6.0
14.9
|
L
 -52.6%
H
3.8
37.5
|
L
 -97.9%
H
3.8
339.5
|
L
 -98.9%
H
3.8
825
|
L
H
3.8
1100
|
Legend Biotech Corp ADR |
|
6,244.0
|
33.8
|
L
 1.1%
H
33.5
34.7
|
L
 -5.9%
H
33.2
36.5
|
L
 -8.6%
H
33.2
38.4
|
L
 -10.1%
H
32.4
45.3
|
L
 -32.1%
H
27.3
52.3
|
L
 -24.0%
H
27.3
77.3
|
L
 10.4%
H
23.4
77.3
|
L
H
23.4
77.3
|
Mustang Bio Inc |
|
11.4
|
1.6
|
L
 11.4%
H
1.4
1.6
|
L
 2.0%
H
1.3
1.6
|
L
 -5.4%
H
1.3
1.9
|
L
 23.6%
H
0.9
7
|
L
 -88.8%
H
0.1
21.9
|
L
 -99.7%
H
0.1
554.2
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
Microbot Medical Inc |
|
188.7
|
3.9
|
L
 9.0%
H
3.6
4.3
|
L
 9.9%
H
3.2
4.7
|
L
 25.9%
H
2.9
4.7
|
L
 49.6%
H
2.3
4.7
|
L
 332.2%
H
0.9
4.7
|
L
 -29.0%
H
0.8
6.1
|
L
 -41.1%
H
0.8
10.7
|
L
 -99.6%
H
0.8
1020.6
|
Moleculin Biotech Inc |
|
11.5
|
0.4
|
L
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -44.1%
H
0.4
0.7
|
L
 -42.4%
H
0.3
1.0
|
L
 -84.0%
H
0.3
3.7
|
L
 -98.2%
H
0.3
132.8
|
L
 -99.5%
H
0.3
132.8
|
L
H
0.3
862.2
|
Seres Therapeutics Inc |
|
153.8
|
17.6
|
L
 -0.1%
H
17.2
18.7
|
L
 -5.0%
H
17
24.7
|
L
 23.7%
H
14.1
24.7
|
L
 112.7%
H
7.2
24.7
|
L
 1605.8%
H
0.4
24.7
|
L
 172.4%
H
0.4
24.7
|
L
 -30.6%
H
0.4
38.5
|
L
 -63.2%
H
0.4
49.7
|
Madrigal Pharmaceuticals Inc |
|
9,794.9
|
439.5
|
L
 2.2%
H
425
439.5
|
L
 1.0%
H
425
457.2
|
L
 27.1%
H
342.7
457.2
|
L
 55.7%
H
275
457.2
|
L
 86.5%
H
200.6
457.2
|
L
 577.5%
H
57.2
457.2
|
L
 338.7%
H
52.3
457.2
|
L
 515.5%
H
5.3
457.2
|
MediWound |
|
207.3
|
19.1
|
L
 3.3%
H
18.7
20.3
|
L
 15.0%
H
16.1
20.3
|
L
 2.3%
H
16.1
20.3
|
L
 -10.5%
H
16.1
21.3
|
L
 13.2%
H
14.1
22.5
|
L
 43.3%
H
7.1
24
|
L
 -17.2%
H
7.1
43.5
|
L
 -61.2%
H
7.1
73.3
|
Lite Strategy Inc |
|
104.1
|
3.2
|
L
 3.3%
H
3.0
3.2
|
L
 -30.0%
H
2.8
4.7
|
L
 -38.9%
H
2.8
5.6
|
L
 37.8%
H
2.2
9
|
L
 2.3%
H
1.5
9
|
L
 -71.1%
H
1.5
11.1
|
L
 -94.3%
H
1.5
91.5
|
L
 -91.4%
H
1.5
102.8
|
Macrogenics Inc |
|
104.3
|
1.7
|
L
 -4.1%
H
1.6
1.8
|
L
 -13.6%
H
1.6
2.2
|
L
 7.1%
H
1.4
2.2
|
L
 -7.3%
H
1.2
2.2
|
L
 -53.7%
H
1.0
5.1
|
L
 -61.1%
H
1.0
21.9
|
L
 -93.9%
H
1.0
36.5
|
L
 -93.7%
H
1.0
36.5
|
Mangoceuticals Inc |
|
22.4
|
2.1
|
L
 -2.7%
H
2.1
2.2
|
L
 -3.6%
H
2.0
2.5
|
L
 14.5%
H
1.4
2.6
|
L
 3.9%
H
1.4
2.6
|
L
 688.9%
H
0.2
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
Magenta Therapeutics Inc |
|
-
|
37.9
|
L
 -0.1%
H
36.2
38.6
|
L
 56.1%
H
23.7
38.6
|
L
 101.8%
H
18.1
38.6
|
L
 101.9%
H
16.6
38.6
|
L
 92.3%
H
16.6
38.6
|
L
 22.6%
H
5.1
38.6
|
L
 -66.9%
H
5.1
227.2
|
L
H
5.1
336
|
MeiraGTx Holdings plc |
|
617.0
|
7.7
|
L
 2.4%
H
7.4
7.8
|
L
 4.6%
H
7.2
8.1
|
L
 -2.7%
H
7.2
8.6
|
L
 11.8%
H
6.1
9.0
|
L
 88.5%
H
3.9
9.0
|
L
 -17.1%
H
3.5
9.4
|
L
 -41.7%
H
3.5
24.9
|
L
H
3.5
30.2
|
Mirum Pharmaceuticals Inc |
|
3,817.6
|
76.0
|
L
 1.5%
H
73.7
76.2
|
L
 1.9%
H
71.9
78.1
|
L
 26.7%
H
58.5
78.1
|
L
 55.1%
H
47.8
78.1
|
L
 81.9%
H
36.9
78.1
|
L
 202.1%
H
17.3
78.1
|
L
 288.9%
H
12.8
78.1
|
L
H
6.5
78.1
|
Milestone Pharmaceuticals Inc |
|
162.3
|
1.9
|
L
 11.7%
H
1.8
1.9
|
L
 7.3%
H
1.7
1.9
|
L
 27.3%
H
1.5
1.9
|
L
 9.1%
H
1.4
2.6
|
L
 29.1%
H
0.6
2.6
|
L
 -78.1%
H
0.6
9.9
|
L
 -76.6%
H
0.6
9.9
|
L
H
0.6
28.0
|
MoonLake Immunotherapeutics |
|
3,448.1
|
54.3
|
L
 0.2%
H
52.7
55.4
|
L
 -8.7%
H
52.7
61.3
|
L
 3.6%
H
51.7
61.9
|
L
 17.9%
H
42.2
61.9
|
L
 16.5%
H
31.4
61.9
|
L
 605.2%
H
6.9
65.0
|
L
H
4.3
65.0
|
L
H
4.3
65.0
|
Mineralys Therapeutics Inc |
|
2,827.8
|
37.2
|
L
 -3.6%
H
37.1
39.2
|
L
 27.0%
H
29.1
39.2
|
L
 185.9%
H
12.6
39.2
|
L
 131.8%
H
12.6
39.2
|
L
 209.4%
H
8.2
39.2
|
L
H
5.9
39.2
|
L
H
5.9
39.2
|
L
H
5.9
39.2
|
Mannkind Corp |
|
1,663.0
|
5.4
|
L
 -2.7%
H
5.4
5.7
|
L
 -1.6%
H
5.2
5.8
|
L
 54.0%
H
3.4
6.2
|
L
 38.3%
H
3.4
6.2
|
L
 -10.0%
H
3.4
7.6
|
L
 39.7%
H
2.9
7.6
|
L
 226.5%
H
1.6
7.6
|
L
 -71.1%
H
0.7
19.0
|
Mind Medicine Inc |
|
734.2
|
9.7
|
L
 3.4%
H
9.3
9.7
|
L
 6.5%
H
8.7
10.0
|
L
 -2.0%
H
8.7
11.0
|
L
 22.3%
H
6.3
11.0
|
L
 65.2%
H
4.7
11.0
|
L
 16.1%
H
2.1
12.2
|
L
 86.3%
H
2.1
86.6
|
L
H
0.0
154.8
|
Medicinova Inc |
|
61.3
|
1.3
|
L
 -1.6%
H
1.3
1.3
|
L
 -5.3%
H
1.3
1.4
|
L
 -7.4%
H
1.3
1.4
|
L
 -11.4%
H
1.2
1.5
|
L
 -36.2%
H
1.1
2.6
|
L
 -43.4%
H
1.1
2.7
|
L
 -76.8%
H
1.1
10.8
|
L
 -60.9%
H
1.1
14.5
|
Monopar Therapeutics Inc |
|
294.1
|
47.7
|
L
 11.1%
H
42.5
47.8
|
L
 31.6%
H
35.0
47.8
|
L
 37.6%
H
29.2
47.8
|
L
 38.1%
H
29.2
50.1
|
L
 1845.3%
H
2.4
54.1
|
L
 447.8%
H
1.4
54.1
|
L
 74.9%
H
1.4
85.1
|
L
H
1.4
240
|
Marker Therapeutics Inc |
|
12.6
|
1.0
|
L
 6.6%
H
0.9
1.0
|
L
 11.5%
H
0.8
1.0
|
L
 -18.5%
H
0.8
1.3
|
L
 -42.6%
H
0.8
4.1
|
L
 -64.1%
H
0.8
6.0
|
L
 -78.4%
H
0.7
9.7
|
L
 -93.7%
H
0.7
37.7
|
L
 -98.3%
H
0.7
135.5
|
Moderna |
|
9,878.7
|
25.4
|
L
 4.4%
H
24.5
25.9
|
L
 5.6%
H
23.3
25.9
|
L
 -2.8%
H
23.3
28.6
|
L
 -8.3%
H
23.3
35.6
|
L
 -68.0%
H
23.2
79.9
|
L
 -82.2%
H
23.2
217.3
|
L
 -55.9%
H
23.2
497.5
|
L
H
11.5
497.5
|
Mersana Therapeutics Inc |
|
37.3
|
7.5
|
L
 1.6%
H
7.3
7.5
|
L
 7.0%
H
6.6
7.7
|
L
 18.6%
H
5.2
8.2
|
L
 -26.6%
H
5.2
10.8
|
L
 -81.1%
H
5.2
70.8
|
L
 -96.2%
H
5.2
240.5
|
L
 -98.4%
H
5.2
727.3
|
L
H
5.2
727.3
|
Merus NV |
|
5,279.3
|
69.8
|
L
 4.0%
H
67.1
70.7
|
L
 4.8%
H
62.8
70.7
|
L
 9.1%
H
62.2
70.7
|
L
 23.7%
H
51.8
70.7
|
L
 40.5%
H
33.2
70.7
|
L
 197.8%
H
12.0
70.7
|
L
 528.8%
H
10.9
70.7
|
L
H
7.3
70.7
|
Maravai LifeSciences Holdings |
|
403.7
|
2.8
|
L
 7.3%
H
2.6
2.8
|
L
 18.2%
H
2.3
2.8
|
L
 26.8%
H
2.0
2.8
|
L
 29.2%
H
2.0
2.9
|
L
 -68.9%
H
1.7
9.5
|
L
 -87.8%
H
1.7
26.6
|
L
H
1.7
63.6
|
L
H
1.7
63.6
|
Mannatech Inc |
|
15.4
|
8.1
|
L
 -0.6%
H
8.1
9.8
|
L
 -14.2%
H
8.1
10.5
|
L
 -3.0%
H
8
10.9
|
L
 -23.3%
H
7.5
10.9
|
L
 8.3%
H
7.1
16.5
|
L
 -59.7%
H
6.8
24.6
|
L
 -52.2%
H
6.8
49.1
|
L
 -52.0%
H
6.5
49.1
|
MaxCyte Inc |
|
157.8
|
1.5
|
L
 4.2%
H
1.4
1.5
|
L
 7.3%
H
1.3
1.5
|
L
 7.3%
H
1.3
1.5
|
L
 -35.9%
H
1.3
2.4
|
L
 -62.6%
H
1.3
5.2
|
L
 -76.8%
H
1.3
7.5
|
L
 -9.2%
H
1.3
17.4
|
L
H
1.3
17.4
|
TNF Pharmaceuticals Inc |
|
7.2
|
4.0
|
L
 11.3%
H
3.6
4.1
|
L
 16.1%
H
3.2
4.2
|
L
 -58.4%
H
3.2
12.2
|
L
 -77.1%
H
3.2
17.7
|
L
 -97.4%
H
3.2
195
|
L
 -100.0%
H
3.2
11610
|
L
 -99.9%
H
3.2
29850
|
L
 -100.0%
H
3.2
29850
|
Mainz Biomed NV |
|
7.7
|
1.7
|
L
 -2.3%
H
1.6
1.7
|
L
 1.2%
H
1.6
1.8
|
L
 17.5%
H
1.4
1.9
|
L
 -19.2%
H
1.3
2.3
|
L
 -87.8%
H
1.3
16.0
|
L
 -99.5%
H
1.3
384.5
|
L
H
1.3
1200
|
L
H
1.3
1200
|
Mesoblast ADR |
|
1,969.2
|
15.4
|
L
 -1.2%
H
15.2
15.5
|
L
 19.3%
H
13.1
15.7
|
L
 2.3%
H
12.7
16.4
|
L
 20.9%
H
9.9
17.6
|
L
 152.0%
H
6
22
|
L
 405.6%
H
1.0
22
|
L
 -3.9%
H
1.0
22
|
L
 37.2%
H
1.0
22
|
Molecular Partners AG ADR |
|
140.2
|
3.8
|
L
 -2.6%
H
3.7
3.8
|
L
 0.8%
H
3.5
3.9
|
L
 2.5%
H
3.5
4.8
|
L
 1.4%
H
3.4
4.8
|
L
 -33.2%
H
3.4
7.6
|
L
 -38.1%
H
3.3
12.7
|
L
 -77.0%
H
3.3
32.0
|
L
 -89.0%
H
3.3
38.8
|
Mereo Biopharma Group Plc |
|
289.4
|
1.8
|
L
 2.3%
H
1.8
1.8
|
L
 5.2%
H
1.7
1.8
|
L
 19.0%
H
1.5
1.8
|
L
 -31.3%
H
1.5
3.1
|
L
 -61.2%
H
1.5
4.7
|
L
 70.1%
H
0.5
5.0
|
L
 -32.8%
H
0.3
5.0
|
L
H
0.3
8.5
|
Natural Alternatives |
|
22.2
|
3.6
|
L
 6.5%
H
3.4
3.9
|
L
 -1.1%
H
3.3
3.9
|
L
 -3.0%
H
3.3
4.0
|
L
 4.1%
H
3.2
4.0
|
L
 -44.4%
H
2.6
6.8
|
L
 -69.9%
H
2.6
12.6
|
L
 -50.8%
H
2.6
19.9
|
L
 -38.6%
H
2.6
19.9
|
NewAmsterdam Pharma Company NV |
|
2,995.9
|
26.6
|
L
 -1.1%
H
25.6
27.4
|
L
 6.9%
H
24.2
27.4
|
L
 5.1%
H
23.7
27.4
|
L
 21.8%
H
17.6
27.4
|
L
 61.5%
H
14.1
27.4
|
L
 167.3%
H
5.6
32.9
|
L
H
5.6
32.9
|
L
H
5.6
32.9
|
Natures Sunshine Products |
|
300.5
|
17.0
|
L
 -0.6%
H
16.8
17.3
|
L
 -1.1%
H
16.8
17.6
|
L
 9.9%
H
15.5
17.6
|
L
 19.2%
H
13.4
17.6
|
L
 30.2%
H
11.0
18.1
|
L
 82.4%
H
7.9
21.7
|
L
 39.1%
H
7.9
21.7
|
L
 41.2%
H
5.5
21.7
|
Nautilus Biotechnology Inc |
|
89.7
|
0.7
|
L
H
0.7
0.8
|
L
 10.9%
H
0.6
0.8
|
L
 -2.7%
H
0.6
0.8
|
L
 -5.3%
H
0.6
0.9
|
L
 -74.8%
H
0.6
3.1
|
L
 -68.7%
H
0.6
4.7
|
L
 -93.4%
H
0.6
25.9
|
L
H
0.6
25.9
|
Neurocrine Biosciences Inc |
|
14,242.5
|
143.6
|
L
 1.7%
H
141.5
143.8
|
L
 5.5%
H
135.7
145.8
|
L
 14.9%
H
123.7
145.8
|
L
 15.1%
H
122.7
145.8
|
L
 20.6%
H
84.2
154.6
|
L
 34.8%
H
84.2
158.0
|
L
 39.4%
H
71.9
158.0
|
L
 168.1%
H
31.3
158.0
|
Minerva Neurosciences Inc |
|
14.9
|
2.1
|
L
 -0.9%
H
2.1
2.2
|
L
 -11.3%
H
2.1
2.4
|
L
 21.0%
H
1.8
2.6
|
L
 18.3%
H
1.6
2.6
|
L
 -21.1%
H
1.2
3
|
L
 -79.4%
H
1.2
14.7
|
L
 -90.8%
H
1.2
32.9
|
L
 -95.6%
H
1.2
126.7
|
Nektar Therapeutics |
|
897.7
|
47.2
|
L
 -2.0%
H
42.1
50.5
|
L
 65.3%
H
31.9
50.5
|
L
 104.7%
H
22.3
50.5
|
L
 315.9%
H
8.0
50.5
|
L
 153.8%
H
6.5
50.5
|
L
 -15.9%
H
6.2
65.6
|
L
 -83.3%
H
6.2
401.3
|
L
 -72.5%
H
6.2
1670.4
|
Nkarta Inc |
|
147.0
|
2.1
|
L
 2.5%
H
2.0
2.1
|
L
 -1.4%
H
2
2.3
|
L
 4.6%
H
2.0
2.5
|
L
 4.0%
H
1.6
2.5
|
L
 -68.2%
H
1.3
6.6
|
L
 -85.8%
H
1.3
16.2
|
L
 -93.4%
H
1.3
79.2
|
L
H
1.3
79.2
|
NLS Pharmaceutics |
|
10.6
|
2.2
|
L
 3.9%
H
2.0
2.2
|
L
 5.9%
H
1.9
2.2
|
L
 0.5%
H
1.9
2.8
|
L
 -15.7%
H
1.7
3.1
|
L
 -56.7%
H
0.1
7.0
|
L
 -93.9%
H
0.1
75.2
|
L
H
0.1
294
|
L
H
0.1
294
|
Neoleukin Therapeutics Inc |
|
-
|
20.1
|
L
 8.0%
H
18.6
20.7
|
L
 1.1%
H
18.4
20.7
|
L
 -5.4%
H
18
21.7
|
L
 -7.0%
H
14.7
23.9
|
L
 11.6%
H
14.7
25.2
|
L
 -7.9%
H
7.5
25.2
|
L
 -91.8%
H
7.5
359
|
L
 -93.9%
H
7.5
447.6
|
9 Meters Biopharma Inc |
|
-
|
7.2
|
L
 0.1%
H
7.2
7.4
|
L
 -1.6%
H
7.2
7.5
|
L
 9.0%
H
6.6
7.5
|
L
 4.0%
H
6.2
7.5
|
L
 1.7%
H
6.2
7.5
|
L
 35.6%
H
0.0
7.5
|
L
 -42.5%
H
0.0
45.2
|
L
H
0.0
1010
|
MetaVia Inc |
|
16.5
|
0.7
|
L
H
0.7
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 7.9%
H
0.6
0.7
|
L
 -12.8%
H
0.6
0.8
|
L
 -82.5%
H
0.6
4.2
|
L
 -91.8%
H
0.4
63.9
|
L
 -99.6%
H
0.4
228.3
|
L
H
0.4
16192.5
|
Nurix Therapeutics Inc |
|
703.3
|
9.2
|
L
 2.8%
H
8.9
9.3
|
L
 -2.8%
H
8.9
10.1
|
L
 -6.5%
H
8.9
11.0
|
L
 -28.1%
H
8.9
14.6
|
L
 -62.3%
H
8.2
29.6
|
L
 -42.0%
H
4.2
29.6
|
L
 -67.5%
H
4.2
52.4
|
L
H
4.2
52.4
|
NeuroSense Therapeutics |
|
28.8
|
1.2
|
L
 -15.4%
H
1.1
1.3
|
L
 7.5%
H
1.0
2.0
|
L
 -8.7%
H
1.0
2.0
|
L
 -46.0%
H
1.0
2.6
|
L
 -0.9%
H
0.8
2.6
|
L
 -42.8%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
NRX Pharmaceuticals Inc |
|
68.5
|
2.9
|
L
 -3.0%
H
2.8
3.0
|
L
 10.8%
H
2.5
3.2
|
L
 14.3%
H
2.3
3.2
|
L
 -21.1%
H
2.3
3.8
|
L
 65.5%
H
1.1
6.0
|
L
 -58.9%
H
1.1
54
|
L
 -97.3%
H
1.1
769.9
|
L
H
1.1
769.9
|
Intellia Therapeutics Inc |
|
1,225.9
|
11.4
|
L
 1.2%
H
11.2
11.8
|
L
 -2.5%
H
10.9
12.3
|
L
 5.8%
H
9.8
12.5
|
L
 34.8%
H
8
14.6
|
L
 -43.2%
H
5.9
23.8
|
L
 -82.3%
H
5.9
69.3
|
L
 -39.7%
H
5.9
202.7
|
L
H
5.9
202.7
|
Nuvalent Inc Ordinary Shares |
|
5,928.5
|
82.2
|
L
 4.7%
H
78.3
83.1
|
L
 3.4%
H
74.4
83.1
|
L
 10.9%
H
71.7
83.1
|
L
 3.5%
H
71.1
86.8
|
L
 -6.0%
H
55.5
113.5
|
L
 367.4%
H
15.6
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
Novavax Inc |
|
1,344.9
|
8.3
|
L
 4.0%
H
8.0
8.3
|
L
 11.9%
H
7.2
8.3
|
L
 -1.1%
H
7.2
10.6
|
L
 15%
H
6.1
10.6
|
L
 -34.8%
H
5.0
15.2
|
L
 -73.9%
H
3.5
33.4
|
L
 -91.1%
H
3.5
331.7
|
L
 -95.9%
H
3.5
331.7
|
Nuvectis Pharma Inc |
|
165.7
|
6.5
|
L
 3.7%
H
6.3
6.6
|
L
 2.5%
H
6.3
6.9
|
L
 8.5%
H
6.0
7.0
|
L
 -27.8%
H
5.9
9.3
|
L
 3.8%
H
4.4
11.8
|
L
 -22.5%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
Nextcure Inc |
|
14.6
|
5.4
|
L
 -0.9%
H
5.2
5.5
|
L
 9.2%
H
4.8
5.5
|
L
 11.7%
H
4.8
5.6
|
L
 -17.6%
H
4.6
9.1
|
L
 -66.4%
H
2.8
19.2
|
L
 -88.1%
H
2.8
48.6
|
L
 -95.0%
H
2.8
172.8
|
L
H
2.8
1308
|
NuCana plc ADR |
|
7.0
|
3.7
|
L
 12.6%
H
3.2
3.8
|
L
 20.7%
H
2.8
3.8
|
L
 -43.0%
H
2.8
5.7
|
L
 -99.9%
H
2.8
8000
|
L
 -100%
H
2.8
330000
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7830000
|
L
H
2.8
32000000
|
Ocugen Inc |
|
334.2
|
1.1
|
L
 2.9%
H
1.0
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 7%
H
1.0
1.1
|
L
 -5.3%
H
0.9
1.3
|
L
 -13.7%
H
0.5
1.3
|
L
 -56.9%
H
0.3
2.5
|
L
 224.2%
H
0.3
18.8
|
L
 -99.7%
H
0.2
375
|
Oculis Holding AG |
|
901.2
|
17.2
|
L
H
17.0
17.3
|
L
 5.3%
H
16.6
17.3
|
L
 -5.4%
H
16
18.4
|
L
 -13.0%
H
16
20
|
L
 43.4%
H
11.8
23.1
|
L
 74.3%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
Ocular Therapeutix Inc |
|
2,221.9
|
12.8
|
L
 -2.2%
H
12.7
13.3
|
L
 -1.3%
H
12.4
13.9
|
L
 4.6%
H
11.7
13.9
|
L
 43.3%
H
8.0
13.9
|
L
 52.8%
H
5.8
13.9
|
L
 113.5%
H
2
13.9
|
L
 53.7%
H
2
24.3
|
L
 -26.0%
H
2
24.3
|
Opus Genetics Inc |
|
84.5
|
1.4
|
L
 6.0%
H
1.3
1.4
|
L
 10.2%
H
1.2
1.4
|
L
 31.8%
H
1.0
1.4
|
L
 38.2%
H
0.9
1.4
|
L
 9.3%
H
0.7
1.8
|
L
 -41.0%
H
0.7
6.6
|
L
 -81.0%
H
0.7
13.8
|
L
 -99.5%
H
0.7
340.8
|
Insight Molecular Diagnostics |
|
91.0
|
3.2
|
L
 6%
H
2.9
3.3
|
L
 24.2%
H
2.4
3.3
|
L
 23.7%
H
2.3
3.3
|
L
 15.2%
H
2.3
4.2
|
L
 0.6%
H
1.9
4.8
|
L
 -81.8%
H
1.9
18.6
|
L
 -88.3%
H
1.9
131.4
|
L
H
1.9
204.8
|
OKYO Pharma Ordinary Shares |
|
81.6
|
2.2
|
L
 -0.5%
H
2.1
2.4
|
L
 -4.4%
H
2.1
2.4
|
L
 -33.6%
H
2.1
3.3
|
L
 4.8%
H
2.0
3.4
|
L
 97.3%
H
0.9
3.4
|
L
 -33.8%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
Olema Pharmaceuticals Inc |
|
549.1
|
8
|
L
 2.4%
H
7.8
8.3
|
L
 27.2%
H
6.0
8.5
|
L
 72.4%
H
4.5
8.5
|
L
 90.0%
H
3.9
8.5
|
L
 -35.1%
H
2.9
13.9
|
L
 89.6%
H
2.2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
Omeros Corporation |
|
285.8
|
4.2
|
L
 -1.6%
H
4.2
4.3
|
L
 0.5%
H
4.1
4.3
|
L
 3.5%
H
3.9
4.6
|
L
 8.3%
H
3.0
4.6
|
L
 15.4%
H
3.0
13.6
|
L
 -21.5%
H
0.9
13.6
|
L
 -64.0%
H
0.9
23.9
|
L
 -69.5%
H
0.9
27.1
|
Oncolytics Biotech Inc |
|
132.6
|
1.3
|
L
H
1.3
1.4
|
L
 12.9%
H
1.1
1.4
|
L
 52.3%
H
0.8
1.4
|
L
 204.7%
H
0.4
1.4
|
L
 33.7%
H
0.3
1.5
|
L
 -7.1%
H
0.3
3.4
|
L
 -17.1%
H
0.3
4.8
|
L
 -77.6%
H
0.3
8.5
|
Traws Pharma Inc |
|
12.8
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 12.4%
H
1.5
2.0
|
L
 20.7%
H
1.3
2.0
|
L
 -2.7%
H
1.3
2.0
|
L
 -78.5%
H
1.0
19.4
|
L
 -93.8%
H
1.0
37.3
|
L
 -98.0%
H
1.0
723.8
|
L
 -100.0%
H
1.0
106312.5
|
VivoSim Labs Inc |
|
9.6
|
3.7
|
L
 14.9%
H
3.2
3.7
|
L
 46.8%
H
2.1
3.7
|
L
 112.6%
H
1.7
3.7
|
L
 104.4%
H
1.4
3.7
|
L
 -40.7%
H
0.3
22.0
|
L
 -87.8%
H
0.3
40.8
|
L
 -95.7%
H
0.3
287.0
|
L
 -99.4%
H
0.3
1197.6
|
ORIC Pharmaceuticals Inc |
|
1,054.8
|
10.9
|
L
 3.2%
H
10.6
10.9
|
L
 2.5%
H
10.3
11.3
|
L
 17.5%
H
9.0
11.3
|
L
 11.4%
H
8.9
12
|
L
 9.0%
H
3.9
14.7
|
L
 214.8%
H
2.4
16.7
|
L
 -51.1%
H
2.4
40.8
|
L
H
2.4
40.8
|
Oramed Pharmaceuticals Inc |
|
99.6
|
2.4
|
L
 4.3%
H
2.3
2.5
|
L
 10.5%
H
2.2
2.5
|
L
 16.3%
H
2.0
2.5
|
L
 9.0%
H
2.0
2.5
|
L
 1.3%
H
1.8
3.1
|
L
 -71.5%
H
1.7
13.7
|
L
 -23.1%
H
1.7
31.5
|
L
 -57.2%
H
1.7
31.5
|
Outlook Therapeutics Inc |
|
48.4
|
1.1
|
L
 9%
H
1.0
1.2
|
L
 22.5%
H
0.8
1.2
|
L
 -42.6%
H
0.8
3.0
|
L
 -40.8%
H
0.8
3.0
|
L
 -86.0%
H
0.8
7.9
|
L
 -99.8%
H
0.8
812
|
L
 -99.6%
H
0.8
1704
|
L
H
0.8
17568
|
Ovid Therapeutics Inc |
|
88.9
|
1.3
|
L
H
1.2
1.3
|
L
 -6.0%
H
1.2
1.4
|
L
 140.4%
H
0.5
1.4
|
L
 290.6%
H
0.3
1.4
|
L
 12.6%
H
0.2
1.5
|
L
 -42.7%
H
0.2
4.1
|
L
 -78.0%
H
0.2
7.0
|
L
H
0.2
15.9
|
Phibro Animal Health Corp |
|
1,669.6
|
41.2
|
L
 0.0%
H
40.6
41.4
|
L
 7.8%
H
37.8
41.6
|
L
 46.6%
H
27.8
41.6
|
L
 69.2%
H
23.6
41.6
|
L
 97.3%
H
16.2
41.6
|
L
 173.0%
H
9.4
41.6
|
L
 121.7%
H
9.4
41.6
|
L
 22.8%
H
9.4
54.6
|
Palisade Bio Inc |
|
5.4
|
0.6
|
L
 7.4%
H
0.5
0.6
|
L
 -10.8%
H
0.5
0.7
|
L
 -26.6%
H
0.5
0.9
|
L
 -13.4%
H
0.5
1.9
|
L
 -83.7%
H
0.5
4.3
|
L
 -99.5%
H
0.4
136.4
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
2293200
|
Passage Bio Inc |
|
22.2
|
7.0
|
L
 -1.3%
H
6.9
7.3
|
L
 -2.1%
H
6.8
7.6
|
L
 11.2%
H
5.5
7.8
|
L
 -27.4%
H
5.1
9.8
|
L
 -54.9%
H
5.1
26.6
|
L
 -80.7%
H
5.1
38.4
|
L
 -97.8%
H
5.1
617.4
|
L
H
5.1
764.6
|
Paranovus Entertainment |
|
56.6
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 15.1%
H
0.7
1.1
|
L
 7.7%
H
0.7
1.1
|
L
 -6.7%
H
0.7
1.1
|
L
H
0.3
1.5
|
L
 -77.2%
H
0.3
6.7
|
L
 -97.9%
H
0.3
51.6
|
L
H
0.3
122
|
Puma Biotechnology Inc |
|
226.7
|
4.5
|
L
 -0.9%
H
4.5
4.7
|
L
 -12.3%
H
4.5
5.2
|
L
 22.0%
H
3.7
6.1
|
L
 25%
H
3.0
6.1
|
L
 88.3%
H
2.3
6.1
|
L
 64.2%
H
2.1
7.7
|
L
 -53.8%
H
1.6
14.1
|
L
 -95.3%
H
1.6
136.9
|
Pacira BioSciences Inc |
|
1,214.5
|
27.0
|
L
 1.6%
H
25.8
27.1
|
L
 -0.6%
H
25.6
27.6
|
L
 7.4%
H
23.7
27.6
|
L
 8.7%
H
20.9
27.6
|
L
 104%
H
12.6
27.6
|
L
 -51.5%
H
11.2
58.1
|
L
 -54.3%
H
11.2
82.2
|
L
 -56.0%
H
11.2
82.2
|
Processa Pharmaceuticals Inc |
|
9.6
|
0.2
|
L
H
0.2
0.2
|
L
H
0.2
0.2
|
L
 -17.4%
H
0.2
0.2
|
L
 -44.1%
H
0.2
0.8
|
L
 -85.5%
H
0.2
1.5
|
L
 -93.2%
H
0.2
5.9
|
L
 -97.5%
H
0.2
14.2
|
L
 -99.6%
H
0.2
35.9
|
Vaxcyte Inc |
|
4,292.0
|
33.1
|
L
 3.3%
H
31.9
33.2
|
L
 3.0%
H
30.9
33.7
|
L
 10.6%
H
29.5
33.7
|
L
 -11.1%
H
29.1
38.0
|
L
 -71.6%
H
27.7
121.1
|
L
 16.9%
H
20.5
121.1
|
L
 -11.0%
H
15.5
121.1
|
L
H
15.5
121.1
|
PDS Biotechnology Corporation |
|
55.0
|
1.2
|
L
 -4.1%
H
1.2
1.3
|
L
 -9.2%
H
1.1
1.3
|
L
 6.3%
H
1.1
1.5
|
L
 -29.8%
H
1.0
1.9
|
L
 -60.8%
H
0.9
4.3
|
L
 -72.4%
H
0.9
13.7
|
L
 -45.6%
H
0.9
17.9
|
L
H
0.6
517.4
|
PepGen Inc |
|
44.3
|
1.4
|
L
 -3.6%
H
1.3
1.5
|
L
 13.5%
H
1.2
1.9
|
L
 26.2%
H
1.0
1.9
|
L
 -10%
H
1.0
1.9
|
L
 -84.5%
H
0.9
10.1
|
L
 -86.4%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
Precigen Inc |
|
1,233.6
|
4.1
|
L
 1.5%
H
4.1
4.2
|
L
 -12.8%
H
3.9
4.8
|
L
 132.6%
H
1.7
5.2
|
L
 168.8%
H
1.4
5.2
|
L
 322.5%
H
0.7
5.2
|
L
 49.5%
H
0.7
5.2
|
L
 -13.0%
H
0.7
11.1
|
L
 -90.3%
H
0.7
53.4
|
Phathom Pharmaceuticals Inc |
|
855.6
|
12.1
|
L
 -2.1%
H
11.9
12.3
|
L
 1.5%
H
11.3
13
|
L
 23.8%
H
9.5
13
|
L
 34.5%
H
7.6
13
|
L
 -32.7%
H
2.2
19.7
|
L
 30.0%
H
2.2
19.7
|
L
 -65.7%
H
2.2
50.8
|
L
H
2.2
64.5
|
Phio Pharmaceuticals Corp |
|
13.3
|
2.3
|
L
 -6.1%
H
2.3
2.5
|
L
 11.5%
H
2.0
2.6
|
L
 3.1%
H
1.9
2.6
|
L
 -6.1%
H
1.9
3.5
|
L
 -20.6%
H
1.0
9.8
|
L
 -97.0%
H
0.6
110.4
|
L
 -98.9%
H
0.6
470.9
|
L
 -100.0%
H
0.6
385743.6
|
Pharvaris NV |
|
1,511.0
|
23.5
|
L
 1.1%
H
23.4
24.1
|
L
 7.3%
H
21.4
24.8
|
L
 16.8%
H
19.6
25.0
|
L
 29.7%
H
16
26.3
|
L
 9.8%
H
11.5
26.3
|
L
 152.1%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
Pliant Therapeutics Inc |
|
101.3
|
1.7
|
L
 -2.4%
H
1.6
1.7
|
L
 -3.5%
H
1.6
1.9
|
L
 -0.6%
H
1.4
1.9
|
L
 7.1%
H
1.1
1.9
|
L
 -87.3%
H
1.1
16.1
|
L
 -92.6%
H
1.1
36.6
|
L
 -93.7%
H
1.1
43.9
|
L
H
1.1
43.9
|
Pluri Inc |
|
40.5
|
5.1
|
L
 8.4%
H
4.7
5.2
|
L
 -0.2%
H
4.3
5.3
|
L
 6.6%
H
4.3
5.7
|
L
 10.8%
H
3.9
6.0
|
L
 -2.1%
H
3.3
7.1
|
L
 -30.2%
H
0.7
11.6
|
L
 -93.7%
H
0.7
94.8
|
L
 -96.9%
H
0.7
174.4
|
PharmaCyte Biotech Inc |
|
7.0
|
1.0
|
L
 2.0%
H
1
1.1
|
L
 7.3%
H
0.9
1.3
|
L
 24.1%
H
0.8
1.3
|
L
 -4.6%
H
0.8
1.3
|
L
 -38.7%
H
0.8
2.4
|
L
 -61.3%
H
0.8
3.2
|
L
 -94.3%
H
0.8
55.5
|
L
 -99.2%
H
0.8
253.4
|
Praxis Precision Medicines Inc |
|
829.8
|
39.4
|
L
 -2.0%
H
39.4
40.7
|
L
 -15.3%
H
37.2
47.8
|
L
 -14.2%
H
37.2
50.0
|
L
 -14.0%
H
37.2
61.0
|
L
 -33.6%
H
26.7
91.8
|
L
 -22.9%
H
11.9
91.8
|
L
H
11.9
914.3
|
L
H
11.9
914.3
|
PainReform |
|
2.9
|
1.4
|
L
 5.9%
H
1.4
1.5
|
L
 2.1%
H
1.3
1.8
|
L
 8.3%
H
1.3
3.6
|
L
 -29.4%
H
1.3
3.6
|
L
 35.9%
H
0.4
16.6
|
L
 -96.8%
H
0.2
158.5
|
L
 -99.6%
H
0.2
470.4
|
L
H
0.2
471
|
Prelude Therapeutics Inc |
|
68.5
|
1.2
|
L
 1.7%
H
1.1
1.3
|
L
 -0.8%
H
1.1
1.3
|
L
 40.7%
H
0.8
1.3
|
L
 12.0%
H
0.8
1.3
|
L
 -77.5%
H
0.6
5.4
|
L
 -84.4%
H
0.6
8.7
|
L
H
0.6
95.4
|
L
H
0.6
95.4
|
Prime Medicine Inc |
|
727.4
|
4.1
|
L
 4.9%
H
3.9
4.2
|
L
 22.2%
H
3.3
4.2
|
L
 7.9%
H
3.1
4.2
|
L
 163.2%
H
1.4
5.2
|
L
 2%
H
1.1
5.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
ProKidney Corp Ordinary |
|
402.3
|
3.0
|
L
 38.0%
H
2.2
3
|
L
 26.3%
H
2.1
3
|
L
 15.1%
H
2.1
3
|
L
 198%
H
0.5
7.1
|
L
 23.7%
H
0.5
7.1
|
L
 -69.7%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
ProPhase Labs Inc |
|
21.6
|
0.5
|
L
 6.1%
H
0.5
0.5
|
L
 44.4%
H
0.3
0.6
|
L
 67.7%
H
0.3
0.6
|
L
 48.6%
H
0.3
0.6
|
L
 -81.2%
H
0.2
3.0
|
L
 -95.3%
H
0.2
12.7
|
L
 -81.6%
H
0.2
16.0
|
L
 -67.5%
H
0.2
16.0
|
ProQR Therapeutics NV |
|
230.7
|
2.2
|
L
 -2.7%
H
2.1
2.3
|
L
 -9.9%
H
2.1
2.5
|
L
 0.9%
H
1.8
2.5
|
L
 23.7%
H
1.8
2.5
|
L
 19.0%
H
1.1
4.6
|
L
 177.2%
H
0.7
4.6
|
L
 -57.1%
H
0.5
9.5
|
L
 -86.9%
H
0.5
24
|
Prothena Corporation plc |
|
453.8
|
8.4
|
L
 1.6%
H
8.2
8.5
|
L
 0.5%
H
8.1
8.6
|
L
 9.6%
H
7.4
9.0
|
L
 60.3%
H
5.0
9.0
|
L
 -59.4%
H
4.3
22.7
|
L
 -71.0%
H
4.3
79.7
|
L
 -30.7%
H
4.3
79.8
|
L
 -85.4%
H
4.3
79.8
|
AlphaTON Capital Corp |
|
32.8
|
5.5
|
L
 -6.2%
H
5.4
6.4
|
L
H
5.0
7.0
|
L
 -41.4%
H
5.0
9.7
|
L
 -30.0%
H
5.0
10.3
|
L
 73.0%
H
3.0
23.0
|
L
 -96.7%
H
2.1
179
|
L
 -97.3%
H
2.1
899.5
|
L
 -98.7%
H
0.2
1310
|
Plus Therapeutics Inc |
|
46.7
|
0.5
|
L
 2.2%
H
0.5
0.5
|
L
 2.2%
H
0.4
0.6
|
L
 -41.3%
H
0.4
0.9
|
L
 34.3%
H
0.2
0.9
|
L
 -62.7%
H
0.2
2.3
|
L
 -95.5%
H
0.2
11.0
|
L
 -98.7%
H
0.2
81.3
|
L
 -100.0%
H
0.2
55125
|
PTC Therapeutics Inc |
|
4,842.5
|
61.0
|
L
 4.5%
H
57.5
61.1
|
L
 9.7%
H
55.1
61.1
|
L
 34.3%
H
43.2
61.1
|
L
 17.8%
H
43.2
61.1
|
L
 93.3%
H
31.0
61.1
|
L
 13.6%
H
17.5
61.1
|
L
 31.7%
H
17.5
70.8
|
L
 60.8%
H
4.0
70.8
|
Protagonist Therapeutics Inc |
|
3,712.8
|
59.7
|
L
 3.4%
H
57.5
59.7
|
L
 2.7%
H
54.5
61.0
|
L
 16.9%
H
50.6
61.9
|
L
 5.9%
H
49.4
61.9
|
L
 32.9%
H
33.3
61.9
|
L
 575.1%
H
7.2
61.9
|
L
 179.1%
H
6.9
61.9
|
L
H
4.5
61.9
|
Protagenic Therapeutics Inc |
|
2.9
|
3.3
|
L
 16.1%
H
2.8
3.4
|
L
 1.8%
H
2.8
3.4
|
L
 17.3%
H
2.3
6.2
|
L
 -6.2%
H
2.3
6.2
|
L
 222.3%
H
0.2
14.3
|
L
 21.6%
H
0.2
14.3
|
L
 -29.1%
H
0.2
28
|
L
 -100.0%
H
0.2
2391353.0
|
Pulmatrix Inc |
|
18.2
|
5.0
|
L
 -0.2%
H
4.9
5.0
|
L
 7.3%
H
4.7
5.0
|
L
 -1.6%
H
4.4
5.3
|
L
 -41.0%
H
4.4
9.2
|
L
 158.6%
H
1.8
10.4
|
L
 14.4%
H
1.6
10.4
|
L
 -77.3%
H
1.6
60.8
|
L
 -99.6%
H
1.6
1396
|
Polypid |
|
54.8
|
3.5
|
L
H
3.4
3.5
|
L
 0.9%
H
3.4
3.5
|
L
 7.1%
H
3.1
3.6
|
L
 -1.4%
H
3.1
3.9
|
L
 0.3%
H
2.3
3.9
|
L
 -89.4%
H
2.3
66
|
L
 -99.1%
H
2.3
495
|
L
H
2.3
583.5
|
Pyxis Oncology Inc |
|
115.4
|
1.9
|
L
 -0.5%
H
1.8
2
|
L
 26.5%
H
1.4
2
|
L
 75.5%
H
1.0
2
|
L
 38.8%
H
1.0
2
|
L
 -51.3%
H
0.8
5.4
|
L
 -30.9%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
Pharming Group NV ADR |
|
1,014.0
|
14.8
|
L
 9.6%
H
14.5
15.2
|
L
 3.1%
H
13.5
15.6
|
L
 11.9%
H
11
15.6
|
L
 28.5%
H
9.5
17.1
|
L
 110.2%
H
7.1
17.1
|
L
 19.4%
H
6.7
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
Purple Biotech ADR |
|
1.5
|
0.6
|
L
 1.8%
H
0.5
0.6
|
L
 -59.9%
H
0.5
0.9
|
L
 -73.2%
H
0.5
2.4
|
L
 -78.8%
H
0.5
2.9
|
L
 -93.0%
H
0.5
13.4
|
L
 -98.7%
H
0.5
47.4
|
L
 -99.3%
H
0.5
145
|
L
H
0.5
1390
|
PureTech Health Plc ADR |
|
394.2
|
16.3
|
L
 -1.9%
H
15.8
16.5
|
L
 3.1%
H
15.8
16.8
|
L
 -5.5%
H
15.2
19.8
|
L
 -14.6%
H
15.2
19.8
|
L
 -17.6%
H
13.3
25.0
|
L
 -43.9%
H
13.3
38.9
|
L
H
13.3
65.9
|
L
H
13.3
65.9
|
Qualigen Therapeutics Inc |
|
3.5
|
2.1
|
L
 12.4%
H
1.8
2.2
|
L
 20.1%
H
1.7
2.2
|
L
 14.8%
H
1.6
2.2
|
L
 -44.6%
H
1.6
6.7
|
L
 -72.9%
H
0.1
10.5
|
L
 -98.8%
H
0.1
185
|
L
 -99.9%
H
0.1
2735.0
|
L
 -100.0%
H
0.1
468750
|
Qilian International Holding |
|
1,522.7
|
7.6
|
L
 4.3%
H
7
7.6
|
L
 -0.5%
H
7
7.8
|
L
 -1.4%
H
7
8.8
|
L
 -53.6%
H
7
17.2
|
L
 20.5%
H
6.1
17.2
|
L
 26.9%
H
1.8
17.2
|
L
H
1
110
|
L
H
1
110
|
Quince Therapeutics Inc |
|
84.9
|
1.6
|
L
 -1.9%
H
1.6
1.7
|
L
 -1.9%
H
1.6
1.7
|
L
 -4.2%
H
1.5
1.9
|
L
 31.7%
H
1.2
2.1
|
L
 122.5%
H
0.7
2.5
|
L
 -7.6%
H
0.5
2.5
|
L
 -96.7%
H
0.5
122.0
|
L
H
0.5
122.0
|
uniQure NV |
|
929.4
|
16.9
|
L
 -3.1%
H
16.7
17.8
|
L
 -2.5%
H
16.6
18.2
|
L
 27.6%
H
12.9
18.2
|
L
 3.7%
H
12.3
18.2
|
L
 216.6%
H
4.5
19
|
L
 -17.4%
H
3.7
28.3
|
L
 -56.9%
H
3.7
52.2
|
L
 -36.6%
H
3.7
82.5
|
Quoin Pharmaceuticals ADR |
|
4.4
|
7.6
|
L
 1.9%
H
7.5
7.7
|
L
 -2.5%
H
7.4
7.8
|
L
 5.6%
H
7.0
7.8
|
L
 -9.3%
H
6.6
9.9
|
L
 -98.5%
H
5.1
1099
|
L
 -100.0%
H
5.1
36792
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
Rain Oncology Inc |
|
248.4
|
6.8
|
L
 21.1%
H
5.3
6.8
|
L
 37.4%
H
4.4
6.8
|
L
 107.6%
H
3.1
6.8
|
L
 80.7%
H
2.7
6.8
|
L
 464.5%
H
1.4
9.2
|
L
 19.8%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
Rani Therapeutics Holdings Inc |
|
23.9
|
0.5
|
L
 2.0%
H
0.5
0.5
|
L
 4.2%
H
0.4
0.5
|
L
 -5.7%
H
0.4
0.6
|
L
 -13.8%
H
0.4
0.9
|
L
 -80.9%
H
0.4
3.8
|
L
 -94.9%
H
0.4
10.8
|
L
 -99.8%
H
0.4
36.3
|
L
H
0.4
224.5
|
RAPT Therapeutics Inc |
|
259.6
|
15.7
|
L
 11.0%
H
14.1
15.8
|
L
 38.9%
H
11.2
15.8
|
L
 60.0%
H
8.8
15.8
|
L
 64.9%
H
6.9
15.8
|
L
 -1.4%
H
5.7
26.6
|
L
 -92.5%
H
5.7
251.6
|
L
 -94.6%
H
5.7
346.1
|
L
H
5.7
409.7
|
Ultragenyx Pharmaceutical Inc |
|
3,009.7
|
31.2
|
L
 -0.2%
H
30.5
31.6
|
L
 -1.0%
H
30.5
32.3
|
L
 13.4%
H
27
32.6
|
L
 -16.7%
H
25.8
42.4
|
L
 -44.0%
H
25.8
60.4
|
L
 -36.6%
H
25.8
60.4
|
L
 -58.0%
H
25.8
179.7
|
L
 -74.1%
H
25.8
179.7
|
Rocket Pharmaceuticals Inc |
|
353.9
|
3.3
|
L
 3.1%
H
3.2
3.3
|
L
 -1.2%
H
3.1
3.4
|
L
 14.7%
H
2.8
4.1
|
L
 3.8%
H
2.4
4.1
|
L
 -83.3%
H
2.2
22.0
|
L
 -79.5%
H
2.2
32.5
|
L
 -86.1%
H
2.2
67.5
|
L
 -93.5%
H
2.2
67.5
|
Regeneron Pharma |
|
60,222.1
|
568.2
|
L
 2.2%
H
555.8
570.8
|
L
 0.8%
H
552.8
582.0
|
L
 0.9%
H
544.2
610.5
|
L
 8.5%
H
503.3
610.5
|
L
 -50%
H
476.5
1170.6
|
L
 -21.6%
H
476.5
1211.2
|
L
 3.3%
H
441
1211.2
|
L
 7.0%
H
271.4
1211.2
|
Replimune Group Inc |
|
469.1
|
6.0
|
L
 0.3%
H
5.9
6.2
|
L
 1.9%
H
5.7
6.5
|
L
 13.6%
H
4.5
6.5
|
L
 -40.7%
H
2.7
13.2
|
L
 -41.9%
H
2.7
17
|
L
 -67.3%
H
2.7
29.5
|
L
 -77.0%
H
2.7
54.9
|
L
H
2.7
54.9
|
Revelation Biosciences Inc |
|
3.4
|
2
|
L
 -19.0%
H
2.0
2.1
|
L
 -26.7%
H
2.0
2.9
|
L
 -16.0%
H
2.0
2.9
|
L
 -20.6%
H
2.0
3.2
|
L
 -95.1%
H
0.7
60.5
|
L
 -100.0%
H
0.7
25270.6
|
L
H
0.7
569016
|
L
H
0.7
569016
|
Regencell Bioscience Holdings |
|
6,650.9
|
13.5
|
L
 1.1%
H
13.1
13.6
|
L
 -2.7%
H
12.4
13.8
|
L
 -3.7%
H
12.0
16.7
|
L
 -16.9%
H
9.4
83.6
|
L
 7811.8%
H
0.1
83.6
|
L
 1411.2%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
Repligen Corp |
|
6,723.3
|
119.5
|
L
 -0.6%
H
118.9
122.7
|
L
 2.9%
H
112.7
125.3
|
L
 7.3%
H
111.2
128
|
L
 -10.1%
H
110.8
135.6
|
L
 -17.6%
H
103.0
182.5
|
L
 -48.8%
H
103.0
235.1
|
L
 -18.1%
H
103.0
327.3
|
L
 236.4%
H
20.1
327.3
|
Regenxbio Inc |
|
479.4
|
9.5
|
L
 -0.8%
H
9.1
9.8
|
L
 -3.8%
H
9.1
10.1
|
L
 20.9%
H
7.4
10.1
|
L
 -3.3%
H
7.4
10.6
|
L
 -19.5%
H
5.0
13.5
|
L
 -67.1%
H
5.0
29.5
|
L
 -65.7%
H
5.0
50.3
|
L
H
5.0
85.1
|
Rigel Pharmaceuticals |
|
678.4
|
37.8
|
L
 3.7%
H
36.2
37.8
|
L
 -4.5%
H
35.6
42.7
|
L
 19.3%
H
32.4
43.7
|
L
 75.4%
H
18.1
43.7
|
L
 194.3%
H
12.7
43.7
|
L
 2544.8%
H
0.7
43.7
|
L
 1516.2%
H
0.6
43.7
|
L
 1116.1%
H
0.6
43.7
|
Relay Therapeutics Inc |
|
710.3
|
4.1
|
L
 1.5%
H
4.0
4.2
|
L
 0.2%
H
3.9
4.3
|
L
 28.0%
H
3.2
4.3
|
L
 18.1%
H
3.0
4.3
|
L
 -54.2%
H
1.8
8.3
|
L
 -85.8%
H
1.8
29.2
|
L
 -89.0%
H
1.8
64.4
|
L
H
1.8
64.4
|
Relmada Therapeutics Inc |
|
50.5
|
1.5
|
L
 -5.6%
H
1.4
1.7
|
L
 3.4%
H
1.1
1.7
|
L
 157.6%
H
0.6
1.7
|
L
 92.4%
H
0.5
1.7
|
L
 -45.9%
H
0.2
4.0
|
L
 -95.2%
H
0.2
38.7
|
L
 -95.9%
H
0.2
40.9
|
L
 -92.3%
H
0.2
54
|
Avidity Biosciences Inc |
|
5,279.9
|
41.0
|
L
 -11.6%
H
35.7
41.6
|
L
 -13.8%
H
35.7
51.4
|
L
 -11.3%
H
35.7
51.4
|
L
 22.1%
H
27.7
51.4
|
L
 0.6%
H
21.5
56
|
L
 96.6%
H
4.8
56
|
L
 27.0%
H
4.8
56
|
L
H
4.8
56
|
TransCode Therapeutics Inc |
|
9.3
|
11.2
|
L
 4.7%
H
10.7
11.5
|
L
 6.9%
H
10
11.5
|
L
 7.8%
H
9.3
11.8
|
L
 52.0%
H
6.8
17.2
|
L
 -95.3%
H
6.2
739.2
|
L
 -100.0%
H
6.2
1145760
|
L
H
6.2
5174400
|
L
H
6.2
5174400
|
RenovoRx Inc |
|
45.4
|
1.2
|
L
 6.0%
H
1.2
1.4
|
L
 -0.8%
H
1.1
1.4
|
L
 8.8%
H
0.8
1.4
|
L
 -7.5%
H
0.8
1.4
|
L
 12.7%
H
0.8
1.7
|
L
 -55.6%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
Roivant Sciences |
|
9,840.3
|
14.4
|
L
 4.7%
H
13.8
14.5
|
L
 14.5%
H
12.5
14.5
|
L
 25.4%
H
10.9
14.5
|
L
 26.7%
H
10.7
14.5
|
L
 18.2%
H
8.7
14.5
|
L
 299.2%
H
2.9
14.5
|
L
H
2.5
16.8
|
L
H
2.5
16.8
|
Royalty Pharma plc Ordinary |
|
15,865.2
|
36.7
|
L
 1.4%
H
36.0
36.9
|
L
 0.1%
H
34.1
37.3
|
L
 -2.3%
H
34.1
37.9
|
L
 9.3%
H
33.6
38
|
L
 30.8%
H
24.1
38
|
L
 -15.9%
H
24.1
44.5
|
L
 -6.9%
H
24.1
53.2
|
L
H
24.1
56.5
|
Repare Therapeutics Inc |
|
77.8
|
1.8
|
L
 2.8%
H
1.7
1.8
|
L
 5.2%
H
1.7
1.8
|
L
 17.5%
H
1.5
1.8
|
L
 22.3%
H
1.4
1.8
|
L
 -36.9%
H
0.9
4.1
|
L
 -85.8%
H
0.9
18.7
|
L
 -93.6%
H
0.9
46.4
|
L
H
0.9
46.4
|
Revolution Medicines Inc |
|
8,643.8
|
46.2
|
L
 14.3%
H
42.4
46.9
|
L
 16.3%
H
38.5
46.9
|
L
 32.1%
H
34.1
46.9
|
L
 10.2%
H
34
46.9
|
L
 11.1%
H
29.2
62.4
|
L
 113.9%
H
15.5
62.4
|
L
 65.6%
H
14.1
62.4
|
L
H
14.1
62.4
|
Reviva Pharmaceuticals |
|
29.9
|
0.4
|
L
H
0.4
0.5
|
L
 -4.4%
H
0.4
0.5
|
L
 7.3%
H
0.4
0.6
|
L
 -47.6%
H
0.3
0.9
|
L
 -66.9%
H
0.3
4.3
|
L
 -79.7%
H
0.3
9.3
|
L
 -95.9%
H
0.3
15.1
|
L
H
0.3
15.1
|
Recursion Pharmaceuticals Inc |
|
2,117.3
|
4.9
|
L
 6.8%
H
4.5
5.1
|
L
 4.8%
H
4.5
5.1
|
L
 -9.5%
H
4.5
5.8
|
L
 -11.0%
H
4.5
7.2
|
L
 -23.3%
H
3.8
12.4
|
L
 -63.5%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
Rhythm Pharmaceuticals Inc |
|
6,503.9
|
97.9
|
L
 -2.3%
H
96.7
102.5
|
L
 -3.7%
H
96.7
104.7
|
L
 6.5%
H
89.2
106.5
|
L
 45.4%
H
60.7
106.5
|
L
 99.5%
H
45.9
106.5
|
L
 320.3%
H
15.5
106.5
|
L
 222.4%
H
3.0
106.5
|
L
H
3.0
106.5
|
Rezolute Inc |
|
693.4
|
8.0
|
L
 -1.6%
H
7.9
8.2
|
L
 10.1%
H
7.1
8.3
|
L
 37.2%
H
5.8
8.3
|
L
 81.6%
H
4.0
8.3
|
L
 53.3%
H
2.2
8.3
|
L
 251.1%
H
0.7
8.3
|
L
 -66.8%
H
0.7
25
|
L
 -88.8%
H
0.7
100
|